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Abstract 
Long QT syndrome (LQTS) is a cardiac repolarization disorder affecting every 1:2000-1:3000 
individuals.  This disease is characterized by a prolonged QT interval on the surface 
electrocardiogram (ECG) of patients.  Symptoms of LQTS range from dizziness and syncope to 
more severe symptoms such as seizures and sudden cardiac death (SCD).  Clinical features of 
LQTS are a result of the precipitations of Torsades de Pointes, which is a polymorphic form of 
ventricular tachycardia.  A number of genetic forms of LQTS have been identified with more 
than 700 mutations in 12 different genes leading to disease pathogenesis.  However it has been 
estimated that approximately 25% of patients with compelling LQTS have no mutations within 
the known LQT genes.  This proves to be problematic since treatment regimens depend on the 
genetic diagnosis of affected individuals.  Of the known mutated genes, KCNE2 is associated 
with LQT6.  KCNE2 encodes the beta-subunit of potassium ion channel proteins.  These proteins 
contain cytoplasmic C-terminal domains in which many mutations have been identified. 
We hypothesize that genes encoding KCNE2-interacting proteins might be identified as disease-
causing or modifying genes.  The present study aimed to use yeast two-hybrid (Y2H) 
methodology to screen a pre-transformed cardiac cDNA library in order to identify putative 
interactors of the C-terminal of KCNE2.  Through specific selection methods the number of 
KCNE2 ligands was reduced from 296 to 83.  These interactors were sequenced and 14 were 
identified as putative interacting proteins.  False positive ligands were excluded based on their 
function and subcellular location.  Ultimately three strong candidate ligands were selected for 
further analysis: Alpha-B crystallin (CRYAB), Filamin C (FLNC) and voltage-dependent anion-
selective channel protein 1 (VDAC1).  Three-dimensional (3D) co-localization and co-
immunoprecipitation were used to verify these proposed interactions and succeeded in doing so.  
The genes encoding verified interactors will be screened in our SA panel of LQT patients, to 
potentially identify novel LQT causative or modifying genes.  Furthermore, the interactions 
verified in the present study may shed some light on the mechanism of pathogenesis of LQT 
causative mutations in KCNE2. 
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Opsomming 
Lang QT-sindroom (LQTS) is 'n hart her-polariserende siekte wat elke 1:2000-1:3000 individue 
affekteer. Hierdie siekte word gekenmerk deur 'n lang QT-interval op die oppervlak 
elektrokardiogram (EKG) van pasiënte.  Simptome van LQTS wissel van duiseligheid en floutes 
tot meer ernstige simptome soos stuiptrekkings of aanvalle en skielike kardiale dood (SKD). 
Kliniese kenmerke van LQTS is 'n gevolg van die neerslag van Torsades de Pointes; 'n 
polimorfiese vorm van ventrikulêre tagikardie.  Verskeie genetiese vorms van LQTS is 
geïdentifiseer met meer as 700 mutasies in 12 verskillende gene wat lei tot siekte patogenese.  
Dit is ergter beraam dat ongeveer 25% van pasiënte met dwingende LQTS geen mutasies in die 
bekend LQT gene besit nie.  Dit is problematies aangesien siekte behandeling af hang van die 
genetiese diagnose van geaffekteerde individue.  Een van die bekende gemuteerde gene is 
KCNE2 wat verband hou met LQT6.  KCNE2 kodeer die beta-subeenheid van kalium ioonkanaal 
proteïene.  Hierdie proteïene bevat sitoplasmiese C-terminale waarin baie mutasies alreeds 
geïdentifiseer is. 
Ons veronderstel dat gene wat proteïene kodeer wat met KCNE2 interaksie toon, geïdentifiseer 
kan word as siekte veroorsaakende of wysigings gene.  Die huidige studie het die gis twee-
hibried metode gebruik om 'n vooraf-getransformeerde hart cDNS biblioteek te sif om 
vermeende protein interaksies van die C-terminaal van KCNE2 te identifiseer.  Deur middel van 
seleksie metodes is die aantal KCNE2 ligande verminder van 296 tot 83.  Die identiteit van die 
proteïene is bekend gemaak deur volgorderbepaling waarna 14 geïdentifiseer is as proteïene wat 
moontlik interaksie kan toon met KCNE2.  Vals positiewe ligande is uitgesluit op grond van hul 
funksie en subsellulêre lokasering.  Drie kandidaat ligande is gekies vir verdere analise: Alfa-B 
crystallin (CRYAB), Filamin C (FLNC) en spanning-afhanklike anioon-selektiewe kanaal 
proteïen 1 (VDAC1).  Drie-dimensionele (3D) mede-lokalisering en mede-immunopresipitasie 
tegnieke is gebruik om hierdie voorgestelde interaksies te verifieer en het geslaag om dit te doen. 
Die gene wat geverifieerde proteïene kodeer, sal gekeur word in ons Suid-Afrikaanse paneel van 
LQT pasiënte om sodoende potensieel nuwe LQT veroorsakende of wysigings gene te 
identifiseer.  Verder kan die geverifieer interaksies in die huidige studie lig werp op die 
meganisme van die ontstaan van LQT veroorsakende mutasies in KCNE2. 
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1.1 THE HEART 
1.1.1 Mechanism of cardiac muscle contraction 
The heart is the primary organ responsible for the supply of blood and oxygen to all the parts of 
the body.  This organ is composed of involuntary striated muscles known as the myocardium 
which contain cardiac ion channels enabling the heart to contract.  This allows the 
synchronization of every heart beat (Glaaser et al. 2003).   
At rest, all myocardial cells have a negative membrane potential at approximately -70mV that 
will change with stimulation by electrical signals.  This causes opening of the voltage-gated ion 
channels and subsequent influx of positively charged calcium and sodium ions (Ca2+ and Na+) 
into the cardiac muscle cells.  The cell membrane undergoes rapid depolarization due to the 
membrane potential becoming either more positive or less negative (Figure 1.1) (Glaaser et al. 
2003).   
At diastolic levels of intracellular Ca2+, the troponin I in the troponin complex, which is 
composed of cardiac troponin T (cTnT), cardiac troponin I (cTnI) and cardiac troponin C 
(cTnC), inhibits the interaction between myosin and actin. The binding of Ca2+ to cTnC during 
systole induces conformation changes that relieve the inhibitory effects of cTnI; thereby 
promoting the formation of actomyosin cross bridges (Figure 1.2) (Parmacek and Solaro 2004).  
This ultimately leads to the power stroke when actin filaments slide past the myosin filaments 
resulting in cardiac muscle cell contraction (Figure 1.2) (Parmacek and Solaro 2004; Pinnell et 
al. 2007). 
Repolarization follows directly afterwards, changing the membrane potential back to a more 
negative value which causes the cell to return to its resting state.  This occurs as a result of the 
opening of fast acting potassium (K) channels and efflux of K ions (K+) out of the cell (Figure 
1.1).  Following this, the slow K channels are opened, thus releasing excess K+ from the cell 
(Glaaser et al. 2003).  At the same time the Ca2+ channels will close. 
In order for the muscle cells to be able to contract again, it is necessary for the concentrations of 
K+ and Na+ to be restored to their original resting potential state by means of K+/Na+ pumps in 
the sarcolemma (Xu 2013).  The duration of this event, which is more commonly known as the 
refractory period, is much longer for cardiac muscle than for skeletal muscle and plays a role in 
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preventing prolonged cardiac muscle contraction.  The refractory period is important to ensure 
sufficient time between each contraction, allowing the heart chambers to be filled with blood 
before the next contraction (Pinnell et al. 2007). 
 
 
Figure 1.1:  Ion flow in action potential. 1) Depolarization where Na+ channels opens releasing Na+ into the cell.  
2)  Repolarization where Na+ channels are closed and K+ channels are opened, causing K+ ions to leave the cell. 3)  
K+ channels close.  Figure taken from:  http://www.mindcreators.com/neuronbasics.htm  
 
The contraction of the myocardium occurs spontaneously and is controlled by the sinoatrial (SA) 
node (Figure. 1.3) which is the impulse-generating tissue located in the right atrium of the heart 
(Rastogi 1997; Starr et al. 2010).  Once the impulse reaches the atrioventricular (AV) node 
(Figure 1.3), the contraction spreads towards the ventricles and enters the ventricular septum 
where the action potential is conducted through the bundle of His (Figure 1.3) (Rastogi 1997; 
Starr et al. 2010).   
This bundle then separates into two branches that connect with Purkinje fibres and the 
endocardium.  Ultimately, the action potential reaches the ventricular myocardium  (Rastogi 
1997; Starr et al. 2010).  It is this excitation wave spreading over the heart that causes cardiac 
myocyte membrane depolarization (Clancy 2005; Pinnell et al. 2007).  
 
A 
B 
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Figure 1.2:  Contraction of cardiac muscles through cross-bridge formation. a)  When Ca2+ levels are low, the 
myosin binding sites are blocked by tropomyosin. b)  With increase in cytosolic Ca2+ levels, Ca2+ binds to troponin 
which will release the myosin-binding sites on actin, allowing cross-bridge formation of actin and myosin.  Figure 
taken from:  http://biology-forums.com/gallery/.jpeg 
 
The heart has previously been described as a functional syncytium that allows electrical impulses 
to be passed between cells in close proximity through gap junctions; causing the myocardium to 
function as a single contractile unit (Spach and Starmer 1995; Stein 2008).  Gap junctions are 
intercellular connections between cells, connecting the cytoplasm of adjacent cells allowing free 
movement of ions and molecules (<1000Da) from one cell to the other (Kelsell et al. 2001).  This 
makes it possible for the myocardium to depolarize quickly and efficiently thus aiding in 
contraction of the heart.  
The contractility may however be compromised, resulting in damaging effects to the heart should 
there be aberrant electric signals and incorrect signalling between the gap junctions (Spach and 
Starmer 1995; Stein 2008).  For example:  if the gap junctions close incorrectly after an episode 
of myocardial infarction it will lead to tissue damage which ultimately hinders the tissue from 
participating in the synchronous contraction of the myocardium - thus causing an irregular heart 
rhythm (Spach and Starmer 1995; Glaaser et al. 2003). 
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Defects in cardiac ion channels would lead to defects in ion currents that will result in the 
variation in duration and degree of excitation as well as plateau phases during depolarization and 
repolarization (Glaaser et al. 2003).  This irregular beating of the heart results in arrhythmia or 
arrhythmic disorders leading to syncope, seizures and sudden cardiac death (SCD) (Lehnart et al. 
2007; Schwartz et al. 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3:  The electrical conduction system of the heart.  Electrical impulses start at the SA node and run 
through the atria into the AV node.  The signal causes the atria to contract after which the action potential is spread 
through the Bundle of His branching left and right.  Ultimately the ventricles also contract.  Figure taken from:  
http://kakistudy.blogspot.com/2011/03/heartbeat-mechanism.html  
 
1.1.2 Electrocardiography (ECG) 
Electrocardiography (ECG) is a transthoracic, non-invasive diagnostic tool used to interpret the 
electrical activity of the heart over a period of time.  The basic principle of an electrocardiogram 
(ECG) involves the recording of electrical impulses during each phase of the cardiac cycle.  
These impulses are detected by electrodes attached to the surface of the skin (Glaaser et al. 2003; 
Becker 2006).   
A typical EGC tracing of a cardiac cycle consists of a P wave that represents arterial 
depolarization (Figure 1.4), a QRS complex that reflects ventricular depolarization (Figure 1.4) 
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as well as a T wave which is an indicator of ventricular repolarization (Figure 1.4) (Becker 
2006).    
Under normal physiological circumstances, in healthy individuals, the heart beats between 60-
100 times per minute (bpm).  This is referred to as the normal sinus rhythm (Pinnell et al. 2007).   
When looking at the representation of an ECG (Figure 1.4), one can see the QRS complex, the P 
wave peaking before each QRS complex, the P-R interval as well as the T wave, all in normal 
range and duration.  These parameters are used as indicators to determine whether the electrical 
signal was correctly generated by the SA node and is moving at a normal rate through the heart 
(Glaaser et al. 2003; Becker 2006). 
 
 
Figure 1.4:  Schematic diagram of normal sinus rhythm of a human heart as seen on an ECG.  The P-wave is a 
result of atrial depolarization.  The QRS complex is the average of depolarization waves of the inner and outer 
cardiomyocytes.  The T-wave resembles the repolarization of ventricles. Figure created by Agateller (Anthony 
Atkielski). Figure taken from: https://en.wikipedia.org/wiki/QRS_complex 
 
Changes in the duration and magnitude of the action potential may be due to a number of factors, 
some of which include changes in cell-to-cell interaction, inherited ion channel defects and 
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therapeutic interference.  These changes will be recorded and interpreted as inconsistencies on an 
ECG (Shimizu and Antzelevitch 1997; Gima and Rudy 2002; Clancy 2005).   
Previous studies indicated that alterations in the QRS complex cause conduction defects, with 
expansion of this complex resulting in reduction of conduction velocity.  This is thought to be a 
result of defective ion channels (Tan et al. 2001; Clancy 2005). 
Additional abnormalities can be detected by ECGs such as the prolongation of QT intervals 
(Figure 1.5).  This phenomenon occurs as a result of prolonged action potential generated in the 
heart, causing repolarization to be delayed.  The longer QT intervals may ultimately change the 
morphology of the T wave.  Thus, individuals with abnormal ECG findings are at higher risk for 
developing life threatening arrhythmias which are closely associated with sudden cardiac death 
(SCD) (Priori et al. 1997; Shimizu and Antzelevitch 1999; Schwartz et al. 2001).   
Moreover, many of these fatal arrhythmic episodes have been found to be dependent on heart 
rate.  Therefore, abrupt deviations in the normal heart rate due to exercise or auditory stimulation 
at rest, for example, may result in such arrhythmic events (Schwartz et al. 2001; Glaaser et al. 
2003). 
To date a number of diseases have been associated with such life threatening cardiac arrhythmic 
episodes such as cardiomyopathy (Elliott et al. 2008), myocarditis (Feldman and McNamara 
2000) and Long QT syndrome (Schwartz et al. 2008) to name a few.  However, in the present 
study we will be focussing on the last mentioned disease (Long QT syndrome). 
 
1.2 LONG QT SYNDROME 
1.2.1 LQTS – a cardiac ion channel disorder   
Long QT syndrome (LQTS) has an estimated prevalence of 1:2000 – 1:3000 (Schwartz 2009; 
Schulze Bahr 2012) and can either be inherited or acquired, with the latter believed to be induced 
by therapeutic intervention for treating ventricular arrhythmias but also other disorders not 
related to cardiac arrhythmic diseases (Sanguinetti et al. 1995; Moric-Janiszewska 2012).  
However, this acquired form of LQTS may also manifest as a result of electrical or structural 
abnormalities caused by other cardiac disorders such as cardiomyopathies and cardiac ischemia 
(Glaaser et al. 2003; Clancy 2005). 
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Long QT syndrome has been described as an arrhythmogenic ion channel disorder, characterized 
by abnormal ventricular repolarization, ultimately resulting in QT interval prolongation in 
otherwise healthy young individuals (Figure 1.5) (Vincent 1998; Ackerman and Clapham 1997; 
Gordon et al. 2007; Schwartz 2009).  This may result in episodes of malignant ventricular 
tachycardia or arrhythmia, known as Torsades de Pointes (TdP), as well as SCD (Sanguinetti et 
al. 1995; Schwartz et al. 2008).   
The first report of LQTS was published in 1957 by Anton Jervell and Fred Lange-Nielsen, who 
described LQTS in combination with congenital neuronal deafness and episodes of syncope 
(Jervell and Lange-Nielsen 1957).  A number of years later, in 1964, Romano and Ward 
described a similar cardiac condition with symptoms such as recurring syncope, prolongation of 
the QT interval as well as a family history of sudden death, but without the feature of congenital 
neuronal deafness (Romano et al. 1963; Ward 1964).   
Later it became evident, through research and genetic analyses, that this genetic disorder 
described by Jervell and Lange-Nielsen with symptoms including congenital neuronal deafness, 
was a result of homozygous mutations.  This resulted in severe phenotypes and high risk for 
SCD (Medeiros-Domingo et al. 2007a).   
The syndrome described by Romano and Ward (Romano-Ward syndrome) on the contrary, was 
due to the presence of heterozygous mutations which did not result in deafness, but displayed 
variable disease severity.  This meant that patients with one or more disease-causing mutation in 
more than one gene, had a more severe phenotype than patients with a single gene mutation, 
placing the aforementioned affected individuals at higher risk for SCD (Brink et al. 2005).   
The clinical features of LQTS are also extremely variable. Patients can be asymptomatic, 
develop reoccurring seizures and syncope, or in the worst case, present with SCD (Medeiros-
Domingo et al. 2007a). 
It is thought that the clinical variability of LQTS is due to incomplete penetrance of underlying 
mutations, functional status of interacting genes, age, gender, environmental factors (such as 
food and poison) as well as therapeutic interventions (Abbott 1999; Lehnart et al. 2007).  
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Figure 1.5: Illustration of the prolonged QT interval on an electrocardiogram (ECG).  The QRS complex is the 
average of the depolarization waves from all the cardiac cells.  The distance between the consecutive R-peaks in the 
QRS complex represents one heartbeat.   The QT interval of individuals with Long QT syndrome will be longer 
(bottom figure) as compared to the QT intervals of unaffected individuals (top figure).  Adapted from: 
http://www.genedx.com/wp-content/uploads/2010/12/LQT.jpg  
 
As mentioned previously, some of the subtypes of LQTS are known to have a more severe 
phenotype and it has been reported that in 10-15% of lethal cases, SCD was the first and final 
symptom of the patients (Vincent 1998; Goldenberg et al. 2006). 
 
1.2.2 Classification and diagnosis of Long QT syndrome 
The diagnosis of LQTS is based on the clinical and family history of individuals as well as the 
ECG results.  The ECG measurement of the QT interval in patients is absolutely essential for the 
accurate diagnosis of LQTS.  The interval should be measured and calculated as a mean value of 
at least three cardiac cycles from the QRS complex to the end of the T wave (Goldenberg et al. 
2008) (Figure 1.2).  A formula known as the Bazett formula (QT = QT/√RR; [RR being the 
interval from the onset of one QRS complex to the onset of the next QRS complex, measured in 
seconds]) is used to correct the QT interval (QTc) for heart rate which differs between males and 
females (Table 1.1).   
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It is standard practice to use the longest QT interval when evaluating the patient for LQTS.  
When it is found that the QT interval is notably prolonged (Figure 1.5) the diagnosis is 
undeniable, particularly when it is accompanied by a positive clinical and family history 
(Goldenberg et al. 2006).    
 
Table 1.1:  The suggested Bazzet-corrected QTc values (in ms) for prolonged QT diagnosis 
Long QT rating 1-15 yrs Adult male Adult female 
Normal < 400 < 430 < 450 
Borderline 440 – 460 430 – 450 450 – 470 
Prolonged > 460 > 450 > 470 
Abbreviations: <, less than; >, more than; ms, milliseconds; yrs, years. Table adapted from: Goldenberg et al. 2006. 
 
Family history of symptoms such as syncope and a prolonged QT interval both play a vital role 
in the diagnosis of LQTS as this disease is known to segregate within families (Schwartz 2009).  
In order to simplify the diagnosis, Schwartz and colleagues developed a scoring system (Table 
1.2) which is based on personal and available family history as well as symptoms and ECG 
findings (Schwartz 1993; Schwartz 2012).  
Misdiagnosis of LQTS in Africa is not uncommon and exists as result of a number of reasons.  
These range from a lack of communication which include language and cultural obstructions or 
the high incidence of infectious diseases (such as Tuberculosis and HIV), and poverty causing 
famine and early death which masks rare diseases such as LQTS (Brink and Corfield 2009).   
Another possible reason for the misdiagnosis and/or mismanagement of disease such as LQTS 
and other similar diseases is the relatively poor medical infrastructure in rural areas of South 
Africa and Africa in previous years.   
However, the South African Medical Research Council (MRC) has published an annual report 
2011/2012 which includes the mandate of the Centre for Molecular and Cellular Biology 
(CMCB) to improve research on multifactorial disorders (for example cancer) as well as 
infectious diseases such as Tuberculosis  
(http://www.mrc.ac.za/annualreport/annualreport1112.pdf ). 
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Table 1.2:  Long QT syndrome diagnostic criteria 
   Points 
 Electrocardiographic findings#   
A QTc * ≥ 480ms 3 
  460-479ms 2 
  450-459(male)ms 1 
B QTc * 4th minute of recovery from exercise stress test ≥480ms 1 
C Torsades de Pointes (TdP) **  2 
D T wave alternans  1 
E Notched T wave in 3 leads  1 
F Low heart rate for age†  0.5 
 Clinical History   
A Syncope ** With stress 2 
  Without stress 1 
B Congenital deafness   0.5 
 Family History   
A Family members with definite LQTS‡  1 
B Unexplained sudden cardiac death below 
age 30 among immediate family members‡ 
 
0.5 
 
# In the absence of medications or disorders known to affect these ECG features 
* QTc calculated by Bazzet’s formula where QTc = QT/√RR 
** Mutually exclusive 
† Resting heart rate below the second percentile for age 
‡ The same family member cannot be counted in A and B 
 Score  
≤ 1 point Low probability of LQTS 
1.5 – 3 points Intermediate probability of LQTS 
≥ 5 points High probability of LQTS 
Abbreviations: <, less than; ≤, less than or equal to; LQTS, Long QT Syndrome; >, more than; ≥, more than or equal 
to; ms, milliseconds; QTc, corrected QT interval.  Table adapted from: Schwartz 1993; Schwartz 2012. 
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1.2.3 Risk assessment 
In 2008, Goldenberg and co-workers identified a set of risk factors for symptoms such as SCD, 
in individuals with LQTS.  However, these risk factors only serve as a  baseline reference and 
the most useful predictor of lethal cardiac events in LQTS still remains the family history as well 
as the patients’ history of syncope, other cardiac events such as aborted cardiac arrest (ACA) and 
a QTc of >500ms (Table 1.3) (Goldenberg et al. 2008).   
 
Table 1.3:  High-risk subsets for aborted cardiac arrest or sudden cardiac death by age 
Age High risk subsets 
Childhood  (1-12 years) 
Males with prior syncope and/or QTc > 500ms 
Females with prior syncope 
Adolescence  (13-20 years) 
Males and females with either 1, 2 or more of the following:  
QTc ≥ 530ms 
≥ 1 episode of syncope in the past year 
≥ 2 episodes of syncope in the past 2-10 years 
Adulthood  (21-40 years) 
Possess 1 or more of the following: 
Female gender 
Interim syncope after age 18 years 
QTc ≥ 500ms 
41-60 years 
Possess 1 or more of the following: 
Female gender 
Syncope in the past 10 years 
QTc ≥ 500ms 
LQTS3 genotype 
61-75 years Syncope in the past 10 years 
Abbreviations: LQTS, Long QT Syndrome; ≥, more than or equal to; ms, milliseconds; QTc, corrected QT interval.  
Table adapted from: Goldenberg et al. 2008. 
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In 2006 Goldenberg and colleagues presented evidence that most affected individuals in their 
study cohort who experienced at least one cardiac event during early childhood had elevated risk 
for experiencing SCD (Goldenberg et al. 2006).  This emphasized the importance of a patients’ 
history of cardiac events.  It was also reported that of the 44 patients included in this 
investigation, half died at least one or two decades after experiencing their first cardiac event, 
implying a continuous risk for LQTS patients.  These tragedies come to pass despite 88% of 
patients receiving beta-blocker therapy (Goldenberg et al. 2006). 
 
1.2.4 Therapeutic approaches 
There are a number of therapeutic approaches and management strategies available for 
individuals affected by LQTS; some of which include pharmacological therapy, implanted 
cardioverter defibrillators (ICD), surgical approaches, and lifestyle changes.  Moreover, in 
inherited forms of the disease, the treatment strategy is dependent on the causal gene mutation 
(Goldenberg and Moss 2008).   
Pharmacotherapy for the treatment of LQTS generally consists of the administration of beta-
blockers, a heterogeneous group of antihypertensive agents with an antagonistic action on beta-
adrenergic receptors in the heart (Gorre and Vandekerckhove 2010).  The main function of these 
drugs is therefore to depress myocardial function by reversing the beta-adrenergic signal 
transduction abnormalities as well as slowing down the remodelling process and ultimately 
regulate the heart rhythm (Satwani et al. 2004). 
These beta-blockers are divided into three classes based on their anti-adrenergic profile.  The 
first class contains the drugs propranolol and timolol which are non-selective compounds; 
blocking β1 and β2-receptors with equal affinity and do not have any other significant 
pharmacological properties.  The second class includes metoprolol and bisprolol for example, 
which are cardio selective compounds, blocking β1-receptors to a much greater extent than β2-
receptors.  And finally, the third class contains compounds such as carvedilol and bucindolol 
which blocks β1 and β2-receptors with an equal affinity and in addition exhibit antioxidant and 
vasodilator properties respectively (Moss et al. 2000; Satwani et al. 2004).  
This first-line prophylactic therapy is typically administered to all intermediate and high risk 
patients as these drugs interfere with the normal binding to receptors of epinephrine and other 
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stress hormones; weakening the effect of the stress response and ultimately disrupt cardiac 
arrhythmias (Schwartz et al. 2006). 
This medication has been used successfully to reduce the risk of lethal and life threatening 
cardiac events (Schwartz et al. 2001).  However, there are a number of affected individuals who 
do not respond to beta-blocker treatment and experience recurrent cardiac events (Schwartz et al. 
2001).  This may be due to the response to different genetic loci (Napolitano 2005).  Additional 
therapeutic procedures were therefore developed to manage these symptomatic patients 
(Goldenberg et al. 2008) and these procedures are described in detail below.  
Surgical approaches such as the implantation of ICDs and left cardiothoracic sympathetic 
denervation (LCSD) have also been used to successfully treat LQTS.  Studies have shown that 
ICD in combination with beta-blocker medication is effective treatment for patients who do not 
respond to treatment when only beta-blocker medication is administered (Crotti et al. 2008).  
Left cardiothoracic sympathetic denervation involves the removal of the left stellate ganglion to 
provide adequate cardiac denervation.  This procedure is only considered in patients who remain 
symptomatic and experience recurrent syncope despite beta-blocker medication and ICD 
implantation (Goldenberg et al. 2008).  
Ultimately, changes in lifestyle should be considered to improve quality of life and increase life 
expectancy by avoiding stressors including stringent exercise and competitive sports (Schwartz 
et al. 2006). Also, as far as possible, patients are urged to avoid, loud, starling noises and 
situations that could aggravate or excite them (Goldenberg et al. 2008).   
 
1.2.5 Genetics of LQTS 
Inherited forms of LQTS will usually manifest as an autosomal dominant disorder.  Autosomal 
recessive forms of this disease are less common and usually associate with a more severe 
phenotype.  These inherited forms of LQTS are also known to be caused by mutations in genes 
that encode mainly ion channel proteins, accessory subunits as well as proteins involved in 
regulating the action potential within the heart (Glaaser et al. 2003).  
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Yang and colleges also suggested that common polymorphisms, be it inherited or occur as de 
novo polymorphisms, may increase the patients susceptibility to longer QT intervals and 
arrhythmic events (Yang et al. 2002).  
Previous studies have indicated that many inherited forms of arrhythmia syndromes exist without 
the presence of any other structural heart diseases (Goldenberg et al. 2006; Lehnart et al. 2007; 
Schulze Bahr 2012).  Of these, LQTS can be utilized as a model disease due to the relatively 
high prevalence of the disease as well as the fact that LQTS is found across all ethnic groups 
(Lehnart et al. 2007; Schulze Bahr 2012).  
To date, and over 700 mutations in at least 12 genes have been shown to cause inherited forms of 
LQTS.  These mutations are randomly dispersed throughout the coding regions of the 12 genes 
and have been implicated in the development of different sub forms of the disease (Table 1.4).   
Some of these different forms of LQTS are more common than others and manifest with 
arrhythmias alone whereas rare forms of LQTS, such as LQT8, are usually associated with 
additional structural cardiac abnormalities (Schulze Bahr 2012).  
Long QT syndrome has a large genetic component that is evident in at least 75 % of patients 
diagnosed with this condition (Goldenberg et al. 2008).  Mutations identified in the 12 genes 
listed in table 1.4 either lead to decreased repolarising potassium channel currents or to 
inadequate entering of sodium and/or calcium into, and potassium ions out of the cardiomyocytes 
due to defective ion channels (Figure 1.6) (Goldenberg et al. 2008).  
There are three ion currents that are largely involved in the lengthening of cardiac action 
potential and prolongation of QT intervals namely: IKs, IKr and INa channels. IKs channels are 
responsible for the slowly activating delayed rectifier potassium currents (Splawski et al. 2000). 
IKr channels, on the other hand are responsible for the rapidly activating, delayed rectifier 
potassium current which allows potassium ions to move more easily into rather than out of the 
cell (Splawski et al. 2000; Hibino et al. 2010).    
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Table 1.4: Genes associated with specific subtypes of Long QT Syndrome 
Gene Symbol Subtype Gene Name Chromosome 
AKAP9 LQT11 A-kinase anchor protein 9 7q21-q22 
ANK2 LQT4 Ankyrin-B 4q25-q27 
CACNA1c LQT8 Calcium channel, L type, alpha 1 
polypeptide isoform 
12p13.3 
CAV3 LQT9 Caveolin-3 3p25 
KCNE1 LQT5 Voltage-gated potassium channel , 
Isk-related subfamily, member 1 
21p22 
KCNE2 LQT6 Voltage-gated potassium channel , 
Isk-related subfamily, member 2 
21p22 
KCNH2 LQT2 Potassium channel, voltage gated, 
H2 
7q35-q36 
KCNJ2 LQT7 Inwardly rectifying potassium 
channel 
17q23.1-24.2 
KCNQ1 LQT1 KQT-like voltage-gated potassium 
channel-1 
11p15.5 
SCN4B LQT10 Sodium channel, voltage gated, type 
IV beta subunit 
11q23.3 
SCN5A LQT3 Alpha polypeptide of voltage-gated 
sodium channel type V 
3p21-p23 
SNTA1 LQT12 Syntrophin, alpha 1 20q11.2 
Abbreviations: Isk, slow activating delayed rectifier potassium currents ; LQT, Long QT; p, chromosomal short arm; 
q, chromosomal long arm.  Table adapted from: Ackerman et al. 2011  
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INa channels are responsible for sodium current in the heart (Splawski et al. 2000).  When IKs and 
IKr are reduced or INa is increased in the heart, the cardiac action potential will be prolonged, the 
QT interval will lengthen and the risk for arrhythmia will be increase (Splawski et al. 2000).   
The ion channels that are associated with the development of LQTS are generally 
transmembrane proteins that transport specific ions such as potassium (K+), sodium (Na+) and 
calcium (Ca2+) through the cell membrane (Figure 1.6).  These channels are voltage-dependent; 
they are therefore only activated when the intracellular voltage reaches the required value.  The 
specific voltage necessary for activation differs between channels and is dependent on the 
channel subunit, either the alpha (α) or beta (β) subtype (Figure 1.7) (Medeiros-Domingo et al. 
2007a).   
 
 
Figure 1.6:  Ion channels in cardiac cells associated with LQTS.  Potassium ion (K+) channels facilitate the 
efflux of K+ from the cell.  Sodium ion (Na+) channels and calcium ion (Ca2+) channels mediate influx of their 
respective ions.  The Na+/Ca2+ ion exchanger channel carries three Na+ ions to the cytoplasm for each Ca2+ 
transported to the extracellular matrix across the membrane.  Adapted from: Marbán 2002. 
 
These channels form molecular complexes which are essential for the regulation of 
cardiomyocyte, and ultimately cardiac muscle contraction.  These complexes are made up of a 
protein unit that forms the membrane pore (pore-forming or α-subunit) as well as one or more 
secondary regulatory proteins which are usually auxiliary subunits (for example β-subunits) 
(Figure 1.7). 
Interestingly, the location of the mutations is believed to influence the severity of the disease.   In 
a previous study, Moss and colleagues provided evidence that mutations in the pore region of the 
KCNH2 gene was associated with a more severe clinical phenotype (Moss et al. 2002).   
Extracellular 
Cytoplasmic 
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Similarly Brink and co-workers reported that the A341V mutation in the pore region of the 
KCNQ1 protein was related to an unusually severe clinical phenotype in the South African 
population (Brink et al. 2005).  
On the contrary, Shimizu and colleagues suggested that LQTS1 patients with mutations in the 
transmembrane region of the KCNQ1 proteins were at higher risk for cardiac events (Shimizu et 
al. 2004).   
Thus, it appears that the specific genes involved as well as the location of mutations within those 
genes are responsible for the degree of channel impairment.  Accordingly, Vincent suggested 
that a variable degree of impairment in the HERG potassium channel will be present in LQTS2 
patients carrying the different mutations in different locations (Vincent 1998). 
 
Figure 1.7: The structure of a typical voltage-gated cardiac ion channel.  The figure shows the assembled alpha 
(α) and auxiliary (β) subunits of a typical voltage-gated ion channel to form a complete channel for ion transport. 
Adapted from: http://journals.cambridge.org/fulltext_content/ERM/ERM1_19/S1462399499001349sup022.gif 
 
Previously, genetic testing for LQTS was mainly performed for research purposes at universities 
and other institutes.  However, more recently it became commercially available for diagnostic 
purposes (Goldenberg et al. 2008).  Since mutations in different genes are responsible for each of 
the known LQTS subtypes (Table 1.4), genetic testing has become an invaluable and necessary 
tool for the accurate diagnosis of the disease.  
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The various LQTS subtypes are associated with certain harmful stressors (Table 1.5), that can be 
avoided if the LQTS subtype is properly diagnosed.  Moreover, the correlation between genotype 
and phenotype in specific subtypes of LQTS has improved our understanding of the mechanisms 
of arrhythmias as well as the life-threatening cardiac events suffered by individuals with LQTS 
(Schwartz et al. 2001).  
 
Table 1.5:  Stressors associated with some of the more common types of LQTS 
Genotype Stressor for cardiac events 
LQT1 Stringent exercise (swimming) 
LQT2 Startling event (alarm clock) 
LQT3 Resting state 
Abbreviations: LQTS, Long QT Syndrome. Table adapted from: (Goldenberg et al. 2008; Schwartz 2012) 
 
An advantage of genetic testing is that closely related, at-risk family members can be identified 
before they exhibit any symptoms. Furthermore, genetic screening has been shown to be 
beneficial for prenatal and pre-implantation genetic diagnosis of LQTS (Goldenberg et al. 2008). 
Genetic testing should be considered for individuals experiencing symptoms associated with 
LQTS such as syncope and abnormal ECG results as well as individuals with a positive family 
history or familial LQTS.  It is equally important that one month old infants with a QTc > 470ms 
be screened for LQTS mutations.  In a 2009 study, Schwartz and colleagues found that 43% of 
newborns with a QTc > 470ms were identified as carriers of LQTS causing mutations and that 
90% of infants with a QTc > 460ms in the first month of life - who maintained this QTc value for 
at least one year after birth - were carriers of LQTS causing mutations (Schwartz 2009; Schwartz 
2012).   This provided evidence that genetic testing allows for the identification of presumably 
healthy infants who in fact are at high risk for SCD (Schwartz 2012).   
It was also suggested that the diagnostic criteria (Table 1.2) should be used to select patients with 
a score > 3 point regardless of presence or absence of cardiac events for genetic screening.  
Additionally, the results should be used to identify the “silent” mutation carriers through cascade 
screening (Schwartz 2012).       
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Cascade screening is thought to be one of the most important features of genetic testing since it 
allows for the identification of mutation carriers that are generally overlooked.  This form of 
predictive DNA testing consists of screening the entire family for the disease-causing mutation 
identified in the patient/proband.  This is essential since first-degree relatives have a 50% risk of 
carrying the same mutation (Hofman et al. 2010).  This guarantees adequate patient treatment 
and protection from lethal arrhythmic events due to the high success rate of inherited disease 
treatment (Schwartz 2009; Hofman et al. 2010).  This method also allows asymptomatic, yet 
genetically affected individuals to be identified early on and started on the proper medications 
(Schwartz 2012).   
When a patient is selected for genetic screening and mutations are identified, the results can have 
one of the following outcomes: the patient may be positive for any of the known mutations, 
negative for any of the known mutations or a variant of unknown clinical significance may be 
identified.  This distinguishes the carriers from non-carriers (Hofman et al. 2010).    
When a known disease-causing mutation has been identified in an individual a convincing LQTS 
diagnosis can be made (Hofman et al. 2010).  All first-degree family members (parents, siblings 
and children) of these patients will subsequently be given the choice to be screened for the same 
disease-causing mutation.  The identification of mutations allows physicians to advise patients 
on which stressors to avoid (Table 1.5) in order to minimise the chances of experiencing life-
threatening cardiac events (Hofman et al. 2010).  In cases where family members are mutation-
positive it is important to monitor the newly diagnosed individual since variable phenotypic 
expression is observed in individuals of the same family with the same disease-causing mutation 
(Brink et al. 2005). 
In some cases a variant is identified of which the clinical significance is unknown.  The potential 
pathogenic role of the variant can therefore not be confirmed.  In order to prove that the variant 
is pathogenic, closely related family members should be tested.  If it is found that an affected 
relative has the same variant, chances are greater that the variant is indeed pathogenic (disease-
causing) and the variant will then be reconsidered as a family-specific mutation. (Tester et al. 
2006).  To prove that this is true a panel of unrelated control individuals who do not have ECGs 
indicative of LQTS should be screened for the newly identified variant.  If the mutation is absent 
in the control panel and present in affected individuals only, it could be considered pathogenic. 
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For further verification of pathogenesis, functional studies have to be conducted to determine the 
mechanism of pathogenesis. 
Ultimately, the identification of mutations, different types of mutations as well as their different 
functions are vital in determining the disease outcome.  It is clear that LQTS is more complex 
than initially thought, and that mutation-specific risk stratification will be integrated into clinical 
diagnosis (Schwartz 2012).   
 
1.3 SOUTH AFRICAN FOUNDER FAMILY  
In South Africa, a number of LQTS cases have been reported including individuals from Asian, 
Coloured and mostly White ethnicities (Heradien et al. 2007).  In 2005 a study by Brink and co-
workers described a cohort of 22 South African families who shared the same KCNQ1 mutation 
(A341V) (Brink et al. 2005).  Ancestry of this LQTS cohort, which included 345 family 
members, was traced back to a common Afrikaner founder couple (of mixed Dutch and 
Huguenot origin) that married in the year 1730 and gave rise to this South African LQTS founder 
effect (Figure 1.8) (Brink et al. 2005).  A founder effect can be defined as the loss of genetic 
variation that occurs when a new population is established by a small group of individuals from a 
larger population. 
In order to determine if these findings could, without a doubt, be ascribed to a founder effect and 
to ensure that the mutation identified in this cohort did not occur independently on one or more 
occasions, Brink and co-workers used genealogical studies as well as haplotype data to confirm 
the lines of descent of the KCNQ1-A341V mutation (Figure 1.8) (Brink et al. 2005). 
Among the 345 family members, 166 members were mutation carriers which consisted of 54% 
females and 46% males.  The majority (79%) of the mutation carriers were symptomatic and had 
experienced their first cardiac events before the age of 10 years.  Surprisingly, 14% of affected 
individuals experienced SCD before the age of 40 years.  With this evidence, researchers 
speculated that the KCNQ1-A341V mutation was associated with a more prominent  risk of life 
threatening cardiac events when compared to other mutations segregating with the LQTS1 
subtype (Brink et al. 2005). 
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Figure 1.8:  Inheritance lines of the KCNQ1-A341V mutation from the common founder couple (P).  A similar 
haplotype with minimal recombination segregates along with the mutation over 10 generations.  No genealogical 
information could be found for pedigree 170 and 180.  The common haplotypes are indicated with borders, and the 
index cases are indicated as diamonds.  The squares signify males and the circles females.  Ped is an abbreviation for 
pedigree and the letters P, Q and T are indicators for the couples in the first two generations from which the 
mutation was inherited.  Figure taken from:  Brink et al. 2005. 
 
In a subsequent South African study where a total number of 51 cases of KCNQ1-A341V 
mutations were reported, only 29% were correctly diagnosed with the disease while 40% of 
cases were  misdiagnosed as epilepsy and 31% remained undiagnosed (Brink and Corfield 2009). 
LQT1 patients carrying the A341V mutation exhibited more severe symptoms as well as more 
LQTS related deaths than other LQTS1 patients.  This holds true for South African patients as 
well as other individuals that have been examined worldwide.  Symptoms also seemed to appear 
at a younger age for A341V-carriers.  When compared to non-A341V carriers,  Brink and 
Corfield provided evidence showing that A341V-carriers have life threatening cardiac events and 
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longer QTc values earlier in life than other LQTS patients; even when treated with beta-blocker 
medication (Brink et al. 2005; Brink and Corfield 2009).  
 
1.4 GENETIC MODIFIERS 
Over the years genetic modifiers have been shown play an important role in the phenotypic 
variability in complex disease and that Mendelian as well as non-Mendelian genetic disorders 
display extreme inter- and intra-familial phenotypic variability  (Houlston and Tomlinson 1998). 
 
1.4.1 Genetic modifiers of LQTS 
As mentioned previously LQTS is one of many diseases that will present with severe phenotypic 
variability, thought to be caused by incomplete penetrance (Crotti et al. 2005).  Furthermore, it is 
believed that single ion defects might not be the sole cause of arrhythmic events and that the 
arrhythmias might be caused by a combination of ion defects and genetic modifiers (Keating and 
Sanguinetti 2001; Crotti et al. 2009).  Through a myriad of studies over the years, numerous 
single nucleotide polymorphisms (SNPs) in known LQTS genes have been identified and 
confirmed to contribute to the QTc interval durations. 
Mutations in KCNQ1 have been shown to be the cause of LQT1 (Table 1.4) and is by far the 
most common form of inherited LQTS.  LQT1 is believed to be responsible for approximately 45 
% of reported cases (Splawski et al. 2000).  This gene encodes the pore-forming subunit of the 
ion channel that mediates IKs.  Mutations identified in KCNQ1 lead to the loss of channel 
function which results in the reduction in repolarising potassium currents and ultimately a delay 
in repolarization of the cardiac action potential. 
In an interesting study by Yu and colleagues the effect of QT-related and diabetes-related 
variants in KCNQ1 on the QT interval were investigated.  The cohort consisted of 2415 Type 2 
diabetes patients and 1163 control individuals from a Chinese population.  Four SNPs in KCNQ1 
were selected (rs12296050, rs12576239, rs2237892 and rs2237895) and genotyped.  
Interestingly, none showed association with QT interval in patients with Type 2 diabetes.  On the 
contrary one of the SNPs (rs12296050) was found to be associated with a prolonged QT interval 
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in the control group.  This indicated that KCNQ1 is linked to QT interval duration in a Chinese 
population with normal glucose regulation (Yu et al. 2013). 
In our South African founder population, Schwartz indicated that the KCNQ1-A341V mutation 
has a far more severe clinical manifestation than other LQT1-causitve mutations (Schwartz 
2012).  This high degree of severity was previously ascribed to the fact that the A341V mutation 
contains a mildly dominant-negative effect and does not result in a total loss of function effect.  
It should be noted, however that the complete mechanism is not known as arrhythmic risk 
continues to be higher when compared with KCNQ1 mutations that contain a strong dominant 
negative effect (Brink and Corfield 2009).  
In the same South African population it has been found that the occurrence of frequent 
polymorphisms in the NOS1AP gene will increase the risk of sudden death by 2 fold in patients 
with the KCNQ1-A341V mutation (Schwartz 2012).  The NOS1AP gene, which encodes a nitric 
oxide synthase adaptor protein, has subsequently been implicated as a contributor to QT interval 
duration as well as an increased risk factor for SCD in the general population (Crotti et al. 2009). 
Crotti and his co-workers investigated the theory that common variants in NOS1AP could modify 
the risk of clinical expression as well as the degree of QT-interval prolongation in a South 
African LQTS cohort (Crotti et al. 2009).  Two variants of NOS1AP (rs4657139 and 
rs16847548) were significantly associated with the occurrence of symptoms with clinical 
severity as well as the probability of experiencing cardiac arrest and SCD.  Additionally, these 
two variants were also associated with a greater chance of having QT intervals that fell in the top 
40% of values among all mutation carriers in the study.  These results showed that the variants of 
the NOS1AP gene not only influence the QTc interval, but also affect the risk for life-threatening 
cardiac arrhythmias and SCD in LQTS patients - ultimately labeling NOS1AP as a genetic 
modifier of LQTS (Crotti et al. 2009).  
Nonetheless, with genetic tests identifying pathogenic mutations, it is possible to change 
management options and to use a more direct line of attack in order to protect the patients 
(Schwartz 2012). 
Mutations identified in KCNH2 (better known as HERG) are thought to be responsible for up to 
40% of LQTS cases (LQT2, Table 1.4).  HERG mediates the IKr current which is an important 
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regulator of repolarization of the cardiac action potential. Most mutations identified in HERG 
leads to a reduced potassium current and ultimately loss of function or reduced function of IKr 
channels.  Previous studies have provided evidence that HERG channel dysfunctions will not 
only lead to inherited LQTS, but also acquired forms of LQTS (Sanguinetti et al. 1995).   
Another group of investigators screened the KCNH2 gene for novel mutations.  The KCNH2-
K897T (rs1805123) polymorphism was identified and researchers suggested examining a cohort 
of 170 LQT1 patients to elucidate the association between this SNP and QTc interval duration as 
well as its effect on modifying the phenotype of LQTS (Laitinen et al. 2000).  A subsequent 
study demonstrated that the KCNH2-K897T SNP modified the clinical expression of the latent 
A1116V LQT2 mutation and that this common variant (K897T) would most likely not cause 
disease on its own (Crotti et al. 2005). 
In 2007 an American study was conducted which included 1730 unrelated patients from the 
Framingham Heart study (Newton-Cheh et al. 2007).  Seventeen SNPs as well as the previously 
associated SNP - rs1805123 (K897T) – in KCNH2 were selected for genotyping.  The study 
showed that only one of the 17 SNPs (rs3807375) along with the rs1805123 SNP was associated 
with the QT interval duration in both men and women (Newton-Cheh et al. 2007). 
A previous study showed that a subset of patients carrying mutations in ion channels displaying 
incomplete penetrance, were prone to drug-induced forms of LQTS that are commonly 
associated with malignant arrhythmias (Napolitano et al. 2000).  When a mutation screen of 
LQTS-related genes was performed, the Y315C point mutation was identified in KCNQ1.  It was 
established that this mutation caused a severe loss of IKs function within cells causing a delay in 
repolarization of the cardiac action potential, despite the analysis of numerous ECG results that 
ruled out the presence of prolonged QT intervals (Napolitano et al. 2000). 
Kubota and co-workers identified another KCNQ1 mutation in a patient with prolonged QT 
interval as well as TdP induced by hypokalaemia (referring to the condition in which the 
potassium concentration is very low).  This missense mutation, R259C, is believed to be the 
molecular source for the dysfunction of IKs currents underlying sporadic cases of hypokalaemia-
induced LQTS.  Researchers subsequently suggested that cases of patients with acquired LQTS, 
carrying genes with such mild mutations, might be more common than expected and accentuated 
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the significance of performing mutation screening to detect these “silent” forms of LQTS 
(Kubota et al. 2000).  
In the same year a study was completed that included mutation screening of five of the known 
LQTS-related genes (KCNQ1, HERG, SCN5A, KCNE1, and KCNE2).  Of the 262 study subjects, 
68 had mutations in HERG of which 52 of the mutations were novel.  A similar number of 
mutations were identified in KCNQ1 (75 mutations).  Additionally, 8%, 3% and 2% of mutations 
were found in SCN5A, KCNE1 and KCNE2 respectively (Splawski et al. 2000). 
The SCN5A gene, which is associated with the LQT3 subtype, is believed to be responsible for 
7% of cases of inherited LQTS.  This gene encodes the alpha subunit of a sodium channel that is 
in charge of cardiac depolarisation.  Mutations in this gene leads to a gain-of-function that will 
influence the normal upholding of the depolarising current and ultimately leads to the 
prolongation of the action potentials (Wang et al. 1995). 
To date, not a single case of LQTS have been diagnosed and documented in the black South 
African population, whereas 88% of LQTS index cases were identified in the White population 
(Heradien et al. 2007).  On the contrary in other countries such as the United States of America 
(USA), a large number of cases have been documented in black populations.  One such study 
included the SCN5A variant - rs7626962 (S1103Y or S1102Y) - that is believed to be a common 
variant in black populations but a rare variant in other ethnic groups.  Previous studies have 
linked this SNP to the risks of SCD, drug-induced arrhythmias as well as  sudden infant death 
syndrome (SIDS) in black populations (Jeff et al. 2011). 
Subsequently Jeff and co-workers selected 72 variants of the SCN5A gene to be genotyped in 
3054 unrelated individuals and found that 14 had significant associations with the QT interval 
duration.  One of the 14 variants, rs7627552, was found to be the SNP best associated with P-
wave and PR durations on the ECG (Jeff et al. 2011). 
Mutations in minK, better known as the KCNE1 gene, are responsible for approximately 5% of 
inherited LQTS cases (Splawski et al. 1997).  This gene encodes the beta subunit of a potassium 
channel that mediates the IKs current and co-assembles with KCNQ1 in order to form the 
functional channel.  In a previous study, it was found that KCNE1 mutations, similar to KCNQ1 
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mutations, change the repolarization of action potentials in the myocardium (Splawski et al. 
1997). 
In a study by Friedlander and co-workers, a linkage and association analysis was conducted to 
investigate whether variants in KCNE1 had any effect on the QTc intervals of an Israeli 
population.  It was found through a family-based association analysis that the G38S SNP showed 
significant association with QTc intervals and that this SNP is modified by gender (male) 
(Friedlander et al. 2005). 
Over the years, four Finnish founder mutations have been identified; two in KCNQ1 (G589D and 
IVS7-2A>G) and two in KCNH2 (L552S and R176W) (Lahtinen et al. 2011).  In a recent study 
the common D85N variant in KCNE1 was investigated for its effect on age, sex, and QTc 
interval duration in LQTS patients carrying these Finnish founder mutations.  This association 
study was conducted due to the fact that D85N has been linked to prolongation of QT intervals 
through inhibiting IKs (KCNQ1) and IKr (KCNH2) currents, thus making KCNE1 a suitable 
candidate for a modifier gene in LQTS (Lahtinen et al. 2011).  The association between D85N 
and clinical variables resembling disease severity was also investigated.  The results obtained 
from this study indicated an association between D85N and QT prolongation in males with the 
KCNQ1 G589D variant, but not in females with the same variant.  Additionally, within the 
G589D mutation group, KCNE1 D85N carriers were mostly identified as probands.  This led to 
the suggestion that KCNE1 D85N is a gender specific modifier of QT interval in LQT1 and 
could possibly be linked to an increase in disease severity (Lahtinen et al. 2011). 
The LQT6 subtype can be caused by a number of mutations identified in KCNE2, also known as 
the mink-related peptide (MiRP1).  This gene encodes the accessory β-subunit of the voltage-
gated potassium ion channel.  The β-subunit regulates the IKr current in the heart and co-
assembles with HERG to form the complete and functional potassium channel (Abbott 1999).  
The mutations associated with this gene are thought to be loss-of-function mutations and cause 
prolongation of action potentials by inhibiting the IKr current in the heart (Abbott 1999).  In a 
study conducted by Abbott and colleagues, three missense KCNE2 mutations (Q9E, M54T and 
I57T) that are believed to be more commonly found in patients with drug-induced TdP, were 
identified.  It is therefore recognized that missense mutations in the KCNE2 gene are related to 
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inherited and acquired forms of arrhythmias as well as alterations in the ion channel functions 
(Abbott 1999; McCrossan et al. 2009). 
Subsequent investigations of KCNE2 led to the identification of a missense mutation (C29T) 
which encodes the T10M variant.  This variant forms part of a cluster of variants previously 
identified as acquired LQTS SNPs (T8A and Q9E) (Figure 1.9).  However, in this study, the 
T10M variant was inherited from the father of the proband and present in other asymptomatic 
family members but not in 578 ethnically matched controls (Gordon et al. 2007).  Gordon and 
co-workers set out to find the functional significance of this disease causing variant in KCNE2 
ion channels.  Results showed that the variant reduces the current density and slows down the 
inactivation and recovery of KCNE2/HERG but does not affect the KCNE2/KCNQ1 currents.  It 
was proposed that the T10M mutation may likely be intensified when accompanied by 
environmental and/or other genetic factors and that KCNE2 does indeed regulate HERG in the 
human heart (Gordon et al. 2007).  
                                  
McCrossan and co-workers investigated KCNE1 and KCNE2 mutations that have previously 
been associated with LQTS.  Two KCNE1 variants (D76N and S74L) were shown to reduce the 
current density and delayed deactivation of an α-subunit – Kv2.1 (McCrossan et al. 2009).  
Variants in KCNE2 (M45T and I57T) reduced KCNE2/HERG currents and was previously 
shown to be associated with inherited and acquired (drug-induced) LQTS (Abbott 1999; Gordon 
et al. 2007; McCrossan et al. 2009).  The R27C variant present in KCNE2 has been linked to 
atrial fibrillation and an increase in KCNE2/KCNQ1 currents without affecting other KCNE2 
channel functions.  Furthermore, it has also been demonstrated that KCNE1 and KCNE2 were 
Figure 1.9:  A figure representing the 
KCNE2 transmembrane protein and 
three known N-terminal domain 
mutations. Three of the known KCNE2 
mutations (T8A, T10M and Q9E) are 
indicated in this figure of which the 
KCNE2 C29T mutation encodes a T10M 
substitution in KCNE2, close to the LQTS 
variants, T8A and Q9E.  Adapted from: 
Gordon et al. 2007. 
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modifiers of Kv2.1 function and that inherited mutations in either of these subunits may 
contribute to cardiac arrhythmias through a number of mechanisms (McCrossan et al. 2009) 
Following this discussion on genetic modifiers, one can speculate that mutations found in these 
ion channel genes directly influence the current changes that regulate action potential.  The ECG 
findings associated with these mutations include prolonged QT intervals as well as ventricular 
tachycardia.  Evidence also suggests that the mutations identified in such a varied subset of 
genetic modifiers can lead to the susceptibility of severe cardiac arrhythmias (Cheng et al. 2003) 
To date, several studies have been conducted in order to discover novel disease-causing 
mutations in genes associated with LQTS or in genes known to modify disease phenotype.   
However, as mentioned earlier, 25% of patients clinically diagnosed with LQTS have no 
apparent genetic cause for their disease (Napolitano 2005; Medeiros-Domingo et al. 2007b; 
Newton-Cheh et al. 2009).  Consequently, KCNE2 was chosen to be investigated for novel 
interacting modifier genes.  Mutations in KCNE2 have been linked to congenital as well as drug-
induced LQTS and therefore proved to be an interesting candidate for this study (Abbott 1999). 
 
1.5 KCNE2 POTASSIUM ION CHANNEL 
1.5.1 KCNE2 genomic structure 
Abbott and co-workers cloned and characterized the potassium voltage-gated channel, IKs-related 
family, member 2 (KCNE2) gene that encodes the MiRP1 protein (Abbott 1999).  This protein 
forms part of a largely diverse class of membrane proteins with a variety of functions made 
possible by α- and regulatory β-subunits from which these channels are assembled.  These 
subunits are encoded by the KCNE family that comprises five known human genes (KCNE1-5) 
(McCrossan and Abbott 2004).  
KCNE2 was found to be located on the long (q) arm of chromosome 21 at position 21.12 on the 
forward strand.  This gene encodes a small transmembrane protein of 123 amino acids (aa), has a 
transcript length of 803 base pairs (bp) and contains two coding exons (Figure 1.10) (Abbott 
1999; www.ensembl.org).  However, investigators indicated that the KCNE1 gene, encoding 
MinK, was previously mapped to this same locus and found that these two genes are arrayed in 
opposite orientation of each other and are only separated by 79kb.   
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Abbott and colleagues subsequently suggested that KCNE2 and KCNE1 are related by means of 
gene duplication and divergent evolution and that KCNE2 shares a 27% identity and a 45% 
homology to KCNE1 (Abbott 1999).   
Following the identification and classification of KCNE2 several studies have shown high levels 
of expression of KCNE2 in cardiac and skeletal muscle (Abbott 1999) as well as the brain (Ying 
et al. 2012), pancreas, kidney, placenta and colon.  Lower levels of expression are found in liver, 
ovary, testis and small intestines with near to undetectable levels of expression present in the 
lung (Tinel et al. 2000).  When compared to expression of other KCNE proteins, it was found 
that KCNE2 is less expressed in the heart, especially in the ventricles (Bendahhou et al. 2005).  
Nevertheless, KCNE2 is present in the heart and the highest expression levels of KCNE2 is 
localized to the SA node and up to 40% in atrial tissue (Yu et al. 2001). 
 
1.5.2 KCNE2 protein structure 
KCNE2 contains one extracellular N-terminal that includes two predicted N-glycosylation sites 
(N6 and N29) (Figure 1.10 and Figure 1.12) (Zhang et al. 2012), one transmembrane domain and 
one intracellular C-terminal domain that includes protein kinase C-mediated (PKC) consensus 
phosphorylation sites (T71 and S74; Figure 1.10) (Abbott 1999; McCrossan and Abbott 2004).   
This small integral membrane subunit has been shown to co-assemble with HERG - the KCNH2 
gene product - in order to form a functional unit of the IKr channel (Abbott 1999).  However, in a 
subsequent study by Jiang and colleagues it was found that a very small amount of KCNE2 
showed association with HERG in co-immunoprecipitation analysis (Jiang et al. 2009).  
This gave rise to the suggestion that this specific protein has other possible interacting partners 
(Jiang et al. 2004). Other investigators suggested that KCNE2 might interact/associate with 
KCNQ1 and KCNQ3 and draw out a voltage-dependent current.  Or it may also associate with 
Hyperpolarization Activated Cyclic Nucleotide-Gated Potassium Channel 1 and 2 (HCN1and 
HCN2) to increase the potassium current (Yu et al. 2001). 
The association of KCNE proteins with the appropriate α-subunits have been found to take place 
in the endoplasmic reticulum (ER) (Chandrasekhar et al. 2006) as well as at the plasma 
membrane (Jiang et al. 2009) with more than one protein co-assembling with the channel 
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complex.  Evidence suggests that one of the KCNE proteins could take the place of another 
family member to influence the current properties (Eldstrom and Fedida 2011). 
In a 2008 study, Abbott and colleagues determined the secondary structure of KCNE2 as largely 
α-helical and concluded that the predicted transmembrane and intracellular domains require an 
extensive hydrophobic interaction in order for the molecule to take on an ordered, non-
aggregated structure (Abbott et al. 2008).   
The N-terminal domain was found to be the only water-soluble domain in this study which 
indicated the consistency with the predicted extracellular location of this section.  Abbott and co-
workers mention that the function of the N-terminal of KCNE2 has not yet been elucidated but 
the removal of residues four-nine from the N-terminal of KCNE1 results in the loss of channel 
function.  This might be extrapolated to KCNE2 due to the homology shared between these two 
subunits (Abbott et al. 2008). 
Additionally two inherited mutations (Q9E and T8A) located in the N-terminal of KCNE2 
(Figure 1.12) have been associated with acquired (drug-induced) forms of arrhythmias (Abbott 
1999).  One of these mutations - Q9E - was found to increase the sensitivity of IKr channel 
blockage for drugs such as clarithromycin.  This complicates the repolarization action of mutant 
IKr complexes and is believed to contribute to the prolongation of the QTc interval of the cardiac 
action potential; regardless of the presence of drugs (Abbott 1999). 
The transmembrane domain structure of KCNE1 has proven to be more difficult to determine 
than anticipated; with several studies suggesting controversial conformations for this domain.  
Some investigators proposed a β-conformation, while others concluded an α-helical structure for 
this section of the protein (Abbott et al. 2008).   
Similarly, the transmembrane domain of KCNE2 presented with some difficulty but was 
ultimately identified through infrared spectroscopy as predominantly α-helical with a minor 
intra-molecular β-strand conformation (Abbott et al. 2008). 
The intracellular C-terminal domain of KCNE2 was shown to be insoluble in water, indicating 
that a hydrophobic interaction is essential for solubility as well as an ordered secondary structure 
of this domain (Abbott et al. 2008). 
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   Exon 1                                        
     1 GTAAGGTGAAGGTGCCCAGCAGGCTGAGGCTTGTGTGCAACCCAGAAGAGAGCTCGCTAA 
       ............................................................ 
          
    61 CGCCAGCAAGAAGGTTCAGAACAGCCTGGCTTTGGAAAGGAATTTCATCCTGCCCACACA 
       ............................................................ 
               Exon 2                     N-Terminal 
   121 CTGCATAGCAGGAGGGAAGCATGTCTACTTTATCCAATTTCACACAGACGCTGGAAGACG 
       ....................-M--S--T--L--S--N--F--T--Q--T--L--E--D-- 
               
   181 TCTTCCGAAGGATTTTTATTACTTATATGGACAATTGGCGCCAGAACACAACAGCTGAGC 
    14 V--F--R--R--I--F--I--T--Y--M--D--N--W--R--Q--N--T--T--A--E— 
                                       Transmembrane domain    
   241 AAGAGGCCCTCCAAGCCAAAGTTGATGCTGAGAACTTCTACTATGTCATCCTGTACCTCA 
    34 Q--E--A--L--Q--A--K--V--D--A--E--N--F--Y--Y--V--I--L--Y--L-- 
                                                            C-Terminal 
   301 TGGTGATGATTGGAATGTTCTCTTTCATCATCGTGGCCATCCTGGTGAGCACTGTGAAAT 
    54 M--V--M--I--G--M--F--S--F--I--I--V--A--I--L--V--S--T--V--K-- 
            
   361 CCAAGAGACGGGAACACTCCAATGACCCCTACCACCAGTACATTGTAGAGGACTGGCAGG 
    74 S--K--R--R--E--H--S--N--D--P--Y--H--Q--Y--I--V--E--D--W--Q-- 
                  
   421 AAAAGTACAAGAGCCAAATCTTGAATCTAGAAGAATCGAAGGCCACCATCCATGAGAACA 
    94 E--K--Y--K--S--Q--I--L--N--L--E--E--S--K--A--T--I--H--E--N-- 
     
   481 TTGGTGCGGCTGGGTTCAAAATGTCCCCCTGATAAGGGAGAAAGGCACCAAGCTAACATC 
   114 I--G--A--A--G--F--K--M--S--P--*-............................ 
 
   541 TGACGTCCAGACATGAAGAGATGCCAGTGCCACGAGGCAAATCCAAATTGTCTTTGCTTA  
       ............................................................ 
 
   601 GAAGAAAGTGAGTTCCTTGCTCTCTGTTGAGAATTTTCATGGAGATTATGTGGTTGGCCA 
       ............................................................ 
 
   661 ATAAAGATAGATGACATTTCAATCTCAGTGATTTATGCTTGCTTGTTGGAGCAATATTTT 
       ............................................................ 
        
   721 GTGCTGAAGACCTCTTTTACTTTCCGGGCAAGTGAATGTCATTTTAATCAATATCAATGA 
       ............................................................ 
                
   781 TGAAAATAAAGCCAAATTTGAAG 
       ....................... 
Figure 1.10:  KCNE2 genomic and protein sequence.  The sequence in orange marks the beginning of the second 
exon.  The red codons, ATG and TGA, resembles the start and stop codons respectively.  The sequences in blue, 
purple and green indicate the N-terminus, the transmembrane domain and the C-terminus respectively.  The section 
highlighted in light-blue in the protein sequence indicates the two glycosylation sites whereas the grey shaded area 
resembles the two PKC sites.  Adapted from Eldtorm 2011and www.ensembl.org. 
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Finally Abbott and co-workers concluded that, although their findings were consistent with 
previous studies, it should be noted that KCNE2 is glycosylated at two sites in the N-terminal 
domain (Figure 1.10 and Figure 1.12) as well at the PKC sites in the C-terminal domain (Figure 
1.10) and that this, in conjunction with KCNE2 interaction with α-subunits, might alter the 
structure of the KCNE2 protein (Abbott et al. 2008).  
 
1.5.3 KCNE2 trafficking and interacting proteins 
Previous studies have shown the association between KCNE2 and HERG as well as between 
KCNE1 and HERG (McDonald et al. 1997) however, studies elucidating the functional effects of 
KCNE2 on HERG were contradicting.  Abbott showed that the co-assembly between KCNE2 
and HERG lead to altered voltage-dependent activation of the channels, requiring a more 
positive potential when compared to channels formed only with HERG subunits (Abbott 1999).  
On the other hand, Lu and co-workers indicated that there was a significant decrease in current in 
the early phases of action potential for KCNE2/HERG channels (Lu et al. 2003).  Another study 
concluded that KCNE2 accelerated HERG deactivation and shifted HERG activation voltage 
dependence in the hyperpolarizing direction when co-expressed (Weerapura et al. 2002). 
Um and co-workers decided to investigate these discrepancies between KCNE1 and KCNE2 
through studying the biological differences in protein processing and physical interactions with 
HERG.  They found that during biogenesis of channels, HERG had a greater prevalence for 
assembling with KCNE1 rather than KCNE2.  This was ascribed to differences in trafficking 
rates of the KCNE1 and KCNE2 and not due to different affinities for these proteins (Um and 
McDonald 2007).   
It is important that translated proteins are translocated to their specific cellular location in an 
ordered and structural manner through the Golgi apparatus.  Proteins are passed through the ER 
and sent to the Golgi apparatus to be modified by specific enzymes and packaged into vesicles 
from where they are then transported to their final destination.  In the case of KCNE2 the 
proteins are transported to the cell membrane (Peer 2011).  
In a study by Abbott, co-immunoprecipitation experiments of KCNE2 and KCNE1 showed the 
association of the KCNE β-subunits with their respective α-subunits before reaching the cell 
membrane (Abbott 1999). 
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Um and McDonald used an ER retention signal to study the effects of KCNE trafficking and 
their association with HERG (Figure 1.11).  The results indicated that the retention signal of 
KCNE2 yielded an increased amount of higher molecular weight bands which is consistent with 
a protein that can translocate to the Golgi apparatus but is retained within the ER where 
prolonged exposure to glycosylation enzyme is allowed (Um and McDonald 2007).   
Furthermore, with fluorescent staining of both KCNE and HERG protein, it was clear that HERG 
and KCNE2 was predominantly confined to the cell surface.  An enhanced association was found 
between KCNE2/HERG.  Additionally, Um and McDonald suggested that the co-assembly of 
KCNE2 and HERG would be expected more to occur if KCNE2 was retained within the ER for 
longer periods (Um and McDonald 2007). 
 
Figure 1.11:  Schematic representation of proposed trafficking and association of KCNE1, KCNE2 and 
HERG.  The red arrows indicate the more rapid trafficking of KCNE2 whereas the yellow arrow shows the slower 
trafficking of KCNE1and HERG to the cell membrane.  KCNE2 trafficking is facilitated by endosomes as well as 
multivesicular endosomes (MVE).  The export of KCNE2 from the cell surface is enabled through exosomes where 
extracellular proteins may exist as monomers of oligomers.  Adapted from: Um and McDonald 2007. 
  
The association of KCNE1 and KCNE2 with HERG has significant implications for cardiac 
conduction, inherited forms of arrhythmia and pro-arrhythmic drug sensitivity (Abbott and 
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Goldstein 2001).  Thus, it is important to study and characterize their specific functions 
particularly since there is significant controversy surrounding this subject. 
Um and McDonald studied the physical interaction between these proteins and their respective 
trafficking pathways and found that HERG associates more readily with KCNE1 than with 
KCNE2.  However if forward trafficking of KCNE2 is chemically or molecularly interrupted or 
slowed down, co-assembly of HERG and KCNE2 is increased.  Investigators speculate that the 
prevention of forward trafficking changed the subcellular delivery of KCNE2 and that the 
interruption caused a significant increase in KCNE2 accumulation in the cell (Figure 1.11).  This 
was not observed for KCNE1 or HERG.  A large amount of KCNE2 was also reported to be 
exported from the cell (Figure 1.11).  Subsequently it was concluded that KCNE2 is likely to be 
processed and trafficked to the cell surface more rapidly than KCNE1 and HERG (Um and 
McDonald 2007) (Figure 1.11). 
Over the years, several studies have provided evidence that KCNE2 interacts with a variety of 
potassium channels.  Some of these channels include the IKs complex (Jiang et al. 2009), Kv1.4, 
Kv2.1 (McCrossan et al. 2009), Kv3.1 and KV3.2 (Lewis et al. 2004), Kv4.2 (KCND2) and 
Kv4.3 as well as HCN1 and HCN2 as mentioned earlier (Yu et al. 2001). 
 
1.5.4 KCNE2 channel dysfunction and LQTS 
How are changes in the KCNE2 gene related to pathological conditions?  Firstly defects in 
KCNE2 are the cause of long QT syndrome type 6 (LQT6) (Abbott 1999) as well as familial 
atrial fibrillation type 4 (ATFB4) which is a common cardiac arrhythmic disorder characterized 
by the disorganized electrical activity and ineffective contraction of the atria (McMichael 1982; 
Yang et al. 2004).  This causes blood stasis in the atria and ultimately reduces filling of the 
ventricle.  Similarly to LQTS, ATFB4 can result in heart palpitations, syncope and heart failure 
(Yang et al. 2004). 
It has been estimated that more than 10 mutations in KCNE2 have been linked to the most 
common form of LQTS i.e. Romano-Ward syndrome (Eldstrom and Fedida 2011) (Figure 1.12).  
These mutations changes the ability of the protein to regulate cardiac muscle potassium channels, 
causing the potassium channels to open at a slower rate and close more rapidly than usual, 
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reducing the flow of positively charged potassium ions out of these cardiac muscle cells (Towbin 
and Vatta 2001).  This channel dysfunction leads to the symptoms experienced by LQTS 
patients; i.e. cardiac arrhythmia, syncope and SCD (Ward 1964). 
Familial atrial fibrillation is a relatively rare condition found in a small subset of patients and is 
caused by a single mutation in KCNE2.  This mutation changes the arginine amino acid at 
position 27 to a cysteine in the KCNE2 protein - R27C.  Contrasting the mutations found in 
KCNE2 responsible for LQTS, it has been found that the R27C mutation increases the flow of 
potassium ions through channels regulated by KCNE2 in cardiac muscle cells.  This may lead to 
changes in the normal rhythm of the heart and give rise to atrial fibrillation (Yang et al. 2004). 
Many of the mutations identified in KCNE2 have functionally been characterized and are located 
across the entire protein (Figure 1.12).  For example, the I57T and A116V mutations have been 
shown to decrease channel conductance at the cell surface (Abbott and Goldstein 2001).  The 
Q9E mutation causes a positive shift in activation voltage whereas the T8A mutation leads to a 
negative shift in activation.   
Additionally, the KCNE2-M54T mutation was shown to cause a faster deactivation and no shift 
in the voltage-dependent activation (Abbott 1999).  The V56M mutation was found to accelerate 
the inactivation of co-assembled channels (Isbrandt et al. 2002) whereas the T10M mutation 
caused an almost 30% reduction in current amplitude as well as a slower recovery from 
inactivation (Gordon et al. 2007). 
Drug-induced LQTS or acquired LQTS can also be considered another disorder caused by 
mutations in the KCNE2 gene and other LQT genes (Abbott 1999).  These drugs include 
medications used to treat infections, seizures as well as arrhythmias and psychotic disorders such 
as quinidine (used for malaria infection) and thioridazine (used for psychotic disorders).  The 
mechanism by which mutations cause drug-induced LQTS has been shown to mostly involve 
blockage of the rapid component of the delayed rectifier potassium current (IKr) (HERG) and, to 
a lesser extent, other potassium and sodium channels.   
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The structure of ion channels provides high-affinity binding for a wide range of molecule.  Thus, 
by introducing mutation into these channels it would reduce the binding affinity for a variety of 
drugs and ultimately cause disruption of the channel and drug-induced LQTS (Moss et al. 2000; 
Kannankeril et al. 2010). 
 
1.6 PRESENT STUDY  
As mentioned, congenital LQTS can be inherited in either an autosomal dominant or autosomal 
recessive manner with an estimated prevalence of approximately one in 2500 individuals 
(Schwartz 2009; Schulze Bahr 2012).  A number of investigations have shown that it is an 
important cause of cardiac arrest in young, otherwise healthy individuals (Vincent 1998).  Over 
700 mutations in 12 genes have been linked to the pathogenesis of the disorder, however, for 
approximately 25% of patients with compelling LQTS clinical diagnoses, no causative mutations 
have been found (Napolitano 2005; Medeiros-Domingo et al. 2007b; Newton-Cheh et al. 2009).  
It is therefore important to identify new candidate genes to screen for LQTS causative mutations. 
The present study aims to approach this problem by performing yeast two-hybrid analysis (Y2H) 
to identify potential novel candidate genes for LQTS.  It has been well established that LQTS is 
involved in the dysfunction of cardiac ion channels and that eight of the 12 genes that have been 
mutated in congenital LQTS encode ion channels and their accessory proteins.   
Figure 1.12: KCNE2 mutations 
mapped onto a representation of 
the transmembrane protein.  The 
extracellular N-terminus and known 
mutations and two glycosylation 
sites (red capital letter G) in that 
domain, the transmembrane domain 
and known mutations as well as the 
intracellular C-terminal domain with 
previously identified mutations are 
indicated and mapped to their 
positions in this figure.   Adapted 
from: Eldstrom and Fedida 2011. 
 
N-terminal 
Transmembrane domain 
C-terminal 
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Hypothesis: 
We therefore hypothesize that genes encoding proteins that interact with ion channels could also 
be mutated in LQTS.  Furthermore, in addition to environmental factors, other disease-modifying 
genes exist that influences the expression of the LQTS phenotype.  Consequently, we believe 
that the genes encoding KCNE2-interacting proteins may also be considered as candidate 
disease-modifying genes that can be screened in a cohort of LQTS patients. 
Objectives 
In the present study, we used the C-terminal domain of KCNE2, whose encoding gene is 
frequently mutated in LQT6 (Figure 1.13), as bait to screen a pre-transformed cardiac cDNA 
library using Yeast two-hybrid (Y2H) analysis.  
We chose to focus on the C-terminal domain since many of the LQTS causative mutations have 
been found in this part of the KCNE2 gene. We foresee that this study will help us gain a better 
understanding into the role of KCNE2 in LQTS as well as provide us with novel candidate genes 
to screen for LQTS-causative mutations.  
The objectives of the study are to perform an Y2H screen and to verify the newly identified 
interactions using independent biochemical analysis, which include 3D co-localization and co-
immunoprecipitation. 
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VERIFICATION OF TRUE PROTEIN INTERACTORS
Label H9C2 cells with appropriate antibodies 
and perform fluorescence microscopy and co-
locatization analysis
Confirm co-localization with co-
immunoprecipitation analysis
IDENTIFICATION OF PUTATIVE POSITIVE INTERACTORS
NCBI-BLAST sequence inserts to identify 
positive prey clones and alocate protein 
function
Indentify plausible putative interacting 
proteins.
YEAST TWO-HYBRID ASSAY
Mate transformed bait strain (AH109) with 
Y187 yeast strain, pretransformed with 
cardiac cDNA library
Use nutritional and colourometric selection to 
identify positive prey colonies after which 
prey plasmids were rescued from yeats
EXPRESSION OF PROTEINS
Transform purified bait construct into yeast 
strain AH109
Test for autonomous reporter gene activation, 
cell toxicity and mating efficiency
INSERT FRAME AND INTEGRITY VERIFICATION
Transform the bait construct into E.coli to 
select transformed colonies
Extract and purify plasmid DNA in order to 
perform automated DNA sequencing
GENERATION OF BAIT CONSTRUCT
Design primers to amplify the C-terminus 
of KCNE2 from human genomic DNA
Amplify product and clone into pGBKT7 
shuttle vector
                                                                                            
 
 
 
 
 
Figure 2.1: Summary of methodology followed in the present study. 
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2.1 DNA EXTRACTION 
2.1.1 Bacterial plasmid purification using the Zyppy™ Plasmid Miniprep Kit 
In order to isolate the specific plasmids from successfully transformed Escherichia coli (E.coli) 
cultures, single colonies were picked from the antibiotic selection plates and inoculated in 50ml 
polypropylene tubes.  These tubes contained 10ml Luria-Bertani Broth (LB) media (Appendix I) 
as well as the appropriate antibiotic (Ampicillin or Kanamycin).  The bacterial cultures were then 
incubated at 37ºC overnight in a shaking YIH DER model LM-530 (Scilab Instrument Co., Ltd., 
TW) incubator. 
After the incubation period the cultures were centrifuged in a Beckman model TJ-6 centrifuge 
(Beckman Coulter, Scotland, UK) for 10min at 2400rpm.  The supernatant was discarded and the 
pellet resuspended in 600μl dH2O.  The Zyppy™ Plasmid Miniprep Kit (Zymo Research Corp., 
USA) was then used as per manufacturer’s instructions and the plasmid purified and eluted with 
30μl of dH2O. 
After purification, a volume of 2μl of plasmid preparation was used to assess quality and the 
concentration of the plasmid determned using a Nanodrop Spectrophotometer (Thermo 
Scientific, USA).  The remainder of the purified product was used as template for yeast 
transformation reactions (Section 2.11.2).  This kit was also used to assist in yeast plasmid 
purification (Section 2.1.3) and was found to yield higher concentrations than the GTpure™ 
Plasmid Miniprep Kit (Section 2.1.2) initially used for bacterial plasmid purification. 
 
2.1.2 Bacterial plasmid purification using the GTpure™ Plasmid Miniprep Kit 
The specific E.coli colonies containing the plasmids of interest were picked from the antibiotic 
selection plates or 100µl of the bacterial glycerol stock was inoculated in 50ml polypropylene 
tubes containing 10ml of LB media (Appendix I) as well as the appropriate antibiotic.  The 
cultures were incubated at 37ºC shaking in a YIH DER model LM-530 (Scilab Instrument Co., 
Ltd., TW) incubator at 250rpm overnight.  
The following day the cultures were centrifuged for 10 minutes at 2600rpm in a Beckman model 
TJ-6 centrifuge (Beckman Coulter, UK) and the supernatant discarded. The plasmid DNA were 
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then extracted from the pellets using the GTpure™ Plasmid Miniprep kit (Gene Tech Co., Ltd., 
HK) as indicated by the manufacturer’s instructions. 
After purification, 2µl of the plasmid preparation was used to determine the purity and 
concentration of the sample by using a Nonodrop Spectrophotometer (Thermo Scientific, USA) 
and the remainder of the product used for sequencing reactions following recommendation by 
the manufacturer.    
 
2.1.3 Yeast plasmid purification 
Plasmids of interest were isolated from yeast (Saccharomyces cerevisiae) cultures by inoculating 
100µl of the yeast glycerol stocks in 1ml of single dropout (SD) media (Appendix I) containing 
the correct dropout supplement (BD Biosciences, Clontech, USA) in 15ml polypropylene tubes.  
The cultures were placed in a shaking incubator (Scilab Instrument Co., Ltd., TW) at 30ºC 
overnight, shaking at 250rpm.  The following day, 4ml of YPDA media (Appendix I) was added 
to the overnight cultures.  The cultures were incubated in a shaking incubator at 30ºC for an 
additional four to five hours.  Subsequently the cultures were centrifuged at 3000rpm for five 
minutes in a Beckman model TJ-6 centrifuge (Beckman Coulter, UK) and the supernatant 
discarded by pouring off the liquid.   
The pellets were then resuspended in the residual supernatant and transferred to a clean 2ml 
Eppendorf tube and subsequently centrifuged at 15000rpm for 30 seconds in a bench top 
centrifuge (Labnet International Inc., USA). The supernatant was discarded and to the pellet 
200µl yeast lysis buffer (Appendix I), 200µl Phenol Chloroform Isoamyl alcohol (PCI) and 0.3g 
sterile 450-600µm glass beads (Sigma-Aldrich (Pty) Ltd., RSA) was added.  The cells were then 
vortexed for at least two minutes followed by centrifugation at 15000rpm for 10 minutes at room 
temperature in a bench top centrifuge (Labnet International Inc., USA) for phase separation.   
The top aqueous layer was then transferred to sterile 1.5ml Eppendorf tubes.  An additional lysis 
step was included by adding 100µl lysis buffer (Zyppy Plasmid Miniprep Kit, Zymo Research 
Corp., USA) to the aqueous layer as well as 350µl neutralization buffer (Zyppy Plasmid 
Miniprep Kit, Zymo Research Corp., USA) and 200µl membrane binding solution (Wizard® 
Purefection Mini Plasmid DNA purification kit, Promega Corp., USA).  The mixtures were then 
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centrifuged for 10 minutes at 15000rpm in a bench top centrifuge (Labnet International Inc., 
USA).  The aqueous layers were then transferred to the spin columns of the Wizard® Purefection 
Mini Plasmid DNA purification kit and purified as per manufacturers’ instructions (section 
2.1.4).  Following purification, DNA was eluted with 35µl of sterile water. 
 
2.1.4 DNA purification using the Wizard® SV Gel and PCR Clean-up System 
Purification of the yeast plasmid preparations (Section 2.1.3), PCR-amplified products (Section 
2.2) as well as restriction enzyme  digest clean-up experiments (Section 2.6) were performed 
using the Wizard® SV Gel and PCR Clean-up System (Promega Corp., USA) according to the 
manufacturers’ instructions.  The products were used for bacterial transformation reactions 
(Section 2.12.1) and cloning reactions (Section 2.6) respectively. 
 
2.1.5 DNA purification from agarose gels using the Wizard® SV Gel and PCR Clean-up 
System 
When performing restriction enzyme digestions, the final digested product was electrophoresed 
in a 1% agarose gel (Section 2.3.1) and viewed under short wave ultraviolet (UV) light.  If the 
band was indeed the correct size, a sterile blade was used to remove the segment of the gel that 
contained the DNA fragment of interest.  The agarose gel slice was transferred to an autoclaved 
eppendorf tube after which the DNA was purified using the Wizard® SV Gel and PCR Clean-up 
System following the manufacturer’s protocol and instructions.  
 
2.2 POLYMERASE CHAIN REACTION (PCR) 
2.2.1 Oligonucleotide primer design and synthesis 
2.2.1.1 Primers for generation of insert for Y2H cloning 
Primers used to PCR-amplify the C-terminus of KCNE2 were designed using Oligo Analyzer 
Integrated DNA Technologies software (http://eu.idtdna.com/analyzer/applications/oligoanalyzer/) 
and synthesized at the University of Cape Town DNA synthesis Laboratory (University of Cape 
Town, RSA). 
The GenBank database (http://www.ncbi.nlm.nih.gov/Entrez) mRNA sequence for KCNE2 
(NM_172201.1) (Appendix I) was used as a reference sequence for designing the forward and 
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reverse primers.   Each primer set was analysed for self-complementarities, primer-primer 
complementarities and hairpin structures.  The GC content and melting temperature 
compatibility could also be determined using this software.   
The primer sequences were finally submitted to the Basic Local Alignment Search Tool 
(BLAST) (http://www.ncbi.nlm.nih.gov/BLAST) in order to determine whether they were able 
to anneal to other genomic DNA sequences.  
To facilitate the cloning of the PCR-amplified KCNE2 amplicon into the pGBKT7 shuttle vector 
(BD Bioscience, Clontech, USA) restriction enzyme sites were incorporated into the primers.  
The forward primer was designed to contain the NdeI restriction site in the 5 prime (5’) end, 
while the reverse primer contained the EcoR1 restriction enzyme site as well as the stop codon 
(TGA).  
The sequence of the primers used for cloning the KCNE2 C-terminal encoding amplicon into 
pGBKT7 is shown in table 2.1. 
 
Table 2.1: Nucleotide sequences of primers used to amplify the C-terminal of KCNE2  
Primer Sequence Ta (ºC) 
KCNE2-FNde1 5’ - ACTGCAGAACATATG CTCAAATCCAAGAGACGG - 3’ 50 
KCNE2-REcoR1 5’ - ACTGCAGAAGAATTCCTATCAGGGGAACATTTTGAAC - 3’ 51 
Abbreviations: Ta = Annealing temperature, ˚C = Degrees Celsius.  The blue text represents a tag which facilitates 
restriction enzyme digestion, while the green and purple sequences correspond to the Nde1 and EcoR1 restrictions 
sites respectively.  The short pink sequence symbolizes the stop codon and the black text represents the sequence of 
the primer which will anneal to the DNA in the PCR amplification reaction.  
 
2.2.1.2 Primers for Y2H insert sequencing 
Vector-specific primers were designed to flank the multiple cloning sites (MCS) of pGBKT7 and 
pACT2 shuttle vectors (BD Bioscience, Clontech, USA) (Appendix II).  This was necessary in 
order to sequence the inserts cloned into these Y2H vectors.  The sequences used to generate the 
primers were acquired from the Clontech™ Matchmaker™ vector guide (www.clontech.com) 
and are shown in table 2.2. 
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Table 2.2: Primers used for sequencing inserts from Y2H cloning vectors 
Primers Sequence Ta(˚C) 
pGBKT7-F 5’- GTAATACGACTCACTATAGGGC -3’ 64 
pGBKT7-R 5’-AAACCCCTCAAGACCCGTTT-3’ 60 
pACT2-F 5’-CTATTCGATGATGAAGATACCCCACCAAACCC-3’ 68 
pACT2-R 5’-GTGAACTTGCGGGGTTTTTCAGTATCTACGA-3’ 68 
Abbreviations: Ta = Annealing temperature, ˚C = Degrees Celsius  
 
2.2.2 PCR-amplification for generation of KCNE2 C-terminus fragment 
Since the C-terminus of KCNE2 is encoded by a single exon (exon 2) of the KCNE2 gene, the 
fragment of interest was amplified from human DNA (Section 2.13.1) by means of PCR.  The 
product of this amplification was subsequently cloned into the Y2H bait vector, pGBKT7 
(Section 2.7) (Appendix II).   
For the amplification reaction, 20ng of genomic DNA was used in a final reaction volume of 
50μl.  The reaction included 150ng of each primer, forward and reverse (Table 2.1), 5x Buffer, 
10mM dNTP’s (dATP, dCTP, dTTP and dGTP) (Kapa Biosystems (Pty) Ltd., RSA) 
25mM MgCl2, 5u/μl long range Taq™ DNA polymerase (Kapa Biosystems (Pty) Ltd., RSA) as 
well as sterile distilled water to a final volume of 50µl.  The reaction was performed in a 
Mastercycler® ep PCR system (Eppendorf, GER).  The cycle parameters consisted of a 
denaturing step at 95ºC for four minutes, followed by 30 cycles of 95ºC for 30 seconds,  68°C 
for 30 seconds and 72ºC for 30 seconds after which an extension step followed for 10 minutes at 
72ºC.  The products of the PCR reaction was then visualized on a 1% agarose gel under UV light 
to verify amplification of the correct fragment (Section 2.3.1). 
 
2.2.3 Bacterial colony PCR 
The vectors used in Y2H do not support blue-white selection. Therefore, in order to identify 
bacterial colonies harbouring the recombinant plasmid constructs, bacterial colony PCRs were 
performed.  Small amounts from the individual bacterial colonies were used as DNA templates 
which were selected from the appropriate agar plates.  Vector-specific primers were used to 
amplify the desired fragments (Table 2.2).   
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The reaction was carried out in a Mastercycler® ep PCR system with a final reaction volume of 
50µl.  The reaction consisted of 150ng/µl of vector-specific forward and reverse primers 
(Table2.2), 25µl Readymix (Kapa Biosystems (Pty) Ltd., RSA) and distilled water was used to 
make up the final volume.  The thermal cycling parameters were as follows: a denaturing step at 
95ºC for eight minutes, followed by 30 cycles of 94ºC for 30 seconds, Ta (Table 2.2.) for 30 
seconds and 72ºC for one minute, followed by an elongation step at 72ºC for five minutes. 
In each of the PCR reactions described in the paragraphs above, a negative control was included 
(i.e. no DNA was included in one specific sample for each PCR reaction) to detect any 
contamination during the process.   
The final PCR products were then visualized by gel electrophoresis on a 1% agarose gel for 
verification (Section 2.3.1). 
 
2.3 GEL ELECTROPORESIS 
2.3.1 Agarose gel electrophoresis 
In the present study, agarose gel electrophoresis was used either to visualize fragments that have 
been amplified by PCR (Section 2.2), plasmid preparation integrity (Section 2.1.1), for excision 
of DNA fragments for purification after restriction digest (Section 2.1.5) or for visualization of 
identical prey-inserts identified by restriction mapping (Section 2.6.2). 
 
2.3.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  
Proteins from co-immunoprecipitation (Co-IP) reactions (Section 2.15) as well as western blot 
analyses (Section 2.16) were electrophoresed in Mini-PROTEAN® TGX™ precast 
polyacrylamide gels (Bio-Rad Laboratories (Pty) Ltd., RSA) containing 1% Sodium dodecyl 
sulphate (SDS) ranging from 4% to 15% depending on the size of the proteins (Appendix I).  
Typically 10μl - 35μl loading dye (Appendix I) was mixed with 150μg of Co-IP reaction product 
or 50μg whole cell lysate (Section 2.10.4) for western blot analysis and incubated at 95°C for 
five minutes.  Ten microlitres of molecular weight marker (Spectra™ Multicolor Broad Range 
Protein Ladder, Thermo Scientific, USA) was co-electrophoresed with the protein products.  The 
samples were loaded onto the vertical gel along with two negative controls (HA-probe and 
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protein agarose G) and electrophoresed at 100V for approximately 1 hour in 1x SDS-PAGE 
running buffer (Appendix I).  
 
2.4 AUTOMATED DNA SEQUENCING 
The bacterial cultures were grown in 10ml Luria-Bertani (LB) media (Appendix I) along with 
10μl or 20μl of the appropriate antibiotic (either 50mg/ml Ampicillin or 100mg/ml Kanamycin 
respectively) at 37ºC in a shaking incubator (Scilab Instrument Co., Ltd., TW).  Following this, 
the plasmids were extracted and purified using the Zyppy™ Plasmid Miniprep Kit (Section 
2.1.1).  The samples were diluted to a final concentration of 200ng/μl and the gene fragment 
specific primers (Table 2.1) as well as the vector-specific primers (Table 2.2) were diluted to 
1.1pmol each.  The tubes were labeled accordingly and send for automated sequencing on an 
ABI Prism™ 377 or ABI Prism™ 3100 sequencer (P.E. Biosystems, USA) at the Central DNA 
Sequencing Facility at Stellenbosch University (Central Analytical Facilities-DNA Sequencing 
Unit, Department of Genetics, University of Stellenbosch, RSA). 
 
2.5 SEQUENCE ANALYSIS 
All sequenced data was analysed using the BioEdit Sequence Alignment Editor Software system 
(Ibis Biosciences, USA) as well as the DNAman software (Lynnon Corp., USA) to verify the 
sequence integrity and identity of the fragments generated.  The generated fragments were 
compared to their reference sequences obtained from GenBank database 
(www.ncbi.nlm.nih.gov/Entrez).  
 
2.5.1 DNA sequence analysis 
DNA sequence analysis was done to verify the sequence integrity of the KCNE2 fragment 
generated by PCR amplification (Section 2.2.2) as well as to identify Y2H putative interactor 
prey clones selected during the Y2H library screening. 
The C-terminus fragment of KCNE2 generated in this study was compared to the KCNE2 
reference sequence from the GenBank database (www.ncbi.nlm.nih.gov/Entrez) to establish 
whether the sequence integrity and reading frame were maintained. The Y2H prey constructs 
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were identified by BLASTn comparison of the nucleotide sequences against the GenBank 
database (www.ncbi.nlm.nih.gov/Entrez) and the Ensembl database. (www.ensembl.org). 
 
2.5.2 Protein sequence analysis 
The DNA insert sequences identified in the Y2H screen were translated into protein in the frame 
dictated by the of the GAL4 activation domain reading frame (reading frame 1). The protein 
sequences were subsequently compared to human reference protein sequences in the Swissprot 
database using BLASTp in order to identify the protein.  
Once proteins have successfully been identified, GeneCards (http://www.genecards.org/) and 
neXtProt (http://www.nextprot.org/) were used to analyse the proteins and determine their 
location, structure and function.  
 
2.6 RESTRICTON ENZYME DIGESTION 
2.6.1 Restriction enzyme digest for cloning inserts 
In order to clone the PCR-generated (Section 2.2.2) fragment into the specific pGBKT7 bait 
vector (Appendix II) for Y2H analysis, the fragment as well as the plasmid were consecutively 
double-digested using appropriate restriction enzymes (NdeI and EcoRI).  The restriction 
enzymes as well as their corresponding buffers were provided by New England Biolabs (New 
England Biolabs® Inc., RSA).  Primers designed to amplify this insert and specific restriction 
enzyme sites which were included in the primer sequences can be seen in table 2.1.     
The PCR fragment of KCNE2 and the plasmid DNA of the shuttle vector was used as the DNA 
template for the restriction enzyme digest reactions which was prepared in a final volume of 50μl 
consisting of the following reagents: 30μl of the PCR-generated fragment or 20μl of vector 
DNA, 5μl restriction enzyme buffer, 2μl Nde1 restriction enzyme and sterile water to make up 
the final volume of 50µl.  The mixtures were incubated for two hours at 37ºC in a model 329 
stationary CO2 incubator (Former Scientific, USA).  Following the incubation period, the 
enzymes were heat inactivated at 65ºC for 5 minutes after which the samples were purified using 
the Wizard®  SV Gel and PCR Clean-up System (Promega Corp., USA) (Section 2.1.4) and 
eluted with 43μl sterile water. 
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The eluted mixtures were used as templates for the second digest reaction to which 5μl of 
enzyme buffer and 2μl EcoR1 restriction enzyme was added.  The samples were then incubated 
at 37ºC for another two hours.  The samples were subsequently heat inactivated and finally 
purified using the Wizard®  SV Gel and PCR Clean-up System (Promega Corp., USA) (Section 
2.1.4) and eluted with 30μl sterile water. 
To guarantee that the double-digested pGBKT7 vector do not anneal to itself, the vector was 
treated with Calf Intestinal Alkaline Phosphatase (CIAP) (Section 2.7.2) before being used in the 
DNA ligation (Section 2.7.3) reactions.  The final digested fragments were loaded onto a 1% 
agarose gel, electrophoresed (Section 2.3.1) and subsequently purified using the Wizard™ SV 
Gel and PCR Clean-up system (Section 2.1.5). 
 
2.6.2 Restriction mapping for yeast two-hybrid (Y2H) prey clones 
Restriction mapping was performed on Y2H prey-inserts that interacted with the pGBKT7-
KCNE2 construct.  This was carried out with the purpose of grouping identical prey plasmids 
identified by Y2H analysis.  These inserts were transformed into E.coli (Section 2.11.1) and 
ultimately the plasmids purified using the Zyppy™ Miniprep kit (Section 2.1.1).  The purified 
plasmids were digested with HaeIII restriction enzyme (New England Biolabs® Inc., RSA) in a 
final volume of 10µl digest mixture consisting of 5μl plasmid DNA, 1μl enzyme buffer, 0.2μl 
HaeIII enzyme and 3.8μl ddH2O.  The samples were then incubated at 37ºC for two hours and 
subsequently viewed on a 1.5% agarose gel (Section 2.3.1).   
The restriction pattern for each sample was analysed and compared to each other.  Samples that 
showed the same restriction digest patterns for the HaeIII digest were selected and digested with 
a second enzyme, RsaI (Promega Corp., USA), in a subsequent reaction with the same conditions 
as the previously described reaction.  This was done to verify the similarities between inserts.   
If it was found that the inserts had the same patterns for the HaeIII as well as the RsaI restriction 
enzyme digest, they were considered to be identical clones and one sample was chosen out of the 
group as a representative. 
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2.7 GENERATION OF CONSTRUCTS 
2.7.1 Generation of Y2H construct 
The pGBKT7 shuttle vector (Appendix II) was used as the bait vector into which the Y2H bait-
insert was cloned (Section 2.2).  Following automated sequence analysis (Section 2.5) to verify 
the integrity of the insert as well as the reading frame conservation of the sequence, the construct 
was transformed into the yeast strain AH109 (Section 2.11.2).  This construct was subsequently 
used to screen a Clontech MATCHMAKER pre-transformed cardiac cDNA library (BD 
Biosciences, Clontech, USA) (Section 2.13.1).  The library consisted of cardiac cDNAs which 
was cloned into pACT2 prey-vectors (Appendix II) and transformed into the yeast strain Y187. 
 
2.7.2 Alkaline phosphatase treatment of vector 
The ends of the linearised plasmids, which had been double digested with restriction enzymes 
Nde1 and EcoR1, were CIAP-treated to remove the phosphate groups and thus prevent the 
plasmid to re-anneal to itself and reform a circularized vector. 
Briefly, 30μl pGBKT7 vector DNA, 2μl CIAP (Promega Corp., USA), 10μl CIAP buffer 
(Promega Corp., USA) and 58μl of sterile water were transferred to a 1.5ml sterile Eppendorf 
tube.  The reaction mixture was incubated at 37ºC for 15 minutes followed by 15 minute 
incubation at 56ºC to inactivate the CIAP.  Following this, an extra 2μl of CIAP was added to the 
reaction after which the incubation and inactivation cycles were repeated. 
The CIAP-treated pGBKT7 vector was subsequently purified using the Wizard™ SV Gel and 
PCR Clean-up System (Promega Corp., USA) (Section 2.1.4) and used in the ligation reactions 
(Section 2.7.3).    
 
2.7.3 DNA ligation 
In order to generate the construct for Y2H analysis, DNA ligation reactions were performed.  
The ligation reaction was done using three separate dilution ratios to ensure the optimum 
conditions for the constructs to be produced (Table 2.3).     
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Table 2.3: DNA ligation reaction ratios  
 Ratios 
Reagents 1:1 1:3 1:5 
Insert DNA 1µl 3µl 5µl 
Vector DNA 1µl 1µl 1µl 
T4 DNA Ligase buffer (10x buffer) 1µl 1µl 1µl 
T4 DNA Ligase (5 Weiss units/µl) 1µl 1µl 1µl 
ddH2O 6µl 4µl 2µl 
Total volume 10µl 10µl 10µl 
The T4 DNA ligase buffer as well as the 5 Unit T4 DNA ligase reagent was supplied by Promega Corp., USA.  The 
ratio of insert DNA to vector DNA was 1:1. 
 
The ligation reactions were incubated at 4ºC for a period of 16 hours (overnight) to allow 
ligation of the insert and vector DNA to take place.  Subsequently, 5μl of each reaction was 
transformed into E.coli (DH5α bacterial strain; Appendix VI) (Section 2.12.1) and plated onto 
LB agar plates (Appendix I) containing the appropriate antibiotic.  The plates were incubated at 
37˚C in a stationary incubator in a model 329 stationary CO2 incubator (Former Scientific, USA) 
overnight.  Successful transformed colonies were subsequently identified by colony PCR 
(Section 2.2.3). 
 
2.8 BACRTERIAL STRAINS, YEAST STRAINS AND CELL LINES 
2.8.1 Bacterial Strains 
The transformation of ligation reactions (Section 2.7.3) into E.coli strain DH5α was carried out 
in order to select and purify Y2H constructs.  The transformed colonies were selected according 
to their ability to grow on antibiotic selection LB agar plates (Appendix I) and the recombined 
plasmids identified by colony PCR (Section 2.2.3).  For the selection of pGBKT7 recombinant 
plasmids, Kanamycin (100mg/ml stock) was used as the antibiotic and when selecting pACT2 
recombinant plasmids, Ampicillin (50mg/ml stock) was used. 
 
2.8.2 Yeast Strains 
After identification of the recombined KCNE2-pGBKT7 construct, the purified product was 
cloned into the AH109 yeast strain (Section 2.11.2).  The clones present in the pre-transformed 
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Clontech MATCHMAKER cDNA library (Section 2.13.1) which was used in the Y2H screen 
had been transformed into the yeast strain Y187. 
 
2.9 GENERATION OF E.coli DH5α COMPETENT CELLS 
An aliquot of 20μl of E.coli DH5α frozen (-80ºC) glycerol stock was used to inoculate 10ml of 
LB media (Appendix I) without any antibiotics in a 50ml polypropylene tube.  The tube was 
incubated at 37ºC in a shaking incubator (YIH DER model LM-530, Scilab Instrument Co., Ltd., 
TW) for 16 hours at 200rpm after which 300μl of the culture was inoculated in 2L Erlenmeyer 
flask containing 200ml of LB media (Appendix I).  These flasks were shaken on a Labcon orbital 
shaker (Labcon (Pty), Ltd., RSA) at room temperature for 16 hours at 70rpm until the culture 
reach the mid-log growth phase (OD600nm = 0.6). 
Once the culture has reached the acquired optical density, the 200ml liquid culture was 
transferred to 4 x 50ml polypropylene tubes and centrifuged for 15 minutes at 4ºC, 3000rpm in a 
Beckman model TJ-6 centrifuge (Beckman Coulter, Scotland, UK).  The supernatant was 
discarded and the pellet resuspended in 8ml of ice-cold CAP buffer (Appendix I). 
The suspension was centrifuged again in a Beckman model TJ-6 centrifuge (Beckman Coulter, 
Scotland, UK) at 4ºC, 3000rpm to re-pellet the cells.  The supernatant was removed for the 
second time and the pellet resuspended in 4ml of ice-cold CAP buffer (Appendix I).  The cells 
were transferred in volumes of 200µl into 2ml eppendorf tubes and stored at -80ºC until it was 
needed for bacterial transformation reactions (Section 2.12.1). 
 
2.10 CULTURING OF THE H9C2 CELL LINE 
2.10.1 Culture of H9C2 cells from frozen stocks 
2.10.1.1 Thawing the cells 
Frozen Rattus norvegicus (rat) H9C2 cardiac myocytes were purchased from the American Type 
Culture Collection (ATCC, USA).  The frozen stock was thawed rapidly by immersing the tube 
in a 37ºC water bath for 10 minutes.  After adequate thawing of the cells, the vile was 
immediately sterilized by spraying the outside with 70% ethanol.  
 
Stellenbosch University  http://scholar.sun.ac.za
55 
 
2.10.1.2 Removing DMSO from stocks and culturing cells 
Dimethyl sulphoxide (DMSO) is used as a cryoprotectant and added to cell media to reduce ice 
forming, thereby preventing cell death during the freezing process.  It is used in a slow-freeze 
method after which cells can be stored in liquid nitrogen.  In order to remove this toxic substance 
from the frozen stocks and to ensure viability of the cells the following method was used:  The 
thawed stock culture was added to 1ml of pre-warmed growth media (Appendix I) in a 12ml 
Greiner tube (Greiner Bio-one, GER) and mixed by moderate pipetting.  Another 5ml of growth 
media was added to the tube and the cells pelleted by centrifugation at 1000rpm for one minute 
using a Sorval® GLC-4 General Laboratory centrifuge (Separations Scientific, RSA).  The 
supernatant was removed and the pellet resuspended in an additional 5ml of growth media and 
the cells pelleted again using a Sorval® GLC-4 General Laboratory centrifuge (Separations 
Scientific, RSA).  The cell pellet was subsequently resuspended in 10ml of growth media and 
transferred into a T25 culture flask.  The flask was lightly swirled to make sure the cells were 
distributed evenly throughout the flask.  The flask was then incubated in a Farma-therosteri-cycle 
5% carbon dioxide (CO2) humidified incubator (Farma International, USA) at 37ºC.     
 
2.10.2 Splitting cell cultures  
When cells were needed for various experiments, they were cultured at 37ºC in a Farma-
therosteri-cycle 5% CO2 humidified incubator (Farma International, USA) and split every two to 
four days depending on when they reached approximately 80-90% confluency.  Before splitting 
the cells, the growth media was removed with a sterile pipette and the cells washed with trypsin 
to remove dead cells and/or cell debris.  After this wash step, the trypsin was removed and an 
additional volume of trypsin (Table 2.4) was added to facilitate detachment of the cells from the 
growth surface.  The flask was then incubated at room temperature for approximately 10-15 
minutes after which a volume of growth media was added (Table 2.4) in which the detached cells 
were resuspended.   
The suspension was transferred to a 12ml Greiner tube (Greiner Bio-one, GER) and centrifuged 
at 1000rpm for 30 seconds using a Sorval® GLC-4 General Laboratory centrifuge (Separations 
Scientific, RSA) to create a pellet.  The pellet was resuspended in 4ml of growth media.  
Depending on the confluency of the cells before the splitting process began, the size of the flask 
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as wells as the number of flasks into which the cells will be split, an estimated volume of 
resuspended cells were placed into flasks containing fresh sterile growth media. 
 
Table 2.4: Standard Trypsin volumes for detachment of cells from growth surface 
Flask size Volume of Trypsin Volume of media 
Small (25cm2) 1ml 4ml 
Medium (75cm2) 3ml 4ml 
Large (150cm2) 5ml 4ml 
Abbreviations: cm2, square centimetre; ml, millilitre  
 
2.10.3 Differentiation of H9C2 cells 
In order to facilitate differentiation of cardiomyocytes into myotubes, the growth medium was 
removed from the flasks or 6-well plates after 24 hours of incubation at 37ºC in a Farma-
therosteri-cycle 5% CO2 humidified incubator (Farma International, USA).  The cells were 
washed with a small volume of differentiation medium (Appendix I) after which the appropriate 
volume of differentiation medium was added to each container (3ml to each well of the 6-well 
plates or 23ml to a large 150cm2 culture flasks).  The cells were then incubated for 10-14 days at 
37ºC in a Farma-therosteri-cycle 5% CO2 humidified incubator (Farma International, USA).  On 
the fifth day, the cells were washed again and new differentiation media was added and on day 
10-14, the cells were viewed on an Olympus IX 81 motorised inverted microscope (Olympus, 
GER) to confirm differentiation of the cells.  The cells were later used in 3D co-localization 
assays (Section 2.17). 
 
2.11 TRANSFORMATION OF PLASMIDS INTO PROKARYOTIC CELLS 
2.11.1 Bacterial transformations 
Prior to transforming plasmids of interest into the bacteria, tubes containing 200μl aliquots of 
E.coli DH5α cells (Section 2.9) were removed from the -80ºC freezer and thawed on ice for 20 
minutes.  Once the cells had thawed, 5μl of plasmid preparation (Section 2.1.1) or 5μl of ligation 
reaction (Section 2.7.3) was added to the tube and the mixture was incubated on ice for an 
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additional 20 minutes.  Following this incubation step, the samples were heat-shocked for 
exactly 45 seconds at 42ºC in a heating block (Dry Block Heater HB2) (Hägar designs, RSA).  
The samples were removed and incubated at room temperature for two minutes.  Following this, 
1ml of LB media (Appendix I) was added to each sample and incubated at 37ºC for one to two 
hours shaking at 200rpm in a YIH DER model LM-530 (Scilab Instrument Co., Ltd., TW) 
shaking incubator.   
The samples were subsequently centrifuged for four minutes in a bench top centrifuge (Labnet 
International Inc., USA).  Next, 200μl of the supernatant was drawn off with a pipette and the 
rest discarded.  The 200μl was used to resuspend the pellet and plate the sample on LB agar 
plates (Appendix I) containing the appropriate antibiotic.  The plates were inverted and incubated 
for 16 hours at 37ºC in a model 329 stationary CO2 incubator (Former Scientific, USA). 
 
2.11.2 Yeast transformations 
In order to perform yeast transformations, 200μl aliquots of the yeast strain to be transformed 
(AH109 or Y187) were plated onto YPDA agar plates (Appendix I).  These were inverted and 
incubated at 30ºC for three to four days in a Sanyo MIR262 stationary ventilated incubator 
(Sanyo Electronic Co., Ltd., JP).  Once the yeast has grown enough, a volume representing 20-
50μl of yeast cells were picked from the plate and resuspended in 1ml of sterile Millipore water 
in a 2ml Eppendorf tube.  The cells were pelleted by centrifugation for 30 seconds at 2000g in an 
Eppendorf model 5417C centrifuge (Eppendorf International, GER).  The supernatant was 
discarded and the pellet resuspended in 1ml of Lithium Acetate (Appendix I) and incubated at 
30ºC for five minutes in a stationary ventilated incubator (Sanyo Electronic Co., Ltd., JP).  Again 
the cells were pelleted by centrifugation at 2000g for 30 seconds in an Eppendorf model 5417C 
centrifuge (Eppendorf International, GER) and all the Lithium Acetate removed with a pipette.  
Following this, five reagents were rapidly added to the pellet in the following order: 240μl 50% 
Polyethylene glycol (PEG), 36μl 1M Lithium Acetate, 25μl of 2mg/ml heat-denatured and snap-
cooled herring sperm DNA (Promega Corp., USA), 10-20μl E.coli plasmid preparation (Section 
2.1.1) and 30-40μl sterile Millipore water.  The sample was then generously mixed by vortexing 
for at least one minute, using a Snijders model 34524 press-to-mix vortex (Snijders Scientific, 
NL).  The sample was incubated at 42ºC for 25 minutes in a dry heating block (Dry Block 
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Heater, HB2) (Hägar designs, RSA).  After incubation, the cells were pelleted again by 
centrifuging the tubes for 30 seconds at 2000rpm in an Eppendorf model 5417C centrifuge 
(Eppendorf International, GER).  The supernatant was completely removed with a pipette and 
the pellet resuspended in 200μl of sterile Millipore water.  The suspension was plated onto the 
appropriate selection plates (Appendix I), inverted and incubated at 30ºC for two to five days in a 
Sanyo MIR262 stationary ventilated incubator (Sanyo Electronic Co., Ltd., JP). 
 
2.12 ASSESMENT OF Y2H CONSTRUCTS 
2.12.1 Phenotypic assessment of yeast strains 
Both yeast strains used in the Y2H analysis (AH109 and Y187) were assessed based on their 
phenotype, prior to transformations being performed.  The strains were both plated onto agar 
plates lacking individual essential amino acids (Appendix I), i.e., SD-Ade, SD-Trp, SD-His, SD-Leu 
and SD-Ura.  Yeast cells that have not yet been transformed and were able to grow on SD-Ura and 
unable to grow on SD-Ade, SD-Trp, SD-His and SD-Leu plates were used for transformations and 
subsequently Y2H analysis.   
The bait construct was transformed into AH109 (Section 2.11.2) and streaked out onto each of 
the respective plates SD-Ade, SD-Trp, SD-His, SD-Leu and SD-Ura.  The reason for this test was to 
ensure that the transformed AH109 strain was not able to activate transcription of reporter genes 
automatically.  The yeast strain AH109 containing the successfully transformed bait construct 
should be able to grow only on SD-Trp and SD-Ura agar plates, while the Y187 yeast strain 
containing the prey construct should only be able to grow on SD-Leu and SD-Ura plates. 
 
2.12.2 Toxicity test of transformed cells 
In order to continue with the Y2H library mating (Section 2.13.4), it was essential to test whether 
the bait-construct had a toxic effect on the AH109 yeast host strain.  This was done by generating 
a linearised growth curve of AH109 transformed with the KCNE2-pGBKT7 bait construct as 
well as the AH109 transformed with an intact, non-recombinant pGBKT7 vector.  The cultures 
were set up simultaneously under identical experimental conditions which were as follows: each 
of the strains was grown in culture until it reached the stationary phase.  This was done by 
placing the yeast in SD-Trp media (Appendix I) in 50ml polypropylene tubes followed by 
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incubation at 30ºC in a YIH DER model LM-530 (Scilab Instrument Co., Ltd., TW) shaking 
incubator.  A 1:10 dilution of each sample was made in SD-Trp media and incubated for a further 
24 hours in a 200ml Erlenmeyer flask at 30ºC in a YIH DER model LM-530 (Scilab Instrument 
Co., Ltd., TW) incubator shaking at 200rpm.  During this incubation period, 1ml aliquots were 
taken every two hours over a period of eight hours and the optical density (OD) measured at 
600nm.  A reading at the 24 hour time point was also taken.  Following these measurements, a 
linearised growth curve was set up using the log values of these OD measurements over the time 
periods set out.  The slopes of the graphs were used to compare the difference in growth rate 
between these two transformed AH109 strains.   
 
2.12.3 Mating efficiency testing 
Preliminary yeast matings were performed in small scale in order to determine what affect the 
bait construct had on the mating efficiency of the AH109 yeast strain.  In order to do this, AH109 
transformed with the pGBKT7-KCNE2 construct was mated with the prey host strain, Y187 
transformed with a non-recombinant prey vector, pACT2 or the control vector pTD1.1 (BD 
Biosciences, Clontech, USA).  Control matings was also performed which included AH109 
transformed with non-recombinant pGBKT7 or the control vector pGBKT-53 (BD Biosciences, 
Clontech, USA) to be mated with the prey host strain, Y187 transformed with non-recombinant 
prey vector pACT2 or the control vector, pTD1.1.    
 
Table 2.5: Different nutritional selection plates for the yeast strains AH109 and Y187 
 Nutritional Selection plates 
Yeast strains SD-Trp SD-Leu 
AH109 pGBKT7-KCNE2    
AH109 pGBKT7    
AH109 pGBKT-53    
Y187 pACT2    
Y187 pTD1.1    
Abbreviations: SD, single dropout; -Trp, without Tryptophan; -Leu, without Leucine. 
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All the strains used in the mating efficiency testing were plated onto their appropriate selection 
plates (Table 2.5) and incubated at 30ºC for two to five days inverted in a Sanyo MIR262 
stationary ventilated incubator (Sanyo Electronic Co., Ltd., JP). 
After the two to five day incubation period, a single colony was picked from each plate and used 
in the mating efficiency experiment.  The matings were performed in 1ml YPDA media 
(Appendix I) which was placed in a 2ml Eppendorf tube and subsequently incubated at 30ºC in a 
YIH DER model LM-530 (Scilab Instrument Co., Ltd., TW) incubator shaking at 200rpm. 
Following a 16 hour incubation period, serial dilutions (1:10, 1:100, 1:1000 and 1:10 000) of the 
mating cultures were plated onto SD-Trp, SD-Leu and SD-Trp-Leu agar plates and were incubated at 
30ºC for four to five days inverted in a Sanyo MIR262 stationary ventilated incubator (Sanyo 
Electronic Co., Ltd., JP).  Following this, the colonies on each plate were counted and the mating 
efficiency calculated (Appendix III). 
 
2.13 Y2H ANALYSIS 
Briefly, the Y2H screening system is one of the most common molecular techniques used to 
identify protein-protein interactions (Berggård et al. 2007).  The advantages of using Y2H are 
that the system is fairly easy to use, little optimization is needed and can be completed within a 
reasonable time frame and the system is reasonably priced.  The Y2H analysis also allows the 
identification of low affinity interactions and provides simultaneous protein identification and 
gene cloning (Berggård et al. 2007). 
The yeast transcription factor (Gal4) is comprised of two domains; the GAL4 DNA-binding 
domain (GAL4-BD) and the GAL4 activation domain (GAL4-AD) that facilitates transcriptional 
activation (Figure 1.13).  The bait protein (in this study the C-terminal of KCNE2) is expressed 
as a fusion protein along with the GAL4-BD and the prey proteins are expressed as fusion 
proteins with GAL4-AD (Figure 2.2).  If a positive interaction takes place between the bait and 
prey protein, the GAL4-BD and GAL4-AD are brought together and ultimately initiates 
transcriptional activation of the reporter genes (Chapter 2). 
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Figure 2.2: An illustration of a Yeast two-hybrid system.  The yeast transcription factor (Gal4) is comprised of 
two domains; the GAL4 DNA-binding domain (GAL4-BD) and the GAL4 activation domain (GAL4-AD).  In the 
Y2H system two plasmids are constructed; one encoding the bait protein fused to the GAL4-BD and the other 
encoding the prey protein fused with the GAL4-AD.  With positive interaction between the bait and prey proteins, 
transcription is activated and the reporter gene/s are activated.  Adapted from:  http://www.scq.ubc.ca/the-yeast-two-
hybrid-assay-an-exercise-in-experimental-eloquence/ 
 
2.13.1 Cardiac cDNA library  
In order to carry out the Y2H library assay, a pre-transformed Clontech MATCHMAKER human 
cardiac cDNA library (BD Bioscience, Clontech, USA) was used.  This consisted of the 
S.cerevisiae Y187 yeast strain transformed with a cardiac cDNA library in the pACT2 cloning 
vector. 
This library was constructed from a pool of normal, whole hearts of 3 Caucasian males between 
the ages of 28 and 47 years.  The library was XhoI-(dT)15 primed and it was estimated to contain 
approximately 3.5x106 independent clones which were inserted into the pACT2 vector at 
locations between the XhoI and EcoRI sites.  The ranges of insert sizes were between 0.4 and 
4.0kb with the average fragment for this library being approximately 2.0kb in size.    
 
2.13.2 Establishment of bait culture 
After the successful transformation of the bait vector (pGBKT7-KCNE2) into AH109, four 
single colonies were picked from the selection plate and inoculated into four separate 500ml 
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Erlenmeyer flasks, each containing 50ml of SD-Trp liquid media (Appendix I).  The flasks were 
incubated in a shaking YIH DER model LM-530 (Scilab Instrument Co., Ltd., TW) incubator 
shaking at 30ºC overnight.  The reason for generating four bait cultures was to facilitate the 
pooling of the initial cultures which will allow the generation of a final bait culture of at least 
1x1010, i.e. 100-fold excess of bait to prey, to ensure high mating efficiency.  Following 
overnight incubation, the four initial bait cultures were transferred to four separate 50ml 
polypropylene tubes and the cells pelleted by centrifugation at 3000rpm for 10 minutes in a 
Beckman model TJ-6 centrifuge (Beckman Coulter, Scotland, UK).   
The supernatants were discarded and the pellets resuspended together in 50ml SD-Trp media.  
Subsequently the suspension was transferred to a single 500ml Erlenmeyer flask and the pooled 
culture was incubated for 16 hours at 30ºC shaking at 200rpm in a YIH DER model LM-530 
(Scilab Instrument Co., Ltd., TW) incubator.  After incubation, the titre of the bait culture was 
determined by measuring the OD of a 1ml aliquot of the bait culture at 600nm.  The titre was 
confirmed by means of haemocytometer cell count (Section 214.3). 
The pooled bait culture was centrifuged at room temperature at 30ºC for 10 minutes in a 
Beckman model TJ-6 centrifuge (Beckman Coulter, Scotland, UK) to pellet the cells, after which 
the supernatant was removed and the cells resuspended in the residual SD-Trp media.  This 
volume was used to make 10μl aliquots of culture to be used in subsequent control mating 
experiments.  
  
2.13.3 Haemocytometric cell count  
In order to verify the titre of the bait culture that will be used in the library mating experiment, a 
Neubauer Haemocytometer (Figure 2.3) (Superior, GER) was used to count the cells.  This was 
done by placing the glass coverslip over the counting surface of the Haemocytometer and 
pipetting 10μl of the cell culture into the filling notch in counting chamber (Figure 2.3).  The 
chamber filled by means of capillary action. 
The chamber was placed on the platform of a microscope (Nikon TMS, Nikon Instruments Inc., 
USA) and the cells view under the lowest magnification.  The cells that were in the correct areas 
of the Haemocytometer were counted and used in a formula to calculate the number of cells per 
microliter. The calculation specifications are shown in Appendix III. 
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Figure 2.3:  Representation of a Haemocytometric counting chamber.  Neubauer Haemocytometer side view, 
top view and enlarged view of counting grid.  The Haemocytometer consists of a thick glass slide with two counting 
chambers which are each divided into 9 1mm squares.  The grid on the surface of the counting chamber is engraved.  
Figure taken from: http://www.swtafe.vic.edu.au/toolbox/lab_ops/laboratory/studynotes/SNHaemo.htm 
 
2.13.4 Library mating 
To perform library mating experiments, a 1ml aliquot of the pre-transformed cardiac cDNA 
library (BD Bioscience, Clontech, USA) was removed from the -80ºC freezer and thawed at 
room temperature.  The library sample was vortexed using a Snijders model 34524 press-to-mix 
vortex (Snijders Scientific, NL).  A 10μl aliquot was pipetted into a sterile 1.5ml sterile micro-
centrifuge tube for library titering (Section 2.13.5).  
The pellet containing the AH109 pGKKT7-KCNE2 construct (Section 2.13.2) was resuspended 
in 45ml of 2x YPDA media (Appendix I) supplemented with 10μg/ml Kanamycin (Kan) in a 2L 
Erlenmeyer flasks.  The remaining 990μl of the aliquoted library culture was added to the Flask 
This  mating culture was incubated overnight at 30ºC, while shaking at 200rpm in a YIH DER 
model LM-530 shaking incubator (Scilab Instrument Co., Ltd., TW).  After the incubation 
period, the mating culture was transferred into a single sterile 50ml polypropylene centrifuge 
tube and the cells pelleted by centrifugation at 3000rpm for five minutes in a Multex centrifuge 
(MSE Instruments, UK) after which the supernatant was discarded.  The flask in which the 
library mating was performed was rinsed twice with 40ml of 2x YPDA media containing 
10μg/ml Kan and used to resuspend the pellet.  After resuspending the pellet, the cells were re-
pelleted by centrifugation for 10 minutes at 3000rpm (Multex centrifuge, MSE Instruments, 
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UK).  After the final centrifugation step, the supernatant was removed and the pellet resuspended 
in 15ml of 0.5x YPDA media containing 10μg/ml Kan (Appendix I). 
In order to determine the bait:library mating efficiency (Section 2.13.5), a serial dilution (1:1, 
1:100, 1:1000, 1:10 000) of this cell suspension was made and 100μl of each dilution 
subsequently plated onto SD-Leu , SD-Trp and SD –Leu-Trp agar plates.  Two-hundred and fifty 
microlitres of the remaining mating culture was plated onto each of 60 140mm Triple Dropout 
(TDO) agar plates (agar plates lacking tryptophan, leucine and histidine) (Appendix I).  The 
TDO plates were subsequently incubated inverted, in a Sanyo MIR262 stationary incubator at 
30°C for three weeks. 
 
2.13.5 Library titre and Library mating efficiency 
The serial dilution of the mating cultures described in section 2.13.4 were plated onto SD-Leu , 
SD-Trp and SD-Leu-Trp 90mm agar plates (Appendix I) and incubated upside down at 30°C for four 
days in a Sanyo MIR262 stationary ventilated incubator (Sanyo Electronic Co., Ltd., JP).  
Subsequently the colonies were counted in order to perform the calculations necessary to 
establish the mating efficiency of the library and the number of library plasmids screened 
(Appendix II). 
 
2.13.6 Activation detection of nutritional reporter genes 
2.13.6.1 Selection of transformed yeast colonies 
The yeast strain transformed with the bait construct pGBKT7-KCNE2 (Section 2.11.2) was 
plated onto SD-Trp agar plates and incubated for four days at 30°C in a Sanyo MIR262 stationary 
ventilated incubator (Sanyo Electronic Co., Ltd., JP).  Following the incubation period, 
transformant colonies were picked and used in small and large scale bait cultures (Section 
2.13.2) as well as interaction specificity tests (Section 2.13.9). 
 
2.13.6.2 Selection of diploid yeast colonies containing putative interactor peptides 
Diploid colonies, (the yeast colonies containing the bait- and prey-fusion peptides), were 
identified by plating the yeast colonies firstly onto TDO and then quadruple dropout (QDO) 
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plates (Appendix I).  The yeast cells that were able to grow on the TDO plates signified the 
transcriptional activation of the HIS3 nutritional reporter gene, while growth on the QDO plates 
suggested transcriptional activation of the HIS3 as well as the ADE2 nutritional reporter genes.  
For further verification of HIS3 reporter gene activation, 3-Amino-1, 2, 4-triazole (3-AT) was 
added to QDO plates (Appendix I).  This is a heterocyclic organic compound which acts as a 
competitive inhibitor of the product of the HIS3 gene, which is an enzyme catalysing the sixth 
step of histidine production.  Thus, by adding 3-AT to the QDO selection plates, cultures which 
are dependent on plasmids containing the HIS3 gene to produce histidine, would have to produce 
higher levels of histidine in order for them to survive.  The activation of these reporter genes are 
evidence of the bait and prey peptides interacting within the diploid colonies.  Nutritional 
selection was performed as follows: 
The library mating culture (Section 2.13.4) was plated onto 140mm TDO agar plates (Appendix 
I) and incubated at 30°C inverted for three weeks in a Sanyo MIR262 stationary ventilated 
incubator (Sanyo Electronic Co., Ltd., JP).  The growth of the colonies were examined every 
seventh day and colonies with a growth diameter of 2mm and more were selected and plated 
onto QDO agar plates (Appendix I).  These plates were then incubated in a Sanyo MIR262 
stationary ventilated incubator (Sanyo Electronic Co., Ltd., JP) at 30°C for four days.  Following 
the incubation period, the growing colonies were judged on their ability to activate the necessary 
nutritional reporter genes and streaked onto fresh QDO agar plates containing 3-AT (Appendix I) 
and incubated for a further four days at 30°C in a Sanyo MIR262 stationary ventilated incubator 
(Sanyo Electronic Co., Ltd., JP).  These plates were then used for the x-α-galactosidase assay 
(Section 2.13.7) which assessed the activation of the MEL1 reporter gene. 
 
2.13.7 Activation detection of colourimetric reporter genes 
2.13.7.1 X-α-galactosidase assay 
The x-α-galactosidase assays were performed in order to test the activation of the MEL1 reporter 
gene by the specific interactions between the bait and prey peptides (Section 2.13.6.2).  This 
assay was performed as follows:  Diploid yeast colonies (which could activate the HIS3 and 
ADE2 genes) identified through methods in section 2.13.6.3 were replicated onto Hybond N+ 
nylon membranes and placed colony side up onto QDO plates containing 20mg/ml x-α-
Stellenbosch University  http://scholar.sun.ac.za
66 
 
galactosidase solution (BD Bioscience, Clontech, USA).  The plates were placed in a Sanyo 
MIR262 stationary ventilated incubator (Sanyo Electronic Co., Ltd., JP) for two days at 30°C.  
Following the incubation period, the intensity of the blue colour produced by the colonies that 
activated the MEL1 reporter gene was analysed.    
 
2.13.8 Rescuing prey plasmids from diploid colonies  
In order to identify putative proteins interactors detected through the Y2H screen, the prey 
plasmids needed to be isolated from the diploid yeast colonies.  The plasmid DNA was extracted 
from the diploid yeast cells as described in section 2.1.3 after which it was transformed into 
E.coli DH5α bacterial cells as discussed in section (2.11.1).  The transformed cells were plated 
onto LB agar plates containing 50mg/ml Ampicillin (Appendix I), only allowing growth of 
transformed cells containing the prey constructs.  These prey constructs were subsequently 
isolated using the method described in section 2.1.1.  The purified constructs were then 
transformed into the yeast strain Y187 (Section 2.11.2) in order to be used in the interaction 
specificity tests (Section 2.13.9). 
 
2.13.9 Interaction specificity test 
Interaction specificity tests along with nutritional (Section 2.13.6) and colourimetric (Section 
2.13.7) reporter gene assays were necessary to establish whether or not the interactions between 
the pGBKT7-KCNE2 construct and the putative prey interactors identified in the Y2H screen 
were specific.  The Y187 colonies expressing the specific prey plasmids were individually mated 
with the yeast strain AH109 transformed with pGBKT7-KCNE2 bait construct, AH109 
transformed with non-recombinant pGBKT7, AH109 transformed with the pGBKT7-53 control 
bait-plasmid encoding murine p53 (BD Bioscience, Clontech, USA) and AH109 transformed 
with pGBKT7-WFS1.   
The protein encoded by WFS1 is a neuronal-specific transmembrane protein which shows 
highest expression in the brain and is localized to the endoplasmic reticulum, thus no interaction 
with KCNE2 is expected.   
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The diploid colonies were selected and streaked onto TDO and QTO selection plates (Appendix 
I) to test their ability to activate the specific reporter genes (Section 2.13.6.2), thus establishing 
whether the prey-peptides were able to interact with the heterologous baits as well as with the 
AH109 pGBKT7-KCNE2 bait construct.  Prey peptides that only interacted with the AH109 
pGBKT7-KCNE2 bait construct were identified as specific putative interactors.  Inserts of these 
colonies were selected for nucleotide sequencing (Section 2.4) and their sequences subsequently 
analysed (Section 2.5) in order to determine their identities. 
 
2.14 CO-IMMUNOPRECIPITATION (Co-IP) PREPARATION  
2.14.1 Hypoxia treatment of differentiated H9C2 cardiomyocytes 
To create hypoxic conditions, medium tissue culture flasks with 70%–80% confluent 
differentiated H9C2 cells were used.  The culture medium was removed from the flasks and 
replaced with 18ml Esuni buffer (Appendix I).  The flasks were placed in the hypoxia chamber 
along with one Petri dish filled with sterile water to provide adequate humidification of the 
cultures.  A hypoxic environment was created by removing all or most of the oxygen (O2) from 
the system.  This was achieved by flushing the system with a 1% O2 gas mixture at a flow rate of 
20L/minute for approximately four minutes.  The chamber was then placed in a tissue culture 
incubator with 2% O2 and 5% CO2 at 37 °C for two hours.  Following the incubation period, the 
cells were lysed as described in section 2.14.2. 
 
2.14.2 Cell lysis  
After the differentiation of H9C2 cardiomyocytes in large tissue culture flasks or medium tissue 
culture flasks for Hypoxia treatment (section 2.14.1) for approximately 14 days (Section 2.10.3), 
the cells needed to be lysed in order to be used for subsequent co-immunoprecipitation (Section 
2.15) and western blot (Section 2.16) analysis.  Lysis of cells was achieved as follows:  The 
growth media was removed and 5ml of trypsin was added to the flask.  The flask was incubated 
at 37ºC for 10-15 minutes to facilitate the detachment of the cells after which a cell scraper was 
used to scrape the remaining cells off from the growth surface.  The detached cells were 
transferred to a 50ml polypropylene tube to which a volume of 30ml of growth media was added 
to deactivate the trypsin.  The tubes were centrifuged at 4ºC for three minutes at 2500rpm in a 
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Beckman model TJ-6 centrifuge (Beckman Coulter, Scotland, UK).  The supernatant was 
discarded and the pellet resuspended in 1ml of PBS (Appendix I) and the suspension transferred 
to 2ml eppendorf tubes.  The cells were re-pelleted at 9000rpm for two minutes and the PBS 
removed with a pipette.  Lysis buffer was prepared (Appendix I) and 300µl used to resuspend the 
pellet.  The mixture was placed on ice for at least 15 minutes after which one scoop, 
approximately 0.5ml, of ZROB05 Ceria Zirconium Oxide beads (0.5mm diameter) (Next 
Advance Inc., USA) was added to the suspension and placed in a Bullet Blender® (Gentaur, UK) 
for one minute at speed four.  The blending step was repeated three times with five minute 
waiting periods in between.  Centrifugation at 9000rpm followed in a bench top centrifuge 
(Labnet International Inc., USA) for two minutes after which the supernatant was transferred to 
fresh 1.5ml eppendorf tubes and stored at -80ºC until required.   
 
2.14.3 Bradford protein concentration determination 
Before storage of samples prepared in section 2.14.2, 1µl of each lysed sample was aliquoted and 
used to perform a Bradford assay in order to assess the protein concentration.  This was done as 
follows: 
In order to calculate the standard curve, 10µl of serial diluted bovine serum albumin (BSA) 
ranging from 0-1000µg/µl was loaded into the wells of a luminometer plate together with1µl of 
the lysate samples in duplicate.  Two hundred microlitres of Bradford reagent was added to all of 
the standard as well as the lysate samples.  The plates were read on a Synergy HT luminometer 
(BioTek Instruments Inc., USA) and were used to determine the protein concentration of each 
well.  The KC4™ v 3.4 program (BioTek Instruments Inc., USA) was used to calculate and set 
up the standard curve, as well as each sample’s protein concentration at an absorbance of 595nm. 
 
2.15 CO-IMMUNOPRECIPITATION (CO-IP) 
Following sections 2.14, the lysates were thawed on ice and pre-cleared by adding 30µl Protein 
G agarose beads to each sample and incubating it at 4ºC on a rotating wheel for 30 minutes.  
Following incubation, the samples were centrifuged at 9000rpm for 30 seconds in a bench top 
centrifuge (Labnet International Inc., USA) and the supernatant transferred to fresh 1.5ml 
eppendorf tubes.  One microgram of the appropriate primary antibody was added to each lysate 
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samples and the volume made up to 100µl by adding lysis buffer containing protease inhibitors 
and phenylmethylsulfonyl fluoride (PMSF) (Appendix I).  This mixture was incubated overnight 
at 4ºC on a rotating wheel. 
The following morning, 60µl of Protein G agarose was added to each sample after which an 
incubation period of one hour followed at 4ºC rotating.  Afterwards, the beads were collected by 
centrifugation at 9000rpm for 30 seconds in a bench top centrifuge (Labnet International Inc., 
USA).  The beads were washed four times with ice cold prepared lysis buffer (Appendix I) by 
mixing it and collecting it again by means of centrifugation at 9000rpm for 30 seconds in a 
bench top centrifuge (Labnet International Inc., USA).   
After completion of all the wash steps, 35µl of SDS loading dye (Appendix I) was added to each 
sample and denatured at 95ºC for five minutes after which the beads were pelleted again and the 
supernatant loaded onto SDS-PAGE gel (Section 2.3.2).  Co-immunoprecipitation (Co-IP) 
analysis was performed in order to verify the interactions of the putative positive prey interactors 
with the C-terminal of KCNE2 as identified by the Y2H experiments (Section 2.13). 
 
2.16 WESTERN BLOTTING 
2.16.1 Membrane blocking 
Following SDS-PAGE (Section 2.3.2), the proteins were transferred to a membrane using the 
iBlot® Dry Blotting system (Invitrogen, RSA).   
After complete transfer of the proteins onto the membrane, the membranes were removed from 
the transfer apparatus and washed in TBST for approximately two minutes.  Afterwards, the 
membrane was placed in 5% fat free powder milk (Weigh-less) supplemented with 0.01% 
Tween-20 to ensure the blockage of all not specific binding sites.  The membrane was incubated 
at room temperature for one hour shaking on a Stuart® orbital shaker SSL1(Barloworld 
Scientific Ltd., UK).   
 
2.16.2 Addition of primary antibody 
After blocking of the membranes (Section 2.15.1), the membranes were rinsed with TBST and 
the primary antibodies diluted in 5% fat free powder milk supplemented with 0.01% Tween-20 
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(Table 2.6).  The membranes were then placed in a container along with the appropriate primary 
antibody and incubated overnight shaking at 4°C on an Orbit 300 shaker (Labnet International 
Inc., USA). 
 
2.16.3 Addition of secondary antibody 
Following section 2.16.2, the membranes were washed in TBST (Appendix I) for approximately 
15 minutes after which the membranes were placed in 5% fat free powder milk supplemented 
with 0.01% Tween-20 containing the appropriate horseradish peroxidase (HRP) conjugated 
secondary antibodies (Santa Cruz Biotechnology Inc., USA) (Table 2.6).  The membranes were 
placed on a shaker for one hour shaking at room temperature on a Stuart® orbital shaker 
SSL1(Barloworld Scientific Ltd., UK).  Subsequently, the membranes were rinsed twice in 
TBST and then washed for at least 30 minutes in TBST (Appendix I). 
 
Table 2.6: List of primary and secondary antibodies and their optimized concentrations 
used in Co-immunoprecipitation as well as Western blot assays 
Antigen Primary antibody  
Optimum 
ratio 
Secondary antibody  Optimum ratio 
KCNE2 KCNE2* 1:200 Donkey anti-rabbit* 1:2000 
CRYAB CRYAB†  1:1000 Donkey anti-mouse* 1:2000 
FLNC Filamin 2* 1:1000 Donkey anti-goat* 1:2000 
VDAC1 VDAC1†  1:200 Donkey anti-mouse* 1:2000 
Manufacturer: †, Abcam, Biocom Biotech, RSA; *, Santa Cruz Biotechnology Inc., USA.  
 
 
2.16.4 Chemiluminescent visualization of membrane proteins 
Following sections 2.16.1-2.16.3, the membranes were taken to a dark room where the two 
substrate components of the SuperSignal® West Pico Chemiluminescent Substrate kit (Thermo 
Scientific, USA), SuperSignal West Pico Luminol/Enhancer solution and the SuperSignal West 
Pico Stable Peroxide solution, were mixed in a ratio of 1:1 and used to label the membranes for 
five minutes.  After removing the excess chemiluminescent reagent, the membranes were placed 
in an autoradiography cassette and covered with a transparent plastic sheet after which they were 
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exposed to CL-Xposure™ autoradiography film (Thermo Scientific, USA).  A glow-in-the-dark 
sticker was placed on the right hand corner next to the membranes for orientation purposes.   
The exposure time varied between 10 seconds and three minutes, depending on the strength of 
the signal.  Following adequate exposure, the film was developed in a Hyperprocessor™ 
automatic autoradiography film processor (Amersham Pharmacia Biotech UK Ltd., UK) and the 
protein bands visualized.  
 
2.17 THREE-DIMENSIONAL CO-LOCALIZATION 
The co-localization assay was used in order to assess the protein-protein interactions in a 
physical cellular environment.  The bait protein (KCNE2) as well as the prey proteins of interest 
were expressed in H9C2 rat cardiomyocytes and labeled with appropriate primary and secondary 
antibodies (Section 2.16.2 and 2.16.3).  Fluorescence microscopy followed using the Zeiss LSM 
510 Meta confocal microscope housed at the Department of Anatomy imaging facility 
(University of Cape Town, RSA).  The images acquired were processed for co-localization.  The 
protein antibodies are indicated in Table 2.7. 
 
2.17.1 Three-dimensional co-localization assay 
Rat H9C2 cardiomyocytes were detached from the growth surface of flasks (Section 2.10.2 and 
Table 2.4) and counted by means of a Haemocytometric cell counting chamber (Section 2.13.3) 
to establish seeding of 10000 cells per well of a 6-well plate.  Each of the 6-well chambers 
contained 3ml of growth media (Appendix I) and a glass cover slip (Lasec, RSA).  After 24 
hours, the growth media was removed and differentiation media (Appendix I) was added to all 
the wells (Section 2.10.3) and left to differentiate for approximately 14 days. 
 
Subsequently the media was removed and the cells briefly rinsed with PBS (Appendix I).  The 
cells were fixed for five minutes at room temperature in 4% Paraformaldehyde (Appendix I) and 
then washed in PBS three times for 10 minutes.  The cells were then incubated in 1% BSA for 
one hour at room temperature.  The 1% BSA solution acts as the blocking solution to ensure 
blockage of all non-specific binding sites.  Following the incubation period, the cells were 
incubated with the appropriate pair of primary antibodies (Table 2.7) diluted in 1% BSA 
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(Blocking solution).  The slides were then transferred to a sealed container and incubated at 4ºC 
overnight. 
Table 2.7: List of primary and secondary antibodies and their optimized concentrations 
used in co-localization assays 
Antigen Primary antibody  
Optimum 
ratio 
Secondary antibody 
Optimum 
ratio 
KCNE2 KCNE2* 1:50 Donkey anti-rabbit  
Alexa 488 (Green)¥ 
1:500 
CRYAB CRYAB† 1:20 Donkey anti-mouse  
Cy3 red¥ 
1:500 
FLNC Filamin 2* 1:50 
Donkey anti-goat 
Cy3 red¥ 
1:500 
VDAC1 VDAC1† 1:50 Donkey anti-mouse  
Cy3 red¥ 
1:500 
Manufacturer: †, Abcam, Biocom Biotech, RSA; *, Santa Cruz Biotechnology Inc., USA; ¥, Jackson 
ImmunoResearch Laboratories Inc., USA 
 
The following day the cells were washed with PBS for 10 minutes, repeating the wash step three 
times.  The cells were then labeled with the appropriate secondary antibodies (Table 2.7) which 
were diluted in PBS and incubated at room temperature for 90 minutes in the dark.   
With every experiment, negative controls were included that consisted of H9C2 cardiomyocytes 
labeled with secondary antibodies only.  This was necessary for constructing baseline values for 
each fluorochrome (secondary antibodies) before acquiring the single and z-stacks images.  
Subsequently, the cells were washed with PBS for 10 minutes, repeating the wash step three 
times.  A 1:200 dilution of the nucleic acid stain Hoechst H-33342 (Sigma-Aldrich (Pty) Ltd., 
RSA) was made for staining the nuclear material blue and thus for orientation purposes during 
the acquisition of z-stack images as well as single images.  The cells were incubated with 
Hoechst at room temperature for 10 minutes after which a 10 minute wash step with PBS 
followed.  Mowiol, containing n-propylgallate as anti-fade (Appendix I), was used to mount the 
cells onto glass slides.  The completed slides were stored at 4ºC in the dark until viewing.  After 
viewing and acquisition of a minimum of three single images, three overlay images as well as 
three z-stacked images from the appropriately labeled H9C2 cardiomyocytes, the co-localization 
analysis was performed using the ZEN 2011 lite edition software package.  Carl Zeiss 
(http://microscopy.zeiss.com/microscopy/en_de/downloads/zen.html). 
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The following section will describe the results of the processes used to identify plausible 
LQTS candidate genes. 
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3.1 YEAST TWO-HYBRID ANALYSIS        
3.1.1 Generation of Y2H bait construct       
Following successful generation of the pGBKT7-KCNE2 bait construct, the construct was 
sequenced to establish whether the reading frame had been maintained and also to determine the 
integrity of the reading frame.  Sequence analysis confirmed that the pGBKT7-KCNE2 insert 
was in the correct reading frame.  The insert sequence was preserved throughout the multiple 
rounds of PCR amplification that had been used to create the fragment (Section 2.2.2) (Appendix 
IV).  
 
3.1.2 Assessment of the AH109 bait strain   
3.1.2.1 Phenotypic assessment 
The bait construct was successfully transformed into the AH109 S.cerevisiae yeast strain and 
was able to grow on SD-Trp selection plates.  Growth on SD-Leu and SD-Ada plates was however 
inhibited, thus confirming that the pGKBT7-KCNE2 construct did not autonomously activate 
transcription of the host reporter genes (Section 2.13.1).  Conversely, moderate growth was 
observed when colonies were streaked onto SD-His plates.  The transformed yeast cells showed 
growth on SD-Ura plates, indicating that the phenotype of the S.cerevisiae AH109 strain was not 
altered.  Additionally, this growth indicated that the phenotype of the yeast remained conserved 
following transformation with the pGBKT7-KCNE2 bait construct. 
 
3.1.2.2 Toxicity Test 
In order to establish whether the pGBKT7-KCNE2 bait construct was toxic to the yeast strain 
AH109, a growth curve was generated (Section 2.12.2) in which growth of AH109 transformed 
with the bait construct was compared to that of AH109 transformed with a non-recombinant 
pGBKT7 plasmid.  When comparing the slopes of the linearized test curves of the AH109 strain 
transformed with the bait construct and the AH109 transformed with the non-recombinant 
plasmid, there was no significant difference (Figure 3.1).  This indicates that these transformants 
were able to grow at similar rates.  It was therefore determined that the pGBKT7-KCNE2 
construct was not toxic to the yeast.   
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Figure 3.1: Linear growth curve of the yeast strain AH109 transformed with either pGBKT7-KCNE2 bait 
construct (purple squares and purple line) or a non-recombinant pGBKT7 plasmid (green diamonds and 
green line).  The growth rates of the two yeast transformants were compared to each other by measuring absorbance 
at 600nm every two hours in order to determine whether the bait construct had a toxic effect on the AH109 strain.  
This was determined by calculating the slope of each curve.  It was concluded that the growth of the host strain was 
not affected by the bait construct as the slopes were similar and comparable. 
 
3.1.2.3 Mating efficiency of AH109 transformed with bait construct 
Small scale mating efficiency testing was performed (Section 2.12.3) in order to determine 
whether the transformation of pGBKT7-KCNE2 had affected the ability of the AH109 to mate.  
The mating efficiency results ultimately showed that the bait construct did not affect the mating 
efficiency of the AH109 yeast strain.  The observed mating efficiency was calculated at 10.2% 
(Appendix III), which is higher than the minimum 2% mating efficiency specified by the 
manufacturer of the MATCHMAKER Y2H system (BD Biosciences, clontech, USA) (Table 
3.1). 
 
Table 3.1: Effect of the pGBKT7-KCNE2 bait construct on AH109 mating efficiency 
Mating Mating efficiency 
pGBKT7-KCNE2 (AH109) × pACT2 (Y187) 10.2% 
pGBKT7-53 (AH109) × pACT2 (Y187) 2.15% 
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3.1.3 Y2H screen of pre-transformed cardiac cDNA library 
3.1.3.1 Bait culture titre 
The titre of the bait culture was established by counting the cells with a Haemocytometric 
counting chamber (Section 2.13.3).  The average of the total amount of cells counted on both 
sides of the chamber was 603 and following calculations (Appendix III) the bait culture titre 
amounted to 6.03×109 colony forming units (cfu)/ml, with the commercial transformed bait titre 
estimated at 5×107. 
 
3.1.3.2 Library titre and library mating efficiency  
The library titre and mating efficiency was established as described in section 2.13.5 and after 
the four day incubation period, approximately 2984 cfu were counted on the 1:10000 dilution 
SD-Leu plate.  Following the necessary calculations (Appendix II) a library titre of 2.9×108 was 
established.   
The number of offspring S.cerevisiae cells that were present on the SD-Trp, SD-Leu and SD-Trp-Leu 
media plates was counted (Table 3.2) and the library mating efficiency calculated to 2.1%, which 
is slightly higher than the manufacturer’s recommended minimum value of 2% (Appendix III).   
 
Table 3.2: Library mating efficiency as established by progeny colonies on growth selection 
media  
 Library mating: pGBKT7-KCNE2 × pACT2 
Mating culture dilution 1:10 1:100 1:1000 1:10000 
SD-Trp * * * * 
SD-Leu * * 725 87 
SD-Trp-Leu 220 45 15 0 
Mating efficiency (%) 2.1% 
* Too many colonies to count.  Abbreviations: SD, single dropout; -Trp, without Tryptophan; -Leu, without 
Leucine; -Trp-Leu, without Tryptophan and Leucine. 
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Further analysis included determining the number of pre-transformed cardiac cDNA clones 
screened, which was calculated to be 3.066×105 independent clones with a final resuspension 
volume of 14.6ml (Appendix III). 
 
3.1.3.3 Y2H screen of pre-transformed cardiac cDNA library  
The diploid yeast colonies identified through procedures explained in section 2.13.6, were 
exposed to a cascade of nutritional selection with increasing stringency in order to enhance the 
chances of identifying true interactors. 
The screen ultimately yielded 721 clones that were able to grow on TDO plates containing 
10mM 3-AT (Section 2.13.6.2) (Appendix I), thus indicating that they were capable of activating 
the HIS3 reporter gene.  For the second stage, the 721 clones were transferred to QDO plates 
containing 10mM 3-AT (Section 2.13.6.2) and after four days, 427 clones were selected based on 
their ability to activate both the HIS3 and ADE2 reporter genes as determined by the growth on 
the nutritional selection plates (Appendix I).   
Subsequently, the ability of the 427 clones to activate the colourimetric reporter gene, MEL1 
(Section 2.13.7) was evaluated.  After the two day incubation period, it was determined that 379 
clones were able to activate the MEL1 reporter gene.  This was established by plating the 427 
clones onto QDO plates containing 10mM 3-AT as well as 20mg/ml x-α-galactosidase solution 
(Appendix I). 
 
Table 3.3: Grouping of primary and secondary clones based on the x-α-galactosidase 
colour production and intensity 
Group 
x-α-galactosidase Colour 
intensity 
Number of clones per 
group 
Primary +++ (High) 85 
Secondary ++ (Medium) 294 
 
The 379 selected clones were divided into two groups.  This division was based on the x-α-
galactosidase colour intensity of each individual clones (Appendix V).  Clones with a higher or 
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brighter blue colour (labeled +++) were selected as Primary clones and clones with less blue 
colour intensities (labeled ++) were grouped as Secondary clones (Appendix V and Table 3.3). 
To determine whether any of the 294 secondary clones were duplicates of one another, 
restriction enzyme digestion with two frequent cutting enzymes (HaeIII and RsaI) was 
performed on each of the clones and their restriction pattern subsequently compared to each 
other (Section 2.6.2).  
The digests patterns indicated that 83 of the 294 secondary clones were duplicates, and this 
ultimately resulted in the elimination of those 83 samples.  The remaining 211 secondary clones 
along with the 85 primary clones were selected for interaction specificity testing.   
 
3.1.3.4 Interaction specificity test  
The plasmids of the diploid colonies that were able to activate expression of all three reporter 
genes (HIS3, ADE2 and MEL1) were rescued from the selected clones (Section 2.13.8).  This 
was done in order to facilitate heterologous mating experiments and to test the specificity of the 
bait and prey interactions.  The experiments were performed as described in section 2.13.9 and 
the growth of the diploid colonies recorded (Appendix V). 
 
3.1.3.5 Sequence analysis of putative interactor peptides 
Upon completion of the interaction specific tests, 39 primary clones and 44 secondary clones 
were identified as candidate interactors.  These prey constructs were able to grow on QDO 
selection plates when mated with the pGBKT7-KCNE2 bait plasmid but not when mated with the 
pGBKT7, pGBKT7-53 and pGBKT7-WFS1 plasmids (Figure 3.2).    
This was followed by sequencing of the clones and the identification of the inserts in each of 
them.  The identity of the clones was determined through the mining of publically available 
nucleotide (http://www.ncbi.nlm.nih.gov) and protein (http://www.ensemble.org) databases 
(Appendix V). 
Of the 39 primary clones sequenced, 35 contained inserts that were not selected for further 
investigation as their open reading frames (ORF) fused to the GAL4-AD ORF did not match the 
ORFs predicted from the gene locus in either NCBI GenBank or Ensembl protein databases.   
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Prey plasmids 
               
Figure 3.2:  Interaction specificity testing through heterologous mating of baits and prey plasmids.  An 
example of a QDO selection plate showing the growth of diploid colonies following heterologous mating of five 
individual prey colonies (# 693, 718, 774, 893, 1340 in columns) with bait constructs (pGBKT7-KCNE2, pGBKT7, 
pGBKT7-53 and pGBKT7-WFS1 in rows).  Colony #893 is a good example of a specific interactor, as it only 
showed binding specificity for the pGBKT7-KCNE2 bait protein.  No growth was seen when mated with the 
pGBKT7, pGBKT7-53 and pGBKT7-WFS1bait plasmids as indicated by the red colour of colonies.  Colony #1340 
was identified as a non-interactor as it did not show growth when mated with any of the bait plasmids and colony 
#774 was identified as a non-specific interactor as it showed growth with mating of all bait plasmids. 
 
This is not a completely unexpected finding, given that only one out of every six clones 
represented in MatchmakerTM pre-transformed cDNA libraries are in the correct reading frames  
(MATCHMAKER Two-Hybrid Assay Kit User Manual).  Table 3.4 provides the identities of the 
four remaining clones selected for further assessment.    
Thirty-four of the 44 secondary clones were discarded for the same reasons as mentioned above 
and the identities of the remaining 10 secondary prey constructs are shown table 3.5.  
Through the use of NCBI and Ensembl, false positive ligands were identified and eliminated as 
possible interactors.  These online databases also allowed a total of three ligands that were to be 
excluded based on the fact that their cellular location would make it impossible to interact with 
the cytoplasmic C-terminal of a plasma membrane-bound protein such as KCNE2 (#122, #398 
and #1880) (Table 3.4 and Table 3.5).  Additionally, four ligands were excluded because their 
known functions make them unlikely to interact with KCNE2 (#18, #64, #293 and #668) (Table 
3.4 and Table 3.5). 
 
1340         893           774         718          693 
B
ai
t 
p
la
sm
id
s 
 pGBKT7-KCNE2 
 
 pGBKT7 
 
 pGBKT7-53 
 
 pGBKT7-WFS1 
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Table 3.4: Identification of primary putative interactor clones from Y2H screen 
Clone 
# 
BLASTn Acc # 
(e-value) 
Identity 
BLASTp Acc # 
(e-value) 
Identity 
Cellular 
location 
122 
NM_000088.3 
(0.0) 
Homo sapiens 
collagen, type I, 
alpha 1, mRNA 
EAW94630.1 
(7E-157) 
COL1A1 
Extracellular 
matrix 
398 
NC_012920.1 
(0.0) 
Homo sapiens 
mitochondrion, 
complete genome 
ADB44568.1 
(6E-17) 
 
NADH 
dehydrogenase 
subunit 1 
Mitochondrial 
inner 
membrane 
501 
NM_001127487.1 
(0.0) 
Homo sapiens 
filamin C, 
gamma, mRNA 
1V05_A 
(2E-57) 
 
FLNC 
Cytoplasm, 
Cell 
membrane, 
Sarcomere 
668 
NM_002844.3 
(0.0) 
Homo sapiens 
protein tyrosine 
phosphatase, 
receptor type, K, 
mRNA 
EAW48088.1 
(1E-106) 
 
PTPRK 
Cell 
membrane 
Clones in bold were selected for further verification.  Abbreviations:  Acc, Accession; #, number; e-value, 
expectation value. 
 
The seven remaining clones where subsequently prioritised based on their function and 
subcellular location.  Ultimately three clones where chosen for further analysis as part of the 
present study.  These ligands include Alpha-B crystallin (CRYAB), Filamin C (FLNC) as well as 
Voltage-dependent anion-selective channel protein 1 (VDAC1) (Table 3.4 and Table 3.5).  
 
3.2 LIGANDS CHOSEN FOR FURTHER ANALYSIS   
The three above mentioned clones were selected for further analysis as they resembled good 
candidates for true KCNE2 interactors.  In order to verify the interactions between KCNE2 and 
the three candidate interactors, co-immunoprecipitation and 3D co-localization analyses were 
performed. 
A brief summary of each of the three candidate interactors, their functions as well as their 
subcellular locations are given, along with the rationale for selecting these proteins for further 
analysis and verification as possible KCNE2 ligands. 
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Table 3.5: Identification of secondary putative interactor clones from Y2H screen 
Clone 
# 
BLASTn Acc # 
(e-value) 
Identity 
BLASTp Acc # 
(e-value) 
Identity 
Cellular 
location 
15 
NR_036625.1 
(0.0) 
Voltage-
dependent anion-
selective channel 
protein 1 
NP_003365.1 
(0.0) 
VDAC1 
Mitochondrial 
outer 
membrane, 
Cell 
membrane 
18 
NM_002046.3 
(0.0) 
glyceraldehyde
-3-phosphate 
dehydrogenase 
NP_001243728.1 
6E-153 
GAPDH 
Cytoplasm, 
Nucleus 
22 
NM_133379.3 
(0.0) 
Titin 
CAD12458.1 
2E-76 
TTN 
Cytoplasm, 
Nucleus 
64 
NM_006873.3 
(0.0) 
Stonin 1 
protein 
AFE71436.1 
1E-46 
STON1 
Cytoplasm, 
Cell 
membrane 
93 
NM_019856.1 
(0.0) 
Myomesin 1 
NP_062830.1 
2E-56 
MYOM1 
Sarcomere, 
M-band 
95 
NM_001885.1 
(0.0) 
Alpha-B 
crystalline 
EAW67166.1 
6E-55 
CRYAB 
Cytoplasm, 
Nucleus 
250 
NM_005159.4 
(0.0) 
Cardiac alpha 
Actin 
EAW92317.1 
1E-117 
ACTC1 
Cytoplasm, 
Cytoskeleton 
293 
NM_020202.4 
(0.0) 
Nitrilase family 
member 2 
BAG57372.1 
8E-106 
NIT2 Cytoplasm 
436 
NM_015932.5 
(0.0) 
Proteasome 
maturation 
protein 
NP_057016.1 
6E-96 
POMP 
Cytoplasm, 
Nucleus, 
Microsome 
membrane 
1880 
NM_00112295
7.1  (1.00E-
104) 
 
Branched-chain 
alpha-ketoacid 
dehydrogenase 
kinase 
AAB82714.1 
2E-32 
BCKDK 
Mitochondrial 
matrix 
Clones in bold were selected for further verification.  Abbreviations:  Acc, Accession; #, number; e-value, 
expectation value. 
 
3.2.1 Alpha-B crystallin   
Alpha crystallins are composed of two subunits, αA and αB, and from part of the small heat 
shock protein (sHSP) family (Boelens et al. 2001).  These small proteins accumulate under stress 
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conditions after which they have been shown to translocate from the cytoplasm to the nucleus 
(Kato et al. 1992).  These sHSP act as molecular chaperones - but they cannot be seen as so-
called 'conventional chaperones' as they do not renature and release proteins as true chaperones 
would (Vicart et al. 1998).  Alternatively, they hold the proteins in large soluble aggregates 
(Berry et al. 2001).   
Alpha crystallins have been shown to have autokinase activity and play a role in the intracellular 
design of the cell (Clements et al. 2007).  They are differentially expressed - with alpha-B 
crystallin being expressed in a wide range of cell types (Golenhofen et al. 2004), tissues and 
organs such as the heart.  Alpha crystallins have been associated with myofibrillar myopathy and 
desmin-related cardiomyopathy (Vicart et al. 1998; Golenhofen et al. 2004; Ghosh et al. 2007). 
Furthermore, in a parallel Y2H screen conducted in our laboratory, focusing on the identification 
of novel interactors of KCNE1, alpha-B crystallin was also identified as a putative interactor.   
For these reasons, we chose alpha-B crystallin for further analysis.  
 
3.2.2 Filamin C           
Filamin C, also known as acting binding protein, is involved in the cross linking of actin 
filaments into complex networks (Gariboldi et al. 1994).  These networks are located in the 
cortical cytoplasm of the cell.  The filamin protein plays an important role in anchoring 
membrane proteins for the actin cytoskeleton (Gariboldi et al. 1994) and has been linked to 
various signalling networks (Dalkilic et al. 2006).   
This muscle-specific filamin (Gariboldi et al. 1994) may also exhibit structural functions at the 
Z-lines in muscle cells (Dalkilic et al. 2006) and has been shown to interact with KCND2 
(potassium voltage-gated channel subfamily D member 2) (Petrecca et al. 2000). 
The KCND2 gene, which is similar to KCNE2, encodes a protein that forms potassium ion 
channels that are responsible for: regulating heart rate, transporting epithelial electrolytes and 
contraction of smooth muscle.  KCND2, like KCNE2, has also been associated with arrhythmia 
(Drago et al. 2008) and Long QT syndrome (Frank-Hansen et al. 2005).  For these reasons, 
FLNC was identified as a plausible putative interactor of the C-terminal of KCNE2. 
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3.2.3 Voltage-dependent anion-selective channel protein 1     
Voltage-dependent anion-selective channel protein 1 (VDAC1), also known as the mitochondrial 
porin, is a channel protein located on the outer membrane of the mitochondria.  This protein 
plays a key role in the exchange of ions and other metabolites across the mitochondrial 
membrane, forming the main interface between mitochondrial and cellular metabolism.  This 
allows the protein to regulate metabolic and energetic functions of the mitochondria (Shoshan-
Barmatz and Golan 2012).   
VDAC1 also forms channels in the plasma membrane that are thought to be involved in 
transmembrane electron transport, regulating cell volume as well as apoptosis (Kayser et al. 
1989; Okada et al. 2004). 
Expression of this protein is found across a number of different tissues including the heart and 
skeletal muscle with previous studies linking VDAC1 to myocardial ischemia and reperfusion 
(Kerner et al. 2012).  It is therefore reasonable to suggest that VDAC1, which also encodes a 
voltage-dependant channel, may interact with the C-terminus of KCNE2.  
 
3.3 THREE-DIMENSIONAL CO-LOCALIZATION   
In order to evaluate the interactions between KCNE2 and each of its putative interacting 
proteins, 3D co-localization analysis was executed using confocal microscopy (Section 2.17.1).  
The visual co-localization output indicates that each of the three putative interactors namely 
CRYAB (Figure 3.3), FLNC (Figure 3.4) and VDAC1 (Figure 3.5), occupied the same three-
dimensional subcellular space as KCNE2.   
The images were corrected for background noise by including negative control images with 
every experiment and image acquiring (Section 2.17.1).   
In the figures resulting from the co-localization analysis, F represents a scatter diagram which 
considers all pixels that have the same position in both source images (A and B) to be a pair.  For 
each pair of pixels from the two source images, the signal intensity of pixels from channel 1 
(Ch3-T2, red) were interpreted as X-axis coordinates and the signal intensity of pixels from 
channel 2 (Ch2-T1, green) as Y-axis coordinates.  Each pixel of the diagram represents a value 
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that illustrates how often a particular pixel pair has occurred.  These scatterplots are important as 
they provide a qualitative indication of the degree of co-localization (Dunn et al. 2011).  The 
crosshair in each diagram corresponds to the threshold values determined by the pixel intensity 
of the single images acquired for KCNE2 (Ch2-T1) and the three prey interactors; CRYAB 
(Ch3-T2), FLNC (Ch3-T2) and VDAC1 (Ch3-T2).   
In order to quantify the co-localization results, three coefficients were calculated by means of 
specially designed algorithms (Zinchuk et al. 2007; Dunn et al. 2011) (Table 3.6.).   
Considering the visual representation of co-localization (Figure 3.3 - Figure 3.5) as well as the 
quantification coefficients (Table 3.6), significant co-localization was observed between KCNE2 
and all three of the candidate interactors (Table 3.7 - Table 3.9). 
 
Table 3.6: Comparison of coefficients used to quantify co-localization analysis  
Coefficients Meaning Values 
Weighted Co-
localization 
Coefficient 
Illustrates the contribution of 
each of the two channels to 
the pixels of  interest 
0 – 1.0 
If Ch3-T1 is 1.0 and Ch2-T1 is  0.2 for red-
green pair, it means that all (100%) red 
pixels co-localize with green, but only 20% 
of green pixels co-localize with red 
Overlap 
Coefficient 
Signifies the actual overlap 
of signals and represents the 
true degree of co-localization 
0 – 1.0 
Where 0.5 suggests that 50% of both 
selected channels co-localize etc. 
Pearson’s 
correlation 
coefficient 
(Correlation R) 
The correlation of intensity 
distribution between 
channels 
-1.0 – 1.0 
0 indicates no significant correlation,          
-1 indicates negative correlation and           
1 indicates positive correlation 
Table 3.6 Adapted from (Zinchuk et al. 2007) 
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Figure 3.3: Fluorescent imaging and co-localization analysis of KCNE2 and CRYAB in differentiated H9C2 
cardiomyocytes.  The fluorescent imaging of (A) KCNE2 labeled with the rabbit polyclonal anti-KCNE2 primary 
antibody (Abcam: ab69376) as well as a donkey anti-rabbit Alexa 488 secondary antibody (Green).   B) CRYAB 
labeled with the mouse monoclonal anti-Alpha B Crystallin primary antibody (Abcam: ab13496) as well donkey 
anti-mouse Cy3 secondary antibody (Red). C) Nucleus labeled with Hoechst H-33342 (blue).  D) Overlay of images 
A-C.  E) Co-localization of KCNE2 and CRYAB generated from merged images (white).  F) Scatter diagram 
generated by co-localization analysis with quadrant three representing the degree of co-localization.   
  
Table 3.7: Quantification of co-localization for the interaction between KCNE2 and 
CRYAB proteins 
Weighted                
Co-localization 
Coefficient Channel 1 
(Ch3-T2) 
Weighted                 
Co-localization 
Coefficient Channel 2 
(Ch2-T1) 
Overlap 
Coefficient 
Correlation R 
Correlation 
R x R 
0.094 0.195 0.563 0.062 0.093 
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Figure 3.4: Fluorescent imaging and co-localization analysis of KCNE2 and FLNC in differentiated H9C2 
cardiomyocytes.  The fluorescent images of (A) KCNE2 labeled with the rabbit polyclonal anti-KCNE2 primary 
antibody (Abcam: ab69376) as well as a donkey anti-rabbit Alexa 488 secondary antibody (Green).   B) FLNC 
labeled with the goat polyclonal anti-Filamin 2 primary antibody (Santa Cruz Biotechnology: sc-48496) as well as a 
donkey anti-goat Cy3 secondary antibody (Red). C) Nucleus labeled with Hoechst H-33342 (blue).  D) Overlay of 
images A-C.  E) Co-localization of KCNE2 and FLNC generated from merged images (white).  F) Scatter diagram 
generated by co-localization analysis with quadrant three representing the degree of co-localization.   
 
Table 3.8: Quantification of co-localization for the interaction between KCNE2 and FLNC 
proteins 
Weighted                
Co-localization 
Coefficient Channel 1 
(Ch3-T2) 
Weighted                 
Co-localization 
Coefficient Channel 2 
(Ch2-T1) 
Overlap 
Coefficient 
Correlation R 
Correlation 
R x R 
0.361 0.096 0.657 0.201 0.064 
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Figure 3.5: Fluorescent imaging and co-localization analysis of KCNE2 and VDAC1 in differentiated H9C2 
cardiomyocytes.  The fluorescent images of (A) KCNE2 labeled with the rabbit polyclonal anti-KCNE2 primary 
antibody (Abcam: ab69376) as well as a donkey anti-rabbit Alexa 488 secondary antibody (Green).   B) VDAC1 
labeled with the mouse monoclonal anti-VDAC1 primary antibody (Abcam: ab14734) as well as a donkey anti-
mouse Cy3 secondary antibody (Red). C) Nucleus labeled with Hoechst H-33342 (blue).  D) Overlay of images A-
C.  E) Co-localization of KCNE2 and VDAC1 generated from merged images (white).  F) Scatter diagram 
generated by co-localization analysis with quadrant three representing the degree of co-localization.   
 
Table 3.9: Quantification of co-localization for the interaction between KCNE2 and 
VDAC1 proteins 
Weighted                
Co-localization 
Coefficient Channel 1 
(Ch3-T2) 
Weighted                 
Co-localization 
Coefficient Channel 2 
(Ch2-T1) 
Overlap 
Coefficient 
Correlation R 
Correlation 
R x R 
0.321 0.041 0.602 0.086 0.029 
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It should be noted that although co-localization offers proof that proteins occupy the same 
cellular space, it does not provide evidence of a physical interaction nor their functional 
relationship (Dunn et al. 2011).  For this reason, it is important that other confirmatory analysis 
be done that will show a physical interaction between the proteins.  In the present study, co-
immunoprecipitation analysis was chosen for this purpose. 
 
3.4 CO-IMMUNOPRECIPITATION (Co-IP) OF KCNE2 AND PUTATIVE Y2H 
INTERACTORS      
Since autonomous activation of reporter genes and false positive interactor identifications are 
commonly observed with Y2H screens, it was necessary to verify bait-prey interactions.  This 
was achieved by conducting co-immunoprecipitation experiments with the prey proteins 
(CRYAB, FLNC and VDAC1) and the KCNE2 bait protein (Section 2.15) (Figure 3.6).  These 
assays were conducted with lysates from either normal or hypoxia treated differentiated H9C2 
cardiomyocytes (Section 2.14) since both CRYAB and FLNC have been linked to cell stress 
response (Section 4.2.2)  (Djabali et al. 1997; Kesner et al. 2010).  
The results indicate that all three candidate interactors co-immunoprecipitated with KCNE2 
(Figure 3.6, A).  Two of the prey proteins (CRYAB and FLNC) co-immunoprecipitated with 
KCNE2 when using lysates from hypoxia treated cardiomyocytes (Figure 3.6, A, i and Figure 
3.6, A, ii) (Section 2.14.1).  The third prey protein (VDAC1) co-immunoprecipitated with 
KCNE2 when lysates from normal differentiated H9C2 cardiomyocytes were used (Figure 3.6, 
A, iii). 
For comprehensiveness, reciprocal immunoprecipitation analyses were conducted.   The results 
indicated that KCNE2 only immunoprecipitated with FLNC under hypoxic conditions (Figure 
3.6, B, ii).  No co-immunoprecipitation was observed for KCNE2 with either CRYAB or 
VDAC1 (Figure 3.6, B, i and Figure 3.6, B, iii).   
Therefore, in the present study we have provided convincing evidence of the spatial (3D co-
localization) and adequate proof of the physical (Co-IP) interaction between the KCNE2 proteins 
and three novel putative interacting proteins: CRYAB, FLNC and VDAC1.  
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Figure 3.6: Co-immunoprecipitation of KCNE2 with prey proteins CRYAB, FLNC and VDAC1.  A: CRYAB 
(i), FLNC (ii) and VDAC1 (iii) co-immunoprecipitated with KCNE2 in lysates of hypoxia treated differentiated 
H9C2 cardiomyocytes (i and ii) and standard lysates from differentiated H9C2 cardiomyocytes (iii).  B: Reciprocal 
co-immunoprecipitations indicated that KCNE2 only co-immunoprecipitated with FLNC in lysates of differentiated 
H9C2 cardiomyocytes placed under hypoxic conditions (ii).  No co-immunoprecipitation of KCNE2 was observed 
with CRYAB or VDAC1.  Two negative controls, HA-probe and protein agarose G control, were included in all co-
immunoprecipitation experiments.  The clear HA-probe and protein agarose G control lanes indicate that these 
interactions are not false but rather a true physical interaction between the applicable proteins.  Abbreviations: IP, 
immunoprecipitate; Neg., negative control; Prot G, protein agarose G control; WB, western blot.  
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4.1 YEAST TWO-HYBRID ANALYSIS 
LQTS is a cardiac repolarization disorder characterized by a prolonged QT interval on the ECG 
of affected individuals (Vicart et al. 1998; Schwartz et al. 2001).  The symptoms of LQTS range 
from minor symptoms like dizziness and syncope to more severe symptoms such as seizures and 
SCD.  Clinical features of LQTS are a result of the precipitations of Torsades de Pointes, which 
is a form of polymorphic ventricular tachycardia (Sanguinetti et al. 1995).  A number of genetic 
forms of LQTS have been identified with more than 700 mutations in 12 different genes leading 
to disease pathogenesis.  Of these known mutated genes, KCNE2 is associated with LQT6.  This 
gene encodes the β-subunit of potassium ion channels (Abbott et al. 1999; Abbott and Goldstein 
2001; Eldstrom and Fedida 2011). 
KCNE2 is a small transmembrane protein with an extracellular N-terminal and intracellular C-
terminal domain (Section 1.5).  This β-subunit protein assembles with voltage-gated potassium 
channel complex of pore-forming α-subunits to perform functions which included regulating 
heart rate, smooth muscle contraction and cell volume (McCrossan and Abbott 2004; 
www.genecards.org).  
KCNE2 has been shown to associate with a number of different proteins such as HERG, 
KCNQ1-3 as well as HCN1 and HCN2 (Abbott et al. 1999; Tinel et al. 2000; Yu et al. 2001).    
Although several disease-causing mutations have been identified in KCNE2 (many in the C-
terminal domain of the protein), approximately 25% of patients with compelling LQTS have no 
genetic diagnosis (Napolitano 2005; Medeiros-Domingo et al. 2007b; Newton-Cheh et al. 2009).  
Therefore the present study aimed to identify plausible candidate genes for LQTS through 
searching for interactors of proteins encoded by known LQTS-causing genes.  
We implemented an Y2H approach, using the C-terminal of KCNE2 as bait, to screen a cardiac 
cDNA library in order to identify novel protein ligands.  Subsequently, we aim to screen the 
genes encoding novel protein interactors of KCNE2 in a South African LQTS cohort.  This could 
possibly lead to the identification of novel disease-causing mutations or genetic modifier effects.  
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4.1.1 Y2H analysis to identify novel KCNE2 C-terminal domain interactors  
Following successful transformation of the bait construct into yeast AH109, nutritional selection 
indicated that the pGBKT7-KCNE2 construct did not autonomously activate transcription of the 
reporter genes.  However, moderate growth was observed when colonies were streaked onto SD-
His plates, suggesting leaky expression of the HIS3 reporter gene.  Thus, it was decided to add 
10mM of 3-AT to the nutritional (Section 2.13.6) as well as colourimetric selection (Section 
2.13.7) plates/media (Daniel et al. 2006).  The 3-AT is a heterocyclic organic compound which 
acts as a competitive inhibitor of the product of the HIS3 gene, which is an enzyme catalyzing 
the sixth step of histidine production.  Thus, by adding 3-AT to the selection plates, cultures 
which are dependent on plasmids containing the HIS3 gene to produce histidine, would have to 
produce higher levels of histidine in order for them to survive (Joung et al. 2000; Daniel et al. 
2006; Bruckner et al. 2009). 
According to the library mating efficiency calculations (Section 3.1.3.2) (Appendix III) 
approximately 3.066 x 105 pre-transformed cardiac cDNA clones were screened using the 
pGBKT7-KCNE2 bait construct.  Although this was an acceptable number of clones to be 
screened in the present study, it should be noted that it was much less than the calculated library 
titre of 2.9 x 108cfu/ml (Appendix III).  This suggests that approximately 2.8 x 107 independent 
clones were not screened and that important ligands might have been overlooked. 
Subsequently 379 clones were able to activate all the necessary reporter genes (HIS3, ADE2 and 
MEL1) and were divided into primary and secondary clones (Table 3.3), based on their 
phenotype.   
A number of different clones, encoding the same protein, were pulled out multiple times for 
example; NADH dehydrogenase subunit 1, ACTC1 (Appendix V) and others identified through 
restriction enzyme mapping (Section 2.6.2).  This is not uncommon as Y2H have been shown to 
pull out different clones encoding the same protein yet; artefacts may perhaps exist and be the 
rationale behind multiple protein copies being identified. 
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4.2 PUTATIVE PROTEIN ANALYSIS 
Thirty-nine primary clones and 44 secondary clones were selected for sequencing.  Of these, 35 
primary and 34 secondary clones were not selected for further investigation, as they were either 
duplicate clones or their open reading frames (ORF) did not match the ORFs predicted from the 
gene locus in either NCBI GenBank or Ensembl protein databases (Appendix V).  Although the 
insert sequences of the clones had significant genomic matches in the NCBI database 
(http://www.ncbi.nlm.nih.gov), several of these inserts were not in-frame according to the ORF 
determined by the upstream GAL4 activation domain (AD).  Subsequently, mismatch or non-
significant proteins were translated (Appendix V).  The reason for this could be the traditional 
methods used to generate libraries which are derived form oligo-dT primed cDNA.  This causes 
one out of six cloned inserts to be in-frame with the transcription factor activation domain (Van 
Criekinge and Beyaert 1999).  These mismatch peptides were too short and physiologically 
irrelevant and were therefore excluded from further analysis. 
The remaining four primary clones (Table3.4) and 10 secondary clones (Table 3.5) were 
prioritized based on the following: subcellular location, function and likelihood of interaction. 
It is safe to suggest that protein-protein interactions are unlikely to occur when proteins are 
separated by subcellular compartmentalization in vivo.  Therefore, primary preys #122 
(COL1A1) and #398 (NADH dehydrogenase subunit 1) and secondary prey #1880 (BCKDK) 
were eliminated from further analysis due to their subcellular location in the extracellular matrix 
of the cell, the mitochondrial inner membrane and the mitochondrial matrix, respectively (Table 
3.4 and Table 3.5). 
Primary prey #668 (PTPRK) as well as the three secondary preys; #18 (GAPDH), #64 (STON1) 
and #293 (NIT2) were excluded based on their functions.  Although both PTPRK and STON1 
are located at the cell membrane, their functions could not be related to those of KCNE2.  
Functions of PTPRK included cell growth control, tumour invasion, and metastasis, whereas 
STON1 is found to be involved in the endocytic machinery (www.genecards.org).     
GAPDH is located in the cytoplasm and the nucleus and plays a role in glycolysis and nuclear 
related functions such as RNA transport and apoptosis while NIT2 is only present in the 
cytoplasm and has an omega-amidase activity (www.genecards.org).  Taken together, these 
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functions are dissimilar from the known KCNE2 functions, indicating that these proteins are less 
likely to be ligands of the C-terminal of KCNE2 and were subsequently excluded from the study. 
The primary prey #501 (FLNC) and the following secondary prey interactors; #15 (VDAC1), 
#22 (TTN), #93 (MYOM1), #95 (CRYAB), #250 (ACTC1) and #436 (POMP) were all good 
candidates for being true KCNE2 C-terminal ligands.  Subsequently three proteins were selected 
for further verification analysis namely: CRYAB, FLNC and VDAC1.   
In a parallel Y2H screen in our laboratory, focusing on novel KCNE1 interacting proteins, 
CRYAB was identified as a putative interactor and was therefore selected for further 
investigation.  FLNC was selected based on a previous study that showed interaction between 
FLNC and KCND2; a protein functionally comparable and structurally similar to KCNE2.  The 
voltage-dependent ion channel protein, VDAC1, was chosen for further verification because of 
its functional similarity to KCNE2 and plasma membrane localization.  The four remaining 
putative interactor peptides, not selected for further analyses in the present study, will be 
screened in future studies. 
 
4.3 VERIFICATION STUDIES 
Given that post-translational modifications and protein folding may not occur adequately in the 
Y2H system, it was necessary to verify the three selected putative interactions using independent 
assays in mammalian cells. We chose to verify these putative interactions using 3D co-
localization and co-immunoprecipitation analysis. 
 
4.3.1 Three-dimensional co-localization 
In previous years, older methods of co-localization were used to determine whether proteins 
share the same subcellular location by means of overlaying two-dimensional images captured 
from different colour channels (Costes et al. 2004).  However, in the present study, the 
subcellular locations of the proteins were determined through the use of single images as well as 
z-stack analysis.  The z-stack analysis reflects co-localization through the diameter of the cell 
making it a three dimensional application and therefore a much more powerful tool to assess co-
localization.  This 3D co-localization technique also assigns a value to the visual output; making 
this a quantitative method for the detection of co-localization 
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The present study made use of this 3D approach and convincingly showed that KCNE2 occupy 
the same subcellular space in differentiated H9C2 cardiomyocytes as CRYAB, FLNC and 
VDAC1.   
 
4.3.2 Co-immunoprecipitation 
As previously discussed (Section 3.3), significant co-localization was observed between the bait 
protein (KCNE2) and the three prey proteins (CRYAB, FLNC and VDAC1).  Subsequently all 
three prey proteins were selected for further verification studies.   
Following the identification of plausible interactions through the Y2H screen, Co-IP allowed for 
rapid assessment of protein-protein interactions.  Co-IP analysis was selected as the technique to 
confirm the physical bait-prey protein interactions.  This basic method is relatively easy to use, 
inexpensive, and proteins identified by Co-IP will be present in their native state and native 
concentrations (Phizicky and Fields 1995).  This method provides conclusive evidence of the 
physical interactions between two or more proteins (highly specific) and is compatible with most 
downstream analysis methods (Miernyk and Thelen 2008).  Finally, this technique has been well 
established in our laboratory and has proven to be a reliable method for protein-protein 
interaction verification. 
Lysates used for Co-IP reactions initially originated from standard differentiated H9C2 
cardiomyocytes.  When the three prey proteins were co-immunoprecipitated with the bait protein 
(KCNE2), KCNE2 and VDAC1 indicated a relatively strong interaction (Figure 3.6, A, iii), 
KCNE2 and CRYAB a rather weak interaction and KCNE2 and FLNC showed no interaction at 
all (Figures not shown).  However, several studies provided evidence that both CRYAB and 
FLNC have been linked to cell stress response (Djabali et al. 1997; Kesner et al. 2010), 
potentially explaining the weak or lack of interaction between these two proteins and KCNE2 
under typical physiological conditions.  Subsequently, differentiated H9C2 cardiomyocytes were 
subjected to stress by exposing the cells to hypoxic conditions for two hours (Section 2.14.1). 
Thereafter, the Co-IP experiments were repeated using hypoxia lysates and results showed the 
positive interactions between the two putative prey proteins (CRYAB and FLNC) and KCNE2 
(Figure 3.6, A, i and Figure 3.6, A, ii).   
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Furthermore, reciprocal Co-IP analyses were executed for completeness.  The results indicated 
that KCNE2 was able to co-immunoprecipitate with FLNC (Figure 3.6, B, ii).  No Co-IP was 
observed with either CRYAB (expected size of 20kDa) or VDAC1 (expected size of 39kDa) 
(Figure 3.6, B, i and Figure 3.6, B, iii).  This could be explained by inadequate antibodies 
available for these two proteins i.e. antibodies that were not functionally tested for Co-IP 
analysis.  Nonetheless, the present study provided suitable evidence of the interaction of KCNE2 
with CRYAB and VDAC1 as well as irrefutable evidence for the spatial (3D co-localization) as 
well as physical (Co-IP) interaction between KCNE2 and FLNC (Appendix IV).  
Included in each of the Co-IP experiments were two negative controls; lysate with HA-antibody 
and lysate with protein G agarose containing no antibody.  These lanes were uncontaminated in 
all experiments and test antibodies did not bind non-specifically to protein G agarose in the 
absence of an antibody.  Thus Co-IP analyses could proceed without any interference and were 
the reflection of true physical interactions. 
 
4.4. PROTEINS IDENTIFIED AS KCNE2-PROTEIN LIGANDS 
Three proteins, CRYAB, FLNC and VDAC1 were identified as KCNE2-interacting proteins in 
the present study.  In the sections that follow, the functions of these proteins and the potential 
functional significance of their interactions with KNCE2 will be discussed. 
 
4.4.1 Small heat-shock protein (CRYAB) 
Alpha crystallins are known to exist as large soluble aggregates and contain two related subunits 
- αA (alpha-A crystallin or CRYAA) and αB (alpha-B crystallin or CRYAB) - that share a 55% 
amino acid sequence homology (Berry et al. 2001).  These proteins form part of the small heat 
shock protein family (sHSPs) (Figure 4.1) and is characterized by an 80-100 amino acid 
conserved region.  The latter region forms part of the homologous WDPF motifs 
(Tryptophan=W, Aspartic acid=D, Proline=P, Phenylalanine=F) and α-crystallin domains that 
connects the peptide to N- and C-terminal extensions (Boelens et al. 2001). 
Both CRYAA and CRYAB consist of polar, flexible C-terminal domains (Figure 4.1) that are 
believed to be implicated in the chaperone-like activity of these proteins.  When these crystallin 
subunits are subjected to post-translational modifications that includes deamination, glycation, 
Stellenbosch University  http://scholar.sun.ac.za
97 
 
phosphorylation and truncation of the N-terminal and C-terminal regions; it decreases their 
chaperone activity (Berry et al. 2001). 
Alpha-B crystallin (CRYAB) is highly expressed in vertebrate eye lens, skeletal and cardiac 
muscle and has been shown to form complexes with native proteins (alpha-A crystallin, Hsp27 
and Hsp22) and interact with cytoskeletal proteins (actin, tubulin and intermediate filaments) 
(Boelens et al. 2001).   
 
 
Figure 4.1: Structural domains of human HSP27, 
HSP22 and αB crystallin proteins.  The schematic 
representation of Hsp27, αB-crystallin and Hsp22 
structures indicating the N-terminal domains, flexible 
C-terminal domains, WDPF domains and the α-
crystallin domains.  Phosphorylation sites at serine 
(S) and threonine (T) residues are also shown.  Figure 
taken from (Acunzo et al. 2012) 
 
 
In cardiac muscle phosphorylated CRYAB binds to myofibrils under ischemic conditions as well 
as to titin - a large sarcomeric protein (Bullard 2003).  These findings provide evidence of 
CRYAB being involved in the remodelling of the cytoskeleton and stabilizing/modulating 
filament assembly; assigning a protective function to this protein  (Djabali et al. 1997; Boelens et 
al. 2001; Bullard 2003; Ghosh et al. 2007). 
Crystallins function as chaperone-like molecules by preventing precipitation of denatured 
proteins and increasing the cells’ tolerance to stress, even though they do not  renature and 
release proteins as true chaperones would (Boelens et al  2001; Augusteyn 2004).  Additionally, 
alpha crystallins are involved in regulating correct protein-folding, degradation and signalling  
(auto kinase activity) in the cell (Goldfarb et al. 2008). 
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Normally, CRYAB is located in the cytoplasm from where it is subsequently translocated and 
bound to an isolated region of the I-bands in the sarcomere (Bennardini et al. 1992; Bullard 
2003; Ghosh et al. 2007).  However, when stress is induced (specifically heat shock) the proteins 
are translocated to the nucleus where they reside in sub-nuclear structures (Klemenz et al. 1991).  
More recently though, it was found that CRYAB dissociates from filaments in order to interact 
with unfolding proteins in the cytoplasm, such as β- and gamma (γ)-crystallins, under these stress 
conditions (Ghosh et al. 2007).  In our study, we found CRYAB to be located at both the plasma 
membrane as well as in the cytoplasm (Figure 3.3). 
Another study found that the function and localization of CRYAB is largely dependent on its 
phosphorylation status (Clements et al. 2007).  When CRYAB is not phosphorylated it is located 
in the cytoplasm where chaperone and signalling functions are executed.  Then, with stress such 
as ischemia, CRYAB is phosphorylated and cellular protection is enhanced; translocating 
CRYAB to the sarcomere (Golenhofen et al. 2004; Clements et al. 2007).   
Some variants in CRYAB (D109H and R157H) have previously been linked to late onset 
cardiomyopathy (Andley et al. 2011; Sacconi et al. 2012) which is a disease caused by 
conduction blocks, arrhythmias and chronic heart failure; causing patients to experience syncope 
and SCD (Goldfarb et al. 2008). 
CRYAB has been shown to interact with several crystallins such as alpha-A crystallin (CRYAA) 
and beta-crystallin B2 (CRYBB2) (Fu and Liang 2002), also other heat shock proteins like heat 
shock protein beta-1 (HSPB1) (Figure 4.1) and heat shock protein beta-2 (HSPB2) (Fu and Liang 
2002).  CRYAB also interacts with other proteins such as cardiac titin (TTN) (Bullard 2003) 
filamin C (FLNC) (Kley et al. 2007), and voltage dependent anion-selective channel protein 1 
(VDAC1) (Mitra et al. 2013) to name a few.  
In a study by Kundu and colleagues, KCNE2 was shown to be regulated by the estrogen hormone 
E2 (17- β-estradiol) in mice.  This hormone exhibits a protective function, very similar to that of 
CRYAB, as it activates numerous protective signalling pathways during cellular stress.   
Estrogen has also been shown to regulate the expression of regulatory subunits of other cardiac 
K+ channel genes such as KCNE1 (Kundu et al. 2008).  Additionally, high levels of estrogen 
have been shown to cause QT interval prolongation (Eghbali et al. 2005). 
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In the present study we focused on KCNE2 - a LQTS causing gene - and identified CRYAB to be 
a putative interactor of KCNE2; mainly under stress (Section 2.14.1) (Figure 4.2).  This was 
expected since CRYAB is a heat shock protein with known protective functions under stress 
conditions (Clements et al. 2007).   
With normal/optimal physiological conditions, cardiomyocytes require a nutrient rich 
environment with a pH of approximately 7 (Fabiato and Fabiato 1978) and sufficient oxygen 
resources.  Therefore, in the present study stress was induced by replacing enriched growth 
media with Esuni buffer (pH 6.4) and inducing hypoxia for two hours (Section 2.14.1).  With the 
3D co-localization analysis, a significant association was observed between CRYAB and 
KCNE2 (Section 3.3).  However, with Co-IP analysis the physical interaction between these two 
proteins was only verified partially since (not confirmed with reciprocal experiments) (Section 
3.4).  
Nonetheless, we speculate that this interaction is true and that the location of this novel 
KCNE2/CRYAB interaction will most likely take place within the cytoplasm since this is where 
CRYAB is predominantly situated (Bennardini et al. 1992; Bullard 2003).  In a previous study 
by Um and McDonald it was demonstrated that the intracellular trafficking of KCNE2 through 
the cytoplasm takes place before the protein reaches the plasma membrane (Um and McDonald 
2007).  This finding supports our hypothesis of cytoplasmic KCNE2/CRYAB interaction.  We 
propose that this cytoplasmic interaction is necessary in order for CRYAB to regulate the correct 
conformational changes and folding of the KCNE2 protein before it reaches the cell membrane 
which would affect the subsequent functioning of KCNE2 K+ channels.  
However, it should also be considered that the novel KCNE2/CRYAB interaction might occur at 
the plasma membrane.  This suggestion is reinforced with findings from a previous study by 
Clements and co-workers; showing the presence of CRYAB at the cell surface after stress was 
induced (Clements et al. 2007).    
Taken together, these findings provide evidence of the possibility that both KCNE2 and CRYAB 
could be present in the same subcellular compartment at the same time under stress conditions; 
strengthening the findings of the present study (Figure 4.2).  
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Figure 4.2: Predicted association between KCNE2 and CRYAB proteins.  A schematic representation of known 
protein interactions indicated in green, blue and purple lines.  The red dashed line indicates the proposed interaction 
between KCNE2 and CRYAB identified in the present study.  Abbreviations:  CRYAB, Alpha-B crystallin; DES, 
Desmin; FLNC, Filamin C; KCND2, potassium voltage-gated channel, Shal-related subfamily, member 2;   
KCND3, potassium voltage-gated channel, Shal-related subfamily, member 3; KCNE2, potassium voltage-gated 
channel, Isk-related family, member 2; KCNH2, potassium voltage-gated channel, subfamily H (eag-related), 
member 2; KCNQ1, potassium voltage-gated channel, KQT-like subfamily, member 1; KY, kyphoscoliosis 
peptidase; MYOT, Myotilin; MYOZ1, Myozenin 1; SGCD, Sarcoglycan, delta; SCN5A, sodium channel, voltage-
gated, type V, alpha subunit.  Figure adapted from: www.string-db.org.  
 
4.4.2. Filamin (FLNC) 
Filamins are characterized as elongated homodimeric proteins that crosslink filamentous actin 
(F-actin) in the cytoskeleton.  They consist of a conserved actin-binding domain (ABD) at the N-
terminal followed by an extended rod-like domain.  With the ability to form dimers or tetramers, 
filamins are capable of bundling and crosslinking actin filaments into orthogonal networks and 
linking them to the cell membrane.  Additionally, filamins are believed to act as scaffolding 
proteins that bind components of signalling pathways in order to enhance their activation 
(Murray et al. 2004; Popowicz et al. 2006).     
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The ABD consists of two tandem calponin domains whereas the rod regions of human filamin 
proteins are built by 24 immuno-globulin (Ig)-like repeats.  Of these repeats, the last one is 
known to be responsible for dimerization of this protein (Figure 4.3).  Furthermore, unique 
hinges are also located in the rod domain of filamins (Figure 4.3).  This class of proteins is 
comprised of three members, filamin A (FLNA), filamin B (FLNB) and filamin C (FLNC) 
(Figure 4.3).  These proteins share a 70% sequence homology (although the hinge regions are 
less homologous) and have been associated with diseases affecting the brain (periventricular 
nodular heterotopia or PVNH) and cardiovascular development (patent ductus arteriosus and 
aortic aneurysms)  (Gariboldi et al. 1994; Robertson et al. 2003; Popowicz et al. 2006; Zhou et 
al. 2007). 
   
 
 
 
Figure 4.3:  Structure of the human Filamin C protein.  A schematic representation of the filamin C (FLNC) 
protein structure indicating the actin binding domain (ABD) at the N-terminal, 24 Ig-like repeat domains and two 
hinges (green arrows) in the rod region.  Figure adapted from Linnemann et al. 2010. 
 
The filamin protein is located in the cytoplasm at the Z-line, at the stress fibres in non-muscle 
cells (that consist of actin filaments and crosslinking proteins) as well as at the sarcolemmal 
membrane of muscle cells and is thought to be a signal transducer in a variety of systems 
(Kesner et al. 2010).  Therefore, Thompson and colleagues hypothesized that FLNC may be 
involved in muscle maintenance by regulating and protecting the muscle during contraction 
(Thompson et al. 2000).  This hypothesis is consistent with most filamin functions reported, such 
as being involved in actin polymerization (crosslinking).  This process that is essential for 
regulating the contractile apparatus in skeletal and cardiac muscles, cell structure and 
organization of membrane receptors with signalling molecules.  These processes are known to 
control cellular procedures including cell adhesion and migration, cell shape, growth, 
differentiation, apoptosis and survival (Thompson et al. 2000; Dalkilic et al. 2006; Popowicz et 
al. 2006).   
Mutations identified in FLNA and FLNB largely impact human cortical development and results 
in skeletal muscle disorders, whereas mutations in FLNC cause skeletal and cardiac muscle 
NH2 COOH 
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disorders since the expression of FLNC is restricted to muscle cells (Zhou et al. 2007; Gontier et 
al. 2013).   
Mutations in the FLNC gene have previously been implicated in myofibrillar myopathy (MFM), 
which is characterized by the disruption of focal myofibrils and the abnormal accumulation of 
proteins in skeletal muscle fibres.  The onset of MFM is variable and sudden death due to 
cardiovascular complications has previously been described.  In a study by Kley and co-workers, 
it was found that approximately one third of patients with filamin-related myopathies had cardiac 
abnormalities including tachycardia, diastolic dysfunction and left ventricular hypertrophy.  
These investigators also found that FLNC interacts with CRYAB (Section 4.1.3.1) (Kley et al. 
2007). 
Moreover, mutations in FLNC have been associated with desminopathy, which is characterized 
by muscle weakness, conduction blocks, arrhythmias and chronic heart failure resulting in 
unexpected or sudden death (Goldfarb et al. 2008).  This is of particular interest to the present 
study given that mutations in KCNE2 have previously been associated with very similar 
symptoms i.e. arrhythmias, heart failure and SCD (Abbott et al. 1999; Gordon et al. 2007;  
Schwartz 2009).   
In a previous study, FLNC was identified as an interactor of KCND2 (Petrecca et al. 2000).  
KCND2 encodes the α-subunit of the voltage-gated potassium channel protein (also known as the 
Kv4.2 channel) located at the cell membrane and have been found to regulate heart rate and 
muscle contraction (Fiset and Giles 2006).  Petrecca and co-workers proposed that FLNC 
mediates the direct link between KCND2 and the actin cytoskeleton and that this interaction is 
essential for the generation of appropriate KCND2 current densities (Petrecca et al. 2000).  
Following mapping studies, it was found that the C-terminal of FLNC interacted specifically 
with a four amino acid (aa) motif (PTPP) 30aa upstream of the C-terminus of KCND2 (Petrecca 
et al. 2000).  The KCND2 ion channel conducts the fast transient outward current of cardiac 
action potential in the myocardium and has been associated with prolonged action potential as 
well as QT interval prolongation (LQTS) (Barry et al. 1998; Frank-Hansen et al. 2005).   
In addition to the interaction with FLNC, Roepke and colleagues found KCND2 to interact with 
KCNE2 and revealed that KCNE2 regulate ventricular fast transient outward currents by 
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modulating KCND2 channels.  Additionally it was discovered that targeted disruption of KCNE2 
leads to α-subunit targeting and impaired ventricular repolarization (Roepke et al. 2008). 
In the present study FLNC was identified as a putative interactor of KCNE2.   The protein 
structure of KCNE2 is similar to other FLNC interacting proteins identified by Thompson and 
colleagues i.e.; β1-integrins, γ-sarcoglycan and delta (δ)-sarcoglycan, apart from the fact that the 
sarcoglycans have intracellular N-terminal and extracellular C-terminal domains.  These 
sarcoglycans are thought to be important components of structural support as well as signalling 
pathways in muscle cells (Thompson et al. 2000). 
Furthermore, we observed the binding of the C-terminal of KCNE2 with the C-terminal of FLNC 
exclusively under conditions of stress, which is similar to results from a study by Kesner and co-
workers.  Here, in the last mentioned study, it was hypothesized that stress-induced 
conformational changes in filamins could have a direct effect on cell signalling through 
disruption of existing interactions or by presenting novel interactions (Kesner et al. 2010).  It 
may therefore be possible that this stress-induced unfolding of FLNC is necessary for the 
interaction of FLNC with KCNE2. 
The subcellular location of this novel KCNE2/FLNC interaction is thought to be either 
cytoplasmic or membrane associated.  Depending on the phosphorylation state of FLNC, the 
protein can either be present at the membrane interacting with membrane associated proteins or it 
can be found in the cytoplasm interacting with the actin cytoskeleton (Thompson et al. 2000; 
Murray et al. 2004).  At the membrane, FLNC has been shown to interact with the intracellular 
domains of  γ-sarcoglycan, δ-sarcoglycan and β1-integrin proteins (Thompson et al. 2000) as 
well as with the C-terminal of KCND2 .  Hence, with KCNE2 containing of a cytoplasmic 
domain, the newly identified interaction between FLNC and KCNE2 could possibly occur in a 
similar fashion as the previously identified FLNC/KCND2 interaction at the membrane. 
Additionally, it is believed that although FLNC can be recruited to the membrane through a 
specific group of receptor signals, another group of signals could allow FLNC to translocate 
back to the actin cytoskeleton (Thompson et al. 2000).  As explained previously in section 1.5.3, 
premature KCNE2 proteins are trafficked through the ER, Golgi apparatus and the cytoplasm to 
ultimately reach the cell membrane as mature proteins.  The trafficking of both FLNC and 
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KCNE2 through the cytoplasm could be the alternative subcellular location for the novel 
interaction (Um and McDonald 2007). 
In conclusion, literature research revealed several connections between FLNC and KCNE2 
which strengthens the probability of their physical interaction in vitro.  These overlaps include 
mutations in both genes causing similar symptoms (arrhythmia, conduction block, syncope and 
SCD) in different diseases (LQTS, RCM, and MFM); common interacting protein partners 
(KCND2) (Figure 4.2) as well as subcellular localization in cardiac muscle cells.   
 
Figure 4.4: Predicted association between KCNE2 and FLNC proteins.  A schematic representation of known 
protein interactions indicated with green, blue and purple lines.  The red dashed line indicates the proposed 
interaction between KCNE2 and FLNC identified in the present study.  Abbreviations: FLNC, Filamin C; KCND1, 
potassium voltage-gated channel, Shal-related subfamily, member1; KCND2, potassium voltage-gated channel, 
Shal-related subfamily, member 2;   KCND3, potassium voltage-gated channel, Shal-related subfamily, member 3; 
KCNE2, potassium voltage-gated channel, Isk-related family, member 2; KCNIP1, Kv channel interacting protein 1; 
KCNIP2, Kv channel interacting protein 2; KCNIP4, Kv channel interacting protein 4; KY, kyphoscoliosis 
peptidase; MYOT, Myotilin; MYOZ1, Myozenin 1; NCS1, neuronal calcium sensor 1  SGCD, Sarcoglycan, delta.  
Figure adapted from: www.string-db.org.  
 
We hypothesize that the interaction of FLNC with KCNE2 might be required for the membrane 
anchoring of the KCNE2 proteins and the subsequent functioning of these K+ protein channels.  
Additionally, filamin have been shown, in a previous study, to mediate the direct link between 
KCND2 and the actin cytoskeleton and it is thought that the FLNC/KCND2 interaction is 
essential for the generation of appropriate current densities of KCND2 (Petrecca et al. 2000).  
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Accordingly, this can be extrapolated to the findings of the present study since KCNE2 and 
KCND2 are structurally and functionally related.  We therefore propose that the KCNE2/FLNC 
interaction is important for the generation of proper KCNE2 current density and KCNE2-actin 
cytoskeleton association. 
 
4.4.3 Porin ion channel protein (VDAC1) 
The voltage-dependent anion-selective channel proteins (VDACs), also known as mitochondrial 
porins, have three known isoforms namely; VDAC1, VDAC2 and VDAC3.  These proteins are 
mainly located on the outer mitochondrial membrane (OMM) (Sampson et al. 1997; Colombini 
2004; De Pinto et al. 2010).  VDAC1 and VDAC2 are characterized by their ability to form 
pores that allows diffusion of small hydrophilic solutes through the membrane whereas VDAC3 
on the other hand, plays a more important physiological role by means of regulating functions of 
other proteins (Sampson et al. 1997; De Pinto et al. 2010).   
At membrane potentials close to zero, these anion-selective channels are open.  Once the voltage 
changes to values above +20mV or below -20mV, the pores close.  Thus, previous studies have 
suggested that this protein is able to sense the membrane electrical potential and react to it 
accordingly (De Pinto et al. 2010). 
VDACs consist of approximately 285 amino acid residues that contains 12 to 19 transmembrane 
β-strands and one α-helix situated at the N-terminal of the molecule (Figure 4.5) (Bay and Court 
2002; Bayrhuber et al. 2008; Ujwal et al. 2008).  The β-strands are connected by loops of 
different lengths (Figure 4.2) that play particular roles in gating of VDAC channels, pore size, 
ion selectivity as well as structural support of VDAC channels (Bay and Court 2002; Ujwal et al. 
2008). 
VDACs display a variety of functions including metabolite and energy interchange as well as 
cell volume control and apoptosis (Murphy 2004; De Pinto et al. 2010; Kerner et al. 2012).  
These functions have been shown to be dependent on interaction with other proteins and is 
regulated by the phosphorylation of VDACs (Kerner et al. 2012).  VDAC proteins are expressed 
in a variety of tissue including the liver, kidney, heart and skeletal muscle (Kerner et al. 2012). 
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Figure 4.5: Secondary structure of VDAC1.  The VDAC1 protein structure consists of transmembrane β-strands 
(up and down arrows) and one α-helix (blue cylinders) at the N-terminal.  In the β-strands and the α-helix are the 
single-letter amino acid codes of VDAC1.  β1 is mentioned again at the C-terminal to indicate that this is a closed 
barrel.  Figure adapted from (Ujwal et al. 2008). 
 
VDAC1 have been shown to interact with a number of proteins including BCL2-like 1(BCL2L1) 
a potent inhibitor of cell death (Shi et al. 2003) and Gelsolin (GSN) - an intracellular actin 
binding protein that also inhibits apoptosis through stabilizing the mitochondria (Koya 2000).  
Additionally, VDAC1 interact with CRYAB (Mitra et al. 2013); the small heat shock protein 
discussed in section 4.1.3.1 as well as tropomyosin 3 (TPM3); a protein that plays an essential 
role in the troponin complex and muscle contraction that has recently been identified as a 
possible biomarker for risk of arrhythmias (Rosengarten et al. 2013).  
Diseases in which VDACs have been implicated include mitochondrial dysfunction diseases 
such as Alzheimer’s disease, as well as other diseases such as Down syndrome (Yoo et al. 2001), 
cancer (Arbel and Shoshan-Barmatz 2010) type 2 diabetes mellitus, myocardial ischemia 
reperfusion and hypertension (Yuqi et al. 2009; Kerner et al. 2012).  VDACs are also linked to 
hypertension, a major risk factor for coronary heart disease and congestive heart failure.   
Hypertension has been characterized as the risk factor responsible for the poor diagnosis in a 
range of cardiovascular diseases since it has been shown to mask the underlying illness (Yuqi et 
al. 2009). 
In addition to the outer mitochondrial membrane (OMM) localization; VDAC1 was shown to be 
the porin protein most abundantly expressed at the plasma membrane (Kayser et al. 1989; 
Buettner et al. 2000; Okada et al. 2004; De Pinto et al. 2010; Kerner et al. 2012).   
β1 β1 
β18 
β19 β17 β15 β13 β11 β5 β7 β9 β3 
β12 β10 β8 β6 β4 β2 β14 β16 
N-terminus 
C-terminus 
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This protein has been studied extensively with previous studies implicating VDAC1 in the early 
stages of programmed cell death (Shimizu et al. 2001; Zheng et al. 2004). 
Yuqi and co-workers investigated the effect of a mitochondrial transfer-RNA (tRNA) A4263G 
mutation on blood pressure in a family with maternally-inherited hypertension.  Using 
lymphoblastoid cell lines from individuals carrying the mutation and control individuals, they 
showed an increase in VDAC1 expression and increased levels of apoptosis, while the 
mitochondrial potential significantly decreased.  These results indicated that this specific 
A4263G mutation is associated with alterations in the expression of the VDAC1 protein, its 
localization as well as the level of apoptosis (Yuqi et al. 2009). 
Apoptosis is accompanied by cell volume alterations.  It was shown that certain ion channels, 
such as K+ and Na+ channels, activated during apoptosis are important in cell volume regulation 
(Bortner et al. 1997).  The increase in K+ efflux, associated with anion channel activation during 
rapid cell volume decrease, is important to sustain the electro neutrality of the membrane.  This 
emphasizes the necessity for correct intracellular concentrations of cations as well as anions in 
order to regulate apoptosis.  These apoptotic events cause activation of plasma membrane 
associated VDAC1 channels and subsequently the activation of K+ channels (delayed rectified 
type)  (Okada et al. 2004). 
KCNE2, as discussed earlier (Section 1.5), is a voltage-gated K+ channel situated at the plasma 
membrane that regulates the IKr current, which is the rapid delayed rectifier current, in the heart 
(Abbott et al. 1999).  Functions of this channel include the regulation of heart rate, insulin 
secretion, muscle contraction and cell volume control (Yang et al. 2004; Yuqi et al. 2009; 
www.ncbi.nlm.nih.gov). 
We identified the positive interaction between KCNE2 and VDAC1 through the Y2H screen of a 
cardiac cDNA library.  This interaction took place under normal physiological conditions.  
However, when stress was induced through hypoxia (Section 2.14.1), no interaction was 
observed.  This suggested that these two proteins do not interact under stress conditions. 
In view of evidence from previous studies of both KCNE2 and VDAC1, one can deduce that the 
structure and functions of these proteins are relatively similar.  This is supported by the fact that 
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both proteins are voltage-gated ion channels and form transmembrane pores at the plasma 
membrane (Figure 4.6) (Abbott et al. 1999; Okada et al. 2004; De Pinto et al. 2010).   
Furthermore, KCNE2 and VDAC1 have similar functions including ion transport and cell 
volume control and have previously been associated with arrhythmic events and heart failure 
(Yang et al. 2004; Yuqi et al. 2009; www.ncbi.nlm.nih.gov).  
 
 
 
Interestingly, the KCND2 protein, previously shown to interact with KCNE2 (Zhang et al. 2001), 
was found to be even more similar to VDAC1.  KCND2 is a voltage-gated ion channel (Figure 
4.7) with six transmembrane spanning loops and an intracellular N-terminal domain (Isbrandt et 
al. 2000; Barros et al. 2012), almost identical to VDAC1 that contains approximately 19 
transmembrane loops and an intracellular N-terminal domain (Figure 4.5) (Bay and Court 2002; 
Ujwal et al. 2008).   
Through experimental procedures followed in the present study, the novel KCNE2/VDAC1 
interaction was successfully confirmed through 3D co-localization analysis (Section 3.3) yet; Co-
IP analysis could not provide conclusive evidence of the physical interaction between these 
proteins since reciprocal Co-IP results were inadequate (Section 3.4).   
Even so, we hypothesize that this interaction is highly possible and that the subcellular 
localization of the novel KCNE2/VDAC1 association could occur at the plasma membrane.  This 
is supported by previous studies detecting KCNE2 and, more recently, VDAC1 at the plasma 
membrane (Abbott et al. 1999; Okada et al. 2004; De Pinto et al. 2010).  
On the other hand, mitochondria have been shown to be located throughout the cell’s cytoplasm; 
depending on the energy requirements of the cell as well as the specific function of these 
Figure 4.6: Schematic representation of 
KCNE2 transmembrane protein.  In the 
diagram, KCNE2 is shown to stretch through 
the membrane with one pore forming region.  
KCNE2 has an extracellular N-terminal 
domain and an intracellular C-terminal 
domain.  Figure adapted from: Um and 
McDonald 2007. 
COOH 
NH2 
Intracellular 
Extracellular 
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organelles and their role in cell survival (Frederick and Shaw 2007).  Thus, we may speculate 
that membrane bound KCNE2 (more specifically the intracellular C-terminal of KCNE2) could 
associate with the intracellular OMM associated VDAC1 when mitochondria are located close to 
the plasma membrane.  
 
Figure 4.7: Schematic diagram of the Kv channel organization.  This representation of a Kv channel, for 
example KCND2, indicates the six transmembrane regions (labeled S1-S6), the pore domain and the voltage sensor 
domain.  Abbreviations: ext, extracellular; int, intracellular.  It should be noted that this is a general representation of 
Kv channels and although uniformity exists in transmembrane and pore regions, large variability is found in the size 
and location of the N-terminal and C-terminal of different Kv channels.  Figure adapted from: Barros et al. 2012. 
 
Cytoplasmic localization of the novel KCNE2/VDAC1 interaction is another option to be 
explored.  With mitochondria, containing VDAC1 on its outer membrane, situated and 
translocated within the cytoplasm (Frederick and Shaw 2007) and premature KCNE2 being 
trafficked through the ER and cytoplasm (Um and McDonald 2007) it is very possible that these 
proteins might associate here. 
Numerous studies provided evidence that supports the finding of the present study; showing 
positive KCNE2/VDAC1 interaction.  Particularly the study by Okada and colleagues who 
showed that the regulation of cell volume activates VDAC1 as well as delayed rectifier type K+ 
channels (Okada et al. 2004) of which KCNE2 is one.    
NH2 
COOH 
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Taken together, we propose that the interaction between KCNE2 and VDAC1 might be 
necessary for the regulation of cell volume and apoptosis since both of these proteins are 
implicated in these processes.  Additionally, the functions of VDAC1 channels have been shown 
to be dependent upon interactions with other proteins (Kerner et al. 2012).  Consequently, we 
speculate that KCNE2 might be one of these proteins that control VDAC1 functions.   
However, the opposite should also be considered since VDAC proteins were shown to regulate 
the functions of other proteins (De Pinto et al. 2010).  Hence, we can also suggest that the 
KCNE2/VDAC1 interaction is necessary in order for VDAC1 to regulate KCNE2 functions at 
the plasma membrane.  It could also be possible that this novel interaction is essential for the 
activation of KCNE2 and other K+ channels during apoptosis (Okada et al. 2004). 
  
 
 
 
 
 
 
 
 
 
 
Three likely interaction sites/methods were proposed in the current study.  Although, when 
looking at figure 3.5 it seems possible that the association of these proteins takes place at more 
than one of these suggested locations or in more than one way simultaneously i.e. in the 
cytoplasm as well as close to the cell surface. 
Ultimately, we identified VDAC1 to be a novel putative interactor of the C-terminal domain of 
KCNE2 through 3D co-localization and Co-IP analysis.  We also offered relevant evidence 
supporting the findings of the present study. 
Figure 4.8: Predicted association between 
KCNE2 and VDAC1 proteins.  A 
schematic representation of known protein 
interactions indicated with green, blue and 
purple lines.  The red dashed line indicates 
the proposed interaction between KCNE2 
and VDAC1 identified in the present study.  
Abbreviations: CRYAB, Alpha-B crystallin; 
FLNC, Filamin C; KCND2, potassium 
voltage-gated channel, Shal-related 
subfamily, member 2; KCNE2, potassium 
voltage-gated channel, Isk-related family, 
member 2; VDAC1, voltage-dependent anion 
channel 1.  Figure adapted from www.string-
db.org.  
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4.5 IMPLICATIONS FOR KCNE2 
The Y2H system was used to identify novel interactors of the C-terminal of KCNE2 in order to 
elucidate additional functions or pathways in which KCNE2 might be involved.  The putative 
interactors identified and verified in the present study include CRYAB, FLNC and VDAC1.  
This indicates that the C-terminal of KCNE2 is able to interact with at least three classes of 
proteins known as small heat-shock proteins, filamins and porin ion channels, respectively.  
Among these proteins identified, none to our knowledge have previously been proposed as 
interactors of the C-terminal of KCNE2, thus classifying them as novel interactions.   
Following adequate research, it was established that the disruption of pathways in which all three 
interacting proteins are involved lead to cardiac dysfunction.  Therefore, considering that only 
75% of LQTS-causing mutations are known, the novel positive interacting proteins and other 
components of their respective pathways could be model candidates to be investigated for 
disease-causing or disease/phenotype modifiers.  
 
4.6 STUDY LIMITATIONS 
4.6.1 Y2H analysis limitations 
The Y2H system is one of the most widely used and well established genetic techniques 
available to identify novel protein-protein interactions in vivo (Berggård et al. 2007).  The Y2H 
system has proven to be relatively inexpensive, do not require special equipment and can easily 
be performed in any molecular laboratory with high efficacy and over the years, a myriad of 
interactions have successfully been identified using this technique.  However, with the extreme 
application of this method a number of limitations have come to light (Bruckner et al. 2009). 
When using a classic cDNA library Y2H screen, as was done in the present study, the aim is to 
search for pairwise interactions between bait and prey proteins that have been pooled.  This 
means that the pooled prey library do not only contain full length ORFs but small DNA 
fragments as well leading to false positives being identified due to non-specific interactions (Van 
Criekinge and Beyaert 1999).   
Moreover, since Y2H relies on the reconstitution of a transcription factor and the expression of 
reporter genes, all interaction in this assay takes place within the nucleus of the yeast cell (Fields 
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and Song 1989; Bruckner et al. 2009).  This, of course does not represent the true cellular 
compartments where interacting proteins reside in vivo. Therefore interactions may be detected 
in Y2H analysis that cannot take place in vivo because the putative interacting proteins are 
located in cellular compartments that makes it impossible for them to interact.  Furthermore, 
certain proteins may become toxic to the host cell when expressed or could degrade vital yeast 
proteins or proteins necessary for the assay (Van Criekinge and Beyaert 1999).  
One should also be aware that Y2H is notorious for producing false positive interactions, i.e. 
showing reporter gene activation where no bait-prey interaction has taken place.  This could be 
due to the bait construct being able to autonomously activate the transcription of reporter genes 
(auto activation) (Cusick et al. 2005; Lalonde et al. 2008; Bruckner et al. 2009).  In the present 
study, the KCNE2-bait construct was unable to act as an auto-activator of reporter gene 
transcription. 
The detection of false negative interactions is also a possibility when performing an Y2H screen.  
This happens when the interaction between the bait and prey was facilitated by a fusion or 
anchor protein; leading to the prevention of interaction due to a change in molecular structure 
(Van Criekinge and Beyaert 1999).  Moreover, false negatives may also be caused by 
interactions that require specific post-translational modifications and unless the enzymes 
responsible for these modifications are present in the yeast, no interaction will be detected 
(Cusick et al. 2005; Bruckner et al. 2009).   
Additionally, Y2H screening only identifies defined binary interactions in a complex and not all 
the components of a larger complex which could lead to certain protein interactions being 
overlooked (Berggård at al. 2007; Bruckner et al. 2009). 
Another limitation of this system can be ascribed to the bait and prey proteins fusing to the DNA 
binding domain.  This fusion of proteins might change the conformation of the bait and/or prey 
proteins and could influence their functions and binding properties (Fields and Song 1989; 
Bruckner et al. 2009).   
When taking the above mentioned limitations into consideration, it is evident that independent 
verification of protein-protein interaction is crucial.  Thus, in order to address this matter, a co-
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localization assay was selected to determine whether the interacting proteins are located in the 
same subcellular compartment at any given time.   
However, although co-localization of proteins provides evidence of spatial closeness and the 
presence of two or more proteins in the same cellular compartment, it does not offer prove of a 
physical interaction between these proteins (Dunn et al. 2011).  Therefore, an additional 
verification technique is necessary to determine if the interaction is a true specific binary protein 
interaction.  In the present study we used a co-immunoprecipitation (Co-IP) assay to confirm 
this. 
 
4.6.2 Three-dimensional co-localization limitations 
Some of the limitations identified throughout the use of 3D co-localization are as follows:  The 
use of highly specific primary antibodies raised against the proteins of interest and fluorophore-
labeled secondary antibodies required a great deal of optimization to determine the adequate 
concentration for each antibody to be used.  This was necessary in order to acquire suitable 
images for analysis which proved to be somewhat time consuming.  Additionally, when 
investigating endogenous proteins (like in the present study), components of the protein complex 
may not be expressed sufficiently in the cell line studied (Berggård et al. 2007).   
Finally, when using conventional light microscopy the resolution is limited to approximately 
200nm by the diffraction of light, causing objects closer than 200nm to each other to appear as a 
single object (Lalonde et al. 2008).  However, the method used in the present study allowed z-
stack images to be taken roughly 260nm (0.26µm) apart, suggesting that this distance may 
separate proteins that appear co-localized by fluorescence microscopy.  As a result it is possible 
to determine whether two proteins share the same subcellular space yet, no conclusive evidence 
can be given regarding physical association between the proteins of interest.   
This 3D co-localization method should therefore be considered as one technique that could be 
used in conjunction with other techniques - such as Co-IP - in order to verify physical protein-
protein interactions. 
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4.6.3 Co-immunoprecipitation limitations 
Some Co-IP limitations were encountered during the course of this study.  The predicted size of 
KCNE2 has been estimated between 14kDa and 20kDa however, the size of KCNE2 detected 
throughout all the Co-IP and WB experiments in the present study were approximately 40kDa - 
50kDa.  This matter was addressed by conducting experiments with three different KCNE2-
specific antibodies from three different manufacturers, yet all yielded similar results of lysates 
producing an intense protein band at approximately 50kDa. 
Another possible explanation for the bigger protein band of KCNE2 could be attributed to 
complex formation of the protein (Um and McDonald 2007).  Um and McDonald also reported a 
40kDa protein fragment on western blots for the KCNE2 protein.  They analysed the band and 
found that it represented the correct KCNE2 fragment.  Further analysis indicated that the 40kDa 
fragment resulted from the dimerization of KCNE2 proteins (Um and McDonald 2007).  
Subsequently, this provided support for the results presented in the current study. 
 
4.7 FUTURE STUDIES 
The three novel interactors of the C-terminal of KCNE2 identified and verified in the present 
study demands further investigation to elucidate the true nature of their interaction and 
physiological relevance to KCNE2 and LQTS. 
Therefore, genes encoding these novel interacting proteins should be considered as good 
candidates to screen for mutations, especially in our SA cohort of LQTS patients.  With the 
identification of novel disease-causing mutations in patients (possibly segregating in the family) 
and the absence of these mutations in control subjects, functional studies should be considered to 
establish the effect of these mutations on disease phenotype.  This would include the deletion or 
inhibition of gene expression (Knockout experiments) as well as mutagenesis experiments in 
order to elucidate the precise mechanism of function of these mutations and the effect they have 
on K+ flow and general functioning of KCNE2 K+ channels in cardiac muscle cells.   
Through the identification of the three prey interactors, additional pathways were identified in 
which KCNE2 might be implicated.  Therefore it will be interesting to investigate these 
pathways in terms of their contribution to cardiac conduction disorders and heart failure.   
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Furthermore, future studies should include the investigation of the four putative interactors that 
fell outside the scope of the present study (ACTC1, MYOM1, POMP and TTN). 
 
4.8 CONCLUSION 
In this investigation of the C-terminal of KCNE2, seven putative interactors were identified by 
means of Y2H analysis.  Three of these interactors were selected for further investigation and 
were subsequently subjected to direct Y2H protein-protein interaction verification assays 
namely; 3D co-localization and co-immunoprecipitation (Co-IP) analysis.  Although some 
difficulty was experienced with reciprocal Co-IP verification experiments, it is still considered 
that CRYAB and VDAC1 are true KCNE2 C-terminal ligands due to positive co-localization and 
partially positive Co-IP data.  Both protein interaction techniques used for the verification of the 
KCNE2/FLNC interaction provided irrefutable evidence of the subcellular localization as well as 
physical association between these two proteins.   
All three of the putative positive interactors identified in this study are novel and should provide 
new understanding and insight into the mechanisms in which KCNE2 is involved and how it 
contributes to disease pathogenesis.  By means of identifying novel KCNE2 interacting proteins, 
different pathways and targets could be revealed.  With investigation of these new targets and 
pathways the mechanism by which KCNE2 mutations induce cardiac dysfunction, can possibly 
be elucidated.  In conclusion, this study identified interesting and novel interactors that will 
contribute to our current knowledge of KCNE2. 
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Appendix I 
Reagents 
1.  SOLUTION USED IN GENERATION OF COMPETENT CELLS  
CAP buffer: 
60mM CaCl2        2.21g 
15% glycerol        37.5ml 
10mM PIPES        0.76g 
ddH2O up to 250ml. pH 7.0.  Keep in fridge 
 
2.  BACTERIAL MEDIA 
Luria-Bertani (LB) Media 
Bacto tryptone       5g 
Yeast extract        2.5g 
NaCl         5g 
Agar         8g 
ddH2O to final volume of 500ml 
Autoclave for 20 minutes at 121ºC and add appropriate antibiotic to media when the 
temperature has reached ±55ºC (Ampicillin, 50mg/ml and Kanamycin 100mg/ml). 
 
LB Agar Plates  
Bacto tryptone       5g 
Yeast extract        2.5g 
NaCl         5g 
Agar         8g 
ddH2O to final volume of 500ml 
Autoclave for 20 minutes at 121ºC and add appropriate antibiotic to media when the 
temperature has reached ±55ºC, prior to pouring plates (Ampicillin, 50mg/ml and 
Kanamycin 100mg/ml). 
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3. YEAST MEDIA 
YPDA Media 
Difco peptone       10g 
Yeast extract       5g 
Glucose       10g 
L-adenine hemisulphate (0.2% stock)   7.5ml 
ddH2O to a final volume of 500ml; Autoclave at 121ºC for 15 minutes 
 
2X YPDA Media 
Difco peptone       12g 
Yeast extract       6g 
Glucose       12g 
L-adenine hemisulphate (0.2% stock)   9ml 
ddH2O to a final volume of 500ml; Autoclave at 121ºC for 15 minutes 
 
YPDA Agar 
Difco peptone       10g 
Yeast extract       5g 
Glucose       10g 
Bacto agar       10g 
L-adenine hemisulphate (0.2% stock)   7.5ml 
ddH2O to a final volume of 500ml; Autoclave at 121ºC for 15 minutes 
 
4. YEAST TRANSFORMATION REAGENTS 
1M Lithium Acetate (LiAc) 
LiAc        5.1g 
ddH2O to a final volume of 50ml  
 
100mM LiAc 
1M LiAc       5ml 
ddH2O to a final volume of 50ml  
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50% PEG 4000 
PEG 4000       25g 
ddH2O to a final volume of 50ml  
 
Herring Sperm 
Herring Sperm      50mg 
ddH2O to a final volume of 50ml 
 
5. SINGLE DROPOUT MEDIA 
SD-Trp Media 
 Glucose       12g 
 Yeast nitrogen base without amino acids   4g 
 SD-Trp amino acid supplement    0.4g 
 0.2% adenine hemisulphate     9ml 
ddH2O to a final volume of 600ml; Autoclave at 121ºC for 15 minutes 
 
SD-Trp Agar Plates 
 Glucose       12g 
 Yeast nitrogen base without amino acids   4g 
 SD-Trp amino acid supplement    0.4g 
 Bacto agar       12g 
 0.2% adenine hemisulphate     9ml 
ddH2O to a final volume of 600ml; Autoclave at 121ºC for 15 minutes 
 
SD-Leu Media 
 Glucose       12g 
 Yeast nitrogen base without amino acids   4g 
 SD-Leu amino acid supplement    0.4g 
 0.2% adenine hemisulphate     9ml 
ddH2O to a final volume of 600ml; Autoclave at 121ºC for 15 minutes 
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 SD-Leu Agar Plates 
 Glucose       12g 
 Yeast nitrogen base without amino acids   4g 
 SD-Leu amino acid supplement    0.4g 
 Bacto agar       12g 
 0.2% adenine hemisulphate     9ml 
ddH2O to a final volume of 600ml; Autoclave at 121ºC for 15 minutes 
 
SD-Trp/-Leu Media 
 Glucose       12g 
 Yeast nitrogen base without amino acids   4g 
 SD-Trp/-Leu amino acid supplement    0.4g 
 0.2% adenine hemisulphate     9ml 
ddH2O to a final volume of 600ml; Autoclave at 121ºC for 15 minutes 
 
SD-Trp/-Leu Agar Plates  
 Glucose       12g 
 Yeast nitrogen base without amino acids   4g 
 SD-Trp/-Leu amino acid supplement    0.4g 
 0.2% adenine hemisulphate     9ml 
 Bacto agar       12g 
ddH2O to a final volume of 600ml; Autoclave at 121ºC for 15 minutes 
 
TDO Media 
 Glucose        12g 
 Yeast nitrogen base without amino acids   4g 
 SD-Trp-Leu-His amino acid supplement    0.4g 
 ddH2O to a final volume of 600ml; pH 5.8; Autoclave at 121ºC for 15 minutes 
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TDO Agar Plates 
Glucose        12g 
Bacto agar       12g 
 Yeast nitrogen base without amino acids   4g 
 SD-Trp-Leu-His amino acid supplement    0.4g 
 ddH2O to a final volume of 600ml; pH 5.8; Autoclave at 121ºC for 15 minutes 
 
QDO Media 
Glucose        12g 
 Yeast nitrogen base without amino acids   4g 
 SD-Trp-Leu-His-Ade amino acid supplement   0.4g 
 ddH2O to a final volume of 600ml; pH 5.8; Autoclave at 121ºC for 15 minutes 
 
QDO Agar Plates 
Glucose        12g 
Bacto agar       12g 
 Yeast nitrogen base without amino acids   4g 
 SD-Trp-Leu-His-Ade amino acid supplement   0.4g 
 ddH2O to a final volume of 600ml; pH 5.8; Autoclave at 121ºC for 15 minutes 
 
X-α-galactosidase Solutions (20mg/ml) 
x-α-galactosidase      250mg  
Dimethylformamide (DMF)     12.5ml 
 
3-Amino-1,2,4-triazole (3-AT) (10mM) 
 3-AT        0.84g 
 ddH2O to a final volume of 1L 
Add 6ml 3-AT solution and 1ml X-α-Galactosidase solution to TDO and QDO plates when agar 
temperature has reached ± 55ºC 
 
Note: All media or plates containing glucose were autoclaved for 15 minutes to avoid 
crystallisation   
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6. ELECTROPHORESIS SOLUTIONS 
SB Buffer (20X stock) 
Di-sodium tetraborate decahydrate     38.137g/mol 
ddH2O to a final volume of 1L 
 
SDS-PAGE Running buffer (10X) 
Tris base       30g 
Glycine       144g 
10% SDS       100ml 
ddH2O to a final volume of 1L 
 
7. GELS 
1 % Agarose Gel       
Agarose        1g 
SB Buffer (1X)      100ml 
Microwave for 2-3 minutes; add 5µl ethidium bromide (10mglml) when temperature 
reaches ± 55ºC 
 
 
8. LOADING DYES 
Ethidium bromide stock (10mg/ml) 
 Ethidium bromide (Sigma)     500mg 
 ddH2O        50ml 
 Stir for 4 hours using magnetic stirrer and store in dark container at 4ºC 
Bromophenol Blue loading dye 
 Bromophenol blue      1% (w/v) 
 ddH2O to a final volume of 100ml; store at 4ºC 
SDS Loading Dye 
 Laemmli sample buffer (Bio-Rad)    950µl 
 β-mercapto-ethanol      50µl 
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9. CO-IP REAGENTS 
 Lysis buffer 
 Hepes        10ml 
 5M NaCl       4ml 
 0.5M EDTA       4ml 
 Triton X-100       2ml 
 10mM Nappi       80ml 
 1M Na3VO4       400µl 
 ddH2O to final volume of 200ml 
 1 4⁄  tablet protease inhibitor and 100µl PMSF freshly added to 5ml lysis buffer for 
Co-IP experiment 
 
TBST (pH7.6) 
 5M NaCl       60ml 
 1M Tris base       40ml 
 0.1% Tween-20      2ml 
 ddH2O to a final volume of 2L 
 
Membrane blocking solution 
 Powder milk       7.5g 
 Tween-20       15µl 
 TBST solution       150ml 
 
Esuni Buffer 
 NaCl        8.1g 
 KCl        0.9g 
 MgCl2        0.1g 
 CaCl2.H2O        0.13g 
 Hepes        0.95g 
ddH2O to a final volume of 1L; pH6.2;  
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Metabolic inhibition with 2DG     3.28g 
ddH2O to a final volume of 1L; pH6.4 
 
10. CO-LOCALIZATION REAGENTS 
Phosphate buffered saline (PBS) 
 1 PBS Tablet 
 ddH2O to a final volume of 200ml 
 
1% Bovine Serum Albumin (BSA) 
 BSA        0.5g 
 PBS solution        50ml 
 
Cell mounting solution 
 Mowiol       1ml 
 Anti-fade       <0.01g 
 Heat for 1hour at 55ºC; spin tube down before use 
 
11. EUKARYOTIC CELL CULTURE MEDIA 
Growth Media 
 DMEM (4.5g/L glucose, with L-glutamine)   500ml 
 Foetal Bovine Serum      50ml 
 Penicillin/Streptomycin     5ml 
 Pre-warm to 37ºC before use   
 
Differentiation Media 
 DMEM (4.5g/L glucose, with L-glutamine)   500ml 
 Horse Serum       5ml 
 Penicillin/Streptomycin     5ml 
 Pre-warm to 37ºC before use 
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Appendix II 
Vectors 
 
Restriction map and Multiple Cloning Site (MCS) of pGBKT7 Y2H vector.  A)  The 
positions of the Kanamycin resistance gene (Kanr), the trypsin (TRP1) nutritional marker for 
selection in yeast, GAL4-BD coding sequences, f1 bacteriophage and pUC origins of replication, 
the truncated S.cerevisiae ADH1 promoter sequence (PADH1) and the MCS.  B)  The nucleotide 
sequence of the pGBKT7 MCS.  The sequence indicated the positions of all the unique 
restriction enzyme recognition sequences, stop codons in the T7 termination sequence, GAL4-
BD coding sequence, T7 promoter sequence, c-Myc epitope tag, position of screening and 
sequencing primers.  (Adapted from pGBKT7 vector information datasheet, Clontech) 
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Restriction map and Multiple Cloning Site (MCS) of pACT2 Y2H prey vector.  A)  Shows 
the positions of unique restriction enzyme sites indicated in bold font as well as the positions of 
the Ampicillin resistance gene (Ampr), the leucine (LEU2) nutritional marker, GAL4-BD coding 
sequence, 2µ and pBR322 plasmid origin of replication, the S.cerevisiae ADH1 promoter, 
S.cerevisiae ADH1 termination sequence, Lox sites (Lox 1 and Lox 2), the haemagglutinin (HA) 
epitope tag and the MCS.  B)  The nucleotide sequence of the pACT2 MCS.  The position of 
restriction enzyme sites, stop codons, GAL4-BD coding sequence, HA epitope tag and the 
positions of the pACT2-F and pACT2-R primer sequences.  (Adapted from pACT2 vector 
information datasheet, Clontech) 
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Appendix III 
Calculations 
 
CALCULATING YEAST MATING EFFICIENCY  
 Count number of colonies on all plates with 30-300 colonies after 4 days 
 
#colony forming units (cfu)/ml =   #cfu x 1000µl/ml 
     Volume plated (µl) x dilution factor 
 
1. #cfu/ml on SD-Leu plates = viability of prey partner 
2. #cfu/ml on SD-Trp plates = viability of bait partner 
3. #cfu/ml on SD-Leu-Trp plates = viability of diploids 
4. Lowest #cfu/ml of SD-Leu plates or SD-Trp plates = indication of limiting partner 
  
5. Mating efficiency =  #cfu/ml of diploids x 100 
    #cfu/ml of limiting partner 
 
Library titre: 
 Count number of colonies on all plates with 30-300 colonies after 4 days 
 
#cfu/ml =   #colonies 
  Volume plated (µl) x dilution factor 
 
Number of clones screened: 
#cfu/ml x final resuspension concentration 
 
 
HAEMOCYTOMETRIC CELL COUNT 
In order to determine the number of cells per millilitre (ml), the number of cells in each of the 
five larger square blocks was counted.  The amount of the cells in these five squares was added 
together and divided by five to get an average number of cells for each of the 25 large squares of 
the central quadrant of the haemocytometer (See figure 2.2).  The average number of cells was 
subsequently multiplied by 25 to get an estimated average number of cells within the large 
central quadrant.  The formula used to determine the number of cells/ml is as follows:  
 
# cells/ml = # cells x dilution factor x 104 (because the depth of the counting chamber is 0.1mm) 
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Appendix IV 
Aligned sequence of KCNE2 
Colony #1A   ----------------------------------------------------------------------------------------------------  
KCNE2 C-term ----------------------------------------------------------------------------------------------------  
Reference    --ATGTCTACTTTATCCAATTTCACACAGACGCTGGAAGACGTCTTCCGAAGGATTTTTATTACTTATATGGACAATTGGCGCCAGAACACAACAGCTGA  
 
Colony #1A   ----------------------------------------GTAATACGACTCACTATAGGGCGAGCCGCCATCATGGAGGAGCAGAAGCTGATCTCAGAG  
KCNE2 C-term ----------------------------------------------------------------------------------------------------  
Reference    GCAAGAGGCCCTCCAAGCCAAAGTTGATGCTGAGAACTTCTACTATGTCATCCTGTACCTCATGGTGATGATTGGAATGTTCTCTTTCATCATCGTGGCC  
 
Colony #1A   GAGGACCTGCATATGGTGAAATCCAAGAGACGGGAACACTCCAATGACCCCTACCACCAGTACATTGTAGAGGACTGGCAGGAAAAGTACAAGAGCCAAA  
KCNE2 C-term ---------------GTGAAATCCAAGAGACGGGAACACTCCAATGACCCCTACCACCAGTACATTGTAGAGGACTGGCAGGAAAAGTACAAGAGCCAAA  
Reference    ATCCTGGTGAGCACTGTGAAATCCAAGAGACGGGAACACTCCAATGACCCCTACCACCAGTACATTGTAGAGGACTGGCAGGAAAAGTACAAGAGCCAAA  
 
Colony #1A   TCTTGAATCTAGAAGAATCGAAGGCCACCATCCATGAGAACATTGGTGCGGCTGGGTTCAAAATGTCCCCCTGATAGGAATTCCCGGGGATCCGTCGACC  
KCNE2 C-term TCTTGAATCTAGAAGAATCGAAGGCCACCATCCATGAGAACATTGGTGCGGCTGGGTTCAAAATGTCCCCCTGA--------------------------  
Reference    TCTTGAATCTAGAAGAATCGAAGGCCACCATCCATGAGAACATTGGTGCGGCTGGGTTCAAAATGTCCCCCTGATAAGGGAGAAAGGCACCAAGCTAACA  
 
Colony #1A   TGCAGCGGCCGCATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTT----------------------------------------  
KCNE2 C-term ----------------------------------------------------------------------------------------------------  
Reference    TCTGACGTCCAGACATGAAGAGATGCCAGTGCCACGAGGCAAATCCAAATTGTCTTTGCTTAGAAGAAAGTGAGTTCCTTGCTCTCTGTTGAGAATTTTC  
 
Colony #1A   ----------------------------------------------------------------------------------------------------  
KCNE2 C-term ----------------------------------------------------------------------------------------------------  
Reference    ATGGAGATTATGTGGTTGGCCAATAAAGATAGATGACATTTCAATCTCAGTGATTTATGCTTGCTTGTTGGAGCAATATTTTGTGCTGAAGACCTCTTTT  
 
Colony #1A   ----------------------------------------------------------------------- 
KCNE2 C-term -----------------------------------------------------------------------  
Reference    ACTTTCCGGGCAAGTGAATGTCATTTTAATCAATATCAATGATGAAAATAAAGCCAAATTTGAAGAAAAAA  
Figure 1: Sequence analysis of the pGBKT7-KCNE2 construct.  Sequence homology alignment of colony #1A with the C-terminal encoding sequence of KCNE2 in the 
pGBKT7 vector as well as the reference sequence for KCNE2 (GenBank: http://www.ncbi.nlm.nih.gov/Entrez) (NM_172201.1).  The primer nucleotide sequences of the 
pGBKT7 vector are shade grey; the pBGKT7 vector sequences are in the turquoise boxes and the restriction enzyme recognition sequences are shaded yellow.  The start and stop 
codons of the KCNE2 reference sequence are indicated in the green shaded boxes respectively.  
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Appendix V 
Tables of primary and secondary clones 
 
Table 1.1: Activation of nutritional and colourimetric reporter genes of the 427 clones. 
Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
4 +++ +++ ++ (light blue) 
5 +++ ++ ++(light blue) 
8 +++ +++ ++(light blue) 
9 +++ +++ +++ (dark blue) 
10 +++ +++ +++(dark blue) 
11 +++ ++ +++(dark blue) 
15 +++ +++ ++(light blue) 
16 +++ +++ +++(dark blue) 
17 +++ ++ ++(light blue) 
18 +++ ++ ++(light blue) 
22 +++ ++ ++(light blue) 
23 +++ +++ +++(dark blue) 
24 +++ ++ +++(dark blue) 
26 +++ ++ + (no blue) 
28 +++ ++ +(no blue) 
29 +++ +++ ++(light blue) 
30 +++ +++ ++(light blue) 
38 +++ ++ ++(light blue) 
41 +++ ++ ++(light blue) 
42 +++ +++ - (no growth) 
46 +++ +++ +++(dark blue) 
48 +++ +++ ++(light blue) 
53 +++ +++ ++(light blue) 
56 +++ +++ +++(dark blue) 
57 +++ ++ ++(light blue) 
61 +++ +++ ++(light blue) 
64 +++ ++ ++(light blue) 
65 +++ +++ +(no blue) 
66 +++ +++ ++(light blue) 
67 +++ +++ ++(light blue) 
68 +++ +++ +++(dark blue) 
72 +++ ++ ++(light blue) 
73 +++ ++ - (no growth) 
74 +++ +++ +(no blue) 
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Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
79 +++ +++ +++(dark blue) 
81 +++ +++ - (no growth) 
82 +++ +++ +++(dark blue) 
84 +++ +++ +(no blue) 
89 +++ +++ - (no growth) 
92 +++ +++ ++(light blue) 
95 +++ +++ ++(light blue) 
96 +++ +++ +++(dark blue) 
97 +++ +++ ++(light blue) 
98 +++ +++ ++(light blue) 
101 +++ +++ ++(light blue) 
102 +++ +++ +++(dark blue) 
103 +++ ++ ++(light blue) 
105 +++ +++ ++(light blue) 
106 +++ +++ ++(light blue) 
107 +++ +++ +(no blue) 
108 +++ +++ +(no blue) 
111 +++ +++ ++(light blue) 
112 +++ +++ +++(dark blue) 
113 +++ +++ +++(dark blue) 
114 +++ ++ - (no growth) 
116 +++ +++ ++(light blue) 
118 +++ +++ ++(light blue) 
120 +++ ++ ++(light blue) 
121 +++ +++ ++(light blue) 
93 +++ +++ ++(light blue) 
124 +++ ++ - (no growth) 
125 +++ +++ +++(dark blue) 
127 +++ ++ ++(light blue) 
128 +++ ++ ++(light blue) 
129 +++ +++ +(no blue) 
131 +++ ++ - (no growth) 
132 +++ ++ +(no blue) 
134 +++ +++ +(no blue) 
135 +++ ++ ++(light blue) 
137 +++ +++ +++(dark blue) 
138 +++ ++ - (no growth) 
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Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
139 +++ ++ ++(light blue) 
142 +++ ++ ++(light blue) 
143 +++ +++ +++(dark blue) 
144 +++ +++ ++(light blue) 
145 +++ +++ ++(light blue) 
146 +++ ++ ++(light blue) 
148 +++ +++ ++(light blue) 
149 +++ +++ ++(light blue) 
155 +++ +++ ++(light blue) 
157 +++ +++ ++(light blue) 
158 +++ +++ ++(light blue) 
160 +++ +++ ++(light blue) 
162 +++ ++ ++(light blue) 
163 +++ +++ ++(light blue) 
165 +++ +++ ++(light blue) 
170 +++ +++ ++(light blue) 
171 +++ ++ +(no blue) 
174 +++ ++ ++(light blue) 
175 +++ +++ ++(light blue) 
176 +++ ++ +(no blue) 
180 +++ ++ +(no blue) 
181 +++ ++ +(no blue) 
182 +++ ++ +(no blue) 
185 +++ +++ ++(light blue) 
186 +++ ++ - (no growth) 
191 +++ ++ +(no blue) 
192 +++ ++ ++(light blue) 
193 +++ +++ ++(light blue) 
194 +++ ++ ++(light blue) 
196 +++ ++ +(no blue) 
197 +++ +++ ++(light blue) 
198 +++ +++ ++(light blue) 
199 +++ +++ - (no growth) 
202 +++ +++ ++(light blue) 
203 +++ +++ +(no blue) 
205 +++ +++ ++(light blue) 
206 +++ ++ +(no blue) 
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Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
209 +++ +++ +(no blue) 
211 +++ ++ +(no blue) 
212 +++ ++ +(no blue) 
214 +++ +++ ++(light blue) 
216 +++ +++ ++(light blue) 
217 +++ +++ +++(dark blue) 
218 +++ +++ +++(dark blue) 
219 +++ +++ +(no blue) 
222 +++ +++ ++(light blue) 
223 +++ ++ +(no blue) 
226 +++ ++ ++(light blue) 
227 +++ ++ - (no growth) 
228 +++ +++ ++(light blue) 
229 +++ ++ ++(light blue) 
230 +++ +++ +++(dark blue) 
233 +++ ++ ++(light blue) 
234 +++ +++ ++(light blue) 
236 +++ ++ ++(light blue) 
237 +++ +++ ++(light blue) 
238 +++ +++ +++(dark blue) 
239 +++ ++ ++(light blue) 
242 +++ +++ +++(dark blue) 
243 +++ ++ +(no blue) 
244 +++ ++ ++(light blue) 
247 +++ +++ +++(dark blue) 
248 +++ +++ ++(light blue) 
250 +++ +++ ++(light blue) 
251 +++ +++ +++(dark blue) 
252 +++ +++ ++(light blue) 
257 +++ +++ ++(light blue) 
259 +++ +++ ++(light blue) 
261 +++ +++ ++(light blue) 
262 +++ ++ ++(light blue) 
264 +++ ++ ++(light blue) 
265 +++ +++ ++(light blue) 
271 +++ +++ ++(light blue) 
272 +++ +++ ++(light blue) 
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Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
278 +++ +++ ++(light blue) 
279 +++ +++ ++(light blue) 
281 +++ +++ +++(dark blue) 
283 +++ +++ +++(dark blue) 
285 +++ ++ ++(light blue) 
290 +++ ++ +(no blue) 
291 +++ ++ ++(light blue) 
293 +++ ++ ++(light blue) 
295 +++ +++ ++(light blue) 
296 +++ ++ ++(light blue) 
297 +++ ++ +(no blue) 
299 +++ ++ ++(light blue) 
302 +++ +++ +++(dark blue) 
303 +++ +++ +++(dark blue) 
305 +++ ++ ++(light blue) 
307 +++ ++ ++(light blue) 
309 +++ +++ +(no blue) 
317 +++ +++ ++(light blue) 
319 +++ +++ ++(light blue) 
321 +++ ++ ++(light blue) 
323 +++ ++ ++(light blue) 
328 +++ +++ ++(light blue) 
329 +++ ++ ++(light blue) 
330 +++ +++ ++(light blue) 
331 +++ +++ ++(light blue) 
333 +++ +++ ++(light blue) 
334 +++ +++ +(no blue) 
335 +++ +++ ++(light blue) 
336 +++ ++ ++(light blue) 
338 +++ +++ ++(light blue) 
340 +++ +++ +(no blue) 
343 +++ +++ ++(light blue) 
349 +++ +++ +++(dark blue) 
351 +++ +++ ++(light blue) 
355 +++ +++ +++(dark blue) 
358 +++ ++ ++(light blue) 
359 +++ ++ ++(light blue) 
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Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
360 +++ +++ +++(dark blue) 
368 +++ ++ +++(dark blue) 
371 +++ +++ +++(dark blue) 
375 +++ ++ ++(light blue) 
380 +++ +++ ++(light blue) 
383 +++ +++ +++(dark blue) 
395 +++ +++ +++(dark blue) 
396 +++ +++ ++(light blue) 
398 +++ +++ +++(dark blue) 
403 +++ +++ ++(light blue) 
406 +++ ++ ++(light blue) 
407 +++ +++ +++(dark blue) 
409 +++ +++ ++(light blue) 
412 +++ ++ +++(dark blue) 
414 +++ +++ ++(light blue) 
416 +++ +++ +++(dark blue) 
417 +++ ++ +++(dark blue) 
418 +++ +++ +++(dark blue) 
419 +++ +++ +(no blue) 
420 +++ +++ ++(light blue) 
423 +++ ++ ++(light blue) 
424 +++ ++ ++(light blue) 
425 +++ +++ ++(light blue) 
426 +++ +++ ++(light blue) 
427 +++ +++ ++(light blue) 
428 +++ +++ ++(light blue) 
430 +++ +++ ++(light blue) 
431 +++ +++ ++(light blue) 
432 +++ +++ ++(light blue) 
433 +++ +++ ++(light blue) 
434 +++ ++ ++(light blue) 
435 +++ +++ ++(light blue) 
436 +++ +++ ++(light blue) 
437 +++ +++ ++(light blue) 
439 +++ +++ ++(light blue) 
440 +++ ++ ++(light blue) 
441 +++ ++ ++(light blue) 
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Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
442 +++ +++ ++(light blue) 
443 +++ +++ ++(light blue) 
445 +++ ++ ++(light blue) 
446 +++ +++ ++(light blue) 
448 +++ +++ ++(light blue) 
451 +++ +++ ++(light blue) 
452 +++ +++ +++(dark blue) 
453 +++ +++ ++(light blue) 
456 +++ ++ ++(light blue) 
459 +++ ++ ++(light blue) 
461 +++ ++ ++(light blue) 
462 +++ ++ ++(light blue) 
464 +++ +++ +++(dark blue) 
470 +++ ++ ++(light blue) 
475 +++ +++ ++(light blue) 
477 +++ ++ ++(light blue) 
479 +++ +++ ++(light blue) 
480 +++ +++ ++(light blue) 
481 +++ ++ ++(light blue) 
484 +++ +++ +++(dark blue) 
487 +++ +++ ++(light blue) 
490 +++ ++ +(no blue) 
493 +++ ++ ++(light blue) 
494 +++ +++ ++(light blue) 
495 +++ +++ ++(light blue) 
496 +++ ++ +(no blue) 
501 +++ +++ +++(dark blue) 
503 +++ ++ ++(light blue) 
506 +++ +++ ++(light blue) 
507 +++ +++ ++(light blue) 
508 +++ +++ ++(light blue) 
510 +++ +++ +++(dark blue) 
514 +++ +++ +++(dark blue) 
515 +++ +++ ++(light blue) 
520 +++ ++ ++(light blue) 
521 +++ +++ ++(light blue) 
523 +++ ++ ++(light blue) 
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Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
525 +++ ++ ++(light blue) 
526 +++ +++ ++(light blue) 
534 +++ ++ ++(light blue) 
537 +++ +++ ++(light blue) 
538 +++ ++ ++(light blue) 
540 +++ ++ ++(light blue) 
543 +++ ++ ++(light blue) 
546 +++ +++ +++(dark blue) 
550 +++ ++ ++(light blue) 
553 +++ ++ +++(dark blue) 
554 +++ ++ ++(light blue) 
564 +++ +++ ++(light blue) 
578 +++ ++ ++(light blue) 
579 +++ ++ ++(light blue) 
589 +++ ++ +(no blue) 
590 +++ ++ ++(light blue) 
594 +++ ++ ++(light blue) 
598 +++ ++ ++(light blue) 
601 +++ ++ ++(light blue) 
610 +++ +++ +++(dark blue) 
615 +++ ++ ++(light blue) 
616 +++ ++ ++(light blue) 
617 +++ ++ ++(light blue) 
619 +++ ++ ++(light blue) 
623 +++ ++ ++(light blue) 
627 +++ ++ ++(light blue) 
630 +++ ++ ++(light blue) 
634 +++ ++ +(no blue) 
635 +++ +++ ++(light blue) 
636 +++ ++ ++(light blue) 
639 +++ ++ ++(light blue) 
640 +++ ++ ++(light blue) 
645 +++ ++ ++(light blue) 
649 +++ ++ +++(dark blue) 
655 +++ ++ ++(light blue) 
665 +++ ++ ++(light blue) 
668 +++ ++ +++(dark blue) 
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Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
669 +++ ++ ++(light blue) 
684 +++ ++ +++(dark blue) 
686 +++ ++ ++(light blue) 
687 +++ +++ +++(dark blue) 
689 +++ ++ ++(light blue) 
691 +++ +++ ++(light blue) 
693 +++ +++ +++(dark blue) 
695 +++ ++ ++(light blue) 
696 +++ ++ ++(light blue) 
698 +++ +++ ++(light blue) 
700 +++ ++ ++(light blue) 
701 +++ +++ ++(light blue) 
706 +++ ++ ++(light blue) 
710 +++ ++ ++(light blue) 
711 +++ ++ ++(light blue) 
712 +++ ++ ++(light blue) 
713 +++ ++ ++(light blue) 
718 +++ +++ +++(dark blue) 
724 +++ ++ ++(light blue) 
726 +++ ++ ++(light blue) 
727 +++ ++ ++(light blue) 
749 +++ ++ ++(light blue) 
750 +++ ++ ++(light blue) 
753 +++ ++ ++(light blue) 
759 +++ ++ ++(light blue) 
760 +++ ++ ++(light blue) 
770 +++ ++ ++(light blue) 
771 +++ ++ ++(light blue) 
774 +++ ++ +++(dark blue) 
775 +++ ++ +++(dark blue) 
776 +++ ++ +++(dark blue) 
777 +++ ++ +++(dark blue) 
780 +++ ++ ++(light blue) 
781 +++ ++ ++(light blue) 
782 +++ ++ ++(light blue) 
784 +++ ++ ++(light blue) 
785 +++ ++ ++(light blue) 
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Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
787 +++ ++ ++(light blue) 
789 +++ ++ ++(light blue) 
790 +++ ++ ++(light blue) 
798 +++ ++ ++(light blue) 
802 +++ ++ +++(dark blue) 
817 +++ +++ +++(dark blue) 
818 +++ ++ +++(dark blue) 
819 +++ ++ ++(light blue) 
823 +++ ++ ++(light blue) 
832 +++ ++ ++(light blue) 
836 +++ ++ ++(light blue) 
841 +++ ++ ++(light blue) 
842 +++ ++ ++(light blue) 
846 +++ ++ ++(light blue) 
847 +++ ++ ++(light blue) 
852 +++ ++ ++(light blue) 
855 +++ ++ ++(light blue) 
861 +++ +++ ++(light blue) 
864 +++ ++ ++(light blue) 
869 +++ ++ ++(light blue) 
870 +++ ++ +++(dark blue) 
872 +++ +++ +++(dark blue) 
875 +++ ++ ++(light blue) 
876 +++ ++ +++(dark blue) 
881 +++ ++ ++(light blue) 
883 +++ ++ ++(light blue) 
887 +++ ++ +++(dark blue) 
890 +++ ++ ++(light blue) 
893 +++ ++ +++(dark blue) 
1008 +++ ++ ++(light blue) 
1020 +++ ++ +(no blue) 
1340 +++ +++ +++(dark blue) 
1363 +++ ++ ++(light blue) 
1451 +++ ++ ++(light blue) 
1482 +++ +++ +++(dark blue) 
1569 +++ ++ ++(light blue) 
1596 +++ ++ ++(light blue) 
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Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
1649 +++ ++ ++(light blue) 
1661 +++ +++ +++(dark blue) 
1728 +++ +++ +++(dark blue) 
1808 +++ ++ ++(light blue) 
1830 +++ ++ +++(dark blue) 
1848 +++ ++ ++(light blue) 
1857 +++ ++ ++(light blue) 
1859 +++ ++ ++(light blue) 
1860 +++ ++ ++(light blue) 
1880 +++ ++ ++(light blue) 
1940 +++ ++ ++(light blue) 
1951 +++ ++ ++(light blue) 
1962 +++ ++ ++(light blue) 
2011 +++ ++ ++(light blue) 
2102 +++ ++ ++(light blue) 
2138 +++ ++ ++(light blue) 
2180 +++ ++ ++(light blue) 
2189 +++ ++ ++(light blue) 
2222 +++ ++ ++(light blue) 
2223 +++ ++ ++(light blue) 
2264 +++ ++ ++(light blue) 
2322 +++ ++ ++(light blue) 
2358 +++ ++ ++(light blue) 
2391 +++ ++ ++(light blue) 
2393 +++ ++ ++(light blue) 
2641 +++ ++ ++(light blue) 
2736 +++ ++ ++(light blue) 
2753 +++ ++ +++(dark blue) 
2764 +++ +++ +++(dark blue) 
2792 +++ +++ +++(dark blue) 
2948 +++ ++ ++(light blue) 
3005 +++ ++ ++(light blue) 
3006 +++ ++ +++(dark blue) 
3040 +++ ++ ++(light blue) 
3066 +++ ++ ++(light blue) 
3074 +++ ++ ++(light blue) 
3103 +++ ++ ++(light blue) 
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Colony # 
Growth on TD0 with 
3-AT (HIS3 
activation) 
Growth on QDO with 
3-AT (ADE2 
activation) 
X-α-Galactosidase assay 
(Colour) (MEL1 activation) 
3135 +++ ++ ++(light blue) 
3167 +++ ++ ++(light blue) 
3204 +++ +++ +++(dark blue) 
3325 +++ ++ ++(light blue) 
3375 +++ +++ +++(dark blue) 
3404 +++ +++ +(no blue) 
3441 +++ ++ ++(light blue) 
3445 +++ +++ ++(light blue) 
3458 +++ +++ +++(dark blue) 
3481 +++ ++ ++(light blue) 
3483 +++ ++ ++(light blue) 
3496 +++ +++ +++(dark blue) 
3507 +++ ++ ++(light blue) 
3512 +++ ++ ++(light blue) 
3542 +++ ++ ++(light blue) 
3547 +++ ++ ++(light blue) 
3570 +++ ++ ++(light blue) 
3573 +++ ++ ++(light blue) 
3605 +++ +++ +++(dark blue) 
3610 +++ +++ +++(dark blue) 
3624 +++ ++ ++(light blue) 
3628 +++ +++ +++(dark blue) 
3640 +++ ++ ++(light blue) 
Colonies in blue bars were able to activate HIS3, ADE2 and MEL1 reporter genes.  TDO = SD-Leu-Trp-His plates; QDO 
= SD-Leu-Trp-His-Ade plates.  Growth on solid media: +++ = very good; ++ = good, + = weak; - = no growth.  Dark blue 
= primary clones; light blue = secondary clones 
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Table 1.2: Interaction of primary prey clones with heterologous baits in specificity tests 
Clone # 
x pGBKT-KCNE2 
TDO 
x pGBKT7-KCNE2 
QDO 
x pGBKT7 
TDO 
x pGBKT7 
QDO 
x pGBKT-53 
TDO 
x pGBKT-53 
QDO 
x WFS1 
TDO 
x WFS1 
QDO 
9 +++ +++ +++ ++ +++ +++ +++ ++ 
10 ++ - ++ - ++ - ++ - 
*11 +++ +++ +++ +++ +++ - +++ - 
*16 +++ +++ ++ +++ +++ - +++ - 
23 + - + - + - + - 
*24 +++ +++ +++ +++ +++ - ++ - 
46 + - + - + - + - 
56 +++ - +++ - +++ - ++ - 
*68 ++ - ++ - ++ - ++ - 
*79 +++ +++ +++ ++ ++ + - - 
*82 +++ +++ ++ +++ ++ + ++ - 
96 + - + - + - + - 
102 +++ - +++ - +++ - ++ - 
*112 +++ +++ +++ ++ +++ + +++ + 
113 - - - - - - - - 
125 +++ +++ +++ +++ +++ +++ +++ +++ 
*137 +++ +++ +++ +++ +++ - + - 
*143 +++ +++ +++ ++ + + + - 
217 +++ +++ +++ +++ +++ +++ ++ +++ 
*218 +++ - ++ - ++ - +++ - 
230 +++ +++ +++ +++ +++ + +++ +++ 
238 +++ +++ +++ +++ +++ +++ +++ ++ 
242 + - + - + - + - 
247 +++ +++ +++ +++ ++ ++ + - 
*251 ++ +++ ++ ++ ++ - + - 
*281 +++ +++ ++ ++ + - + - 
283 ++ - ++ - ++ - + - 
302 + - + - ++ - ++ - 
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Clone # 
x pGBKT-KCNE2 
TDO 
x pGBKT7-KCNE2 
QDO 
x pGBKT7 
TDO 
x pGBKT7 
QDO 
x pGBKT-53 
TDO 
x pGBKT-53 
QDO 
x WFS1 
TDO 
x WFS1 
QDO 
*303 +++ +++ +++ ++ +++ - ++ - 
*349 +++ +++ +++ +++ +++ ++ +++ - 
*355 +++ +++ +++ ++ ++ - ++ - 
360 +++ +++ +++ +++ ++ +++ ++ +++ 
368 + - ++ - ++ - + - 
371 +++ +++ +++ +++ +++ +++ + - 
383 +++ +++ +++ +++ +++ +++ ++ - 
*395 +++ +++ +++ ++ +++ + ++ - 
*398 ++ ++ +++ - +++ - ++ - 
407 ++ - + - + - + - 
412 ++ - ++ - ++ - ++ - 
416 ++ - ++ - ++ - +++ - 
417 +++ +++ +++ +++ +++ +++ ++ - 
*418 +++ +++ +++ + +++ - ++ - 
*452 ++ +++ +++ + +++ + ++ - 
*464 +++ - ++ - +++ - ++ - 
*484 +++ +++ ++ +++ ++ + + - 
*501 +++ +++ +++ +++ +++ + ++ - 
510 +++ +++ ++ ++ ++ ++ ++ - 
514 +++ +++ +++ +++ +++ +++ - - 
546 +++ +++ +++ +++ +++ ++ +++ - 
*553 +++ +++ +++ ++ +++ ++ +++ - 
610 +++ +++ +++ +++ +++ ++ ++ - 
649 +++ +++ +++ +++ +++ +++ +++ + 
*668 +++ +++ +++ +++ +++ ++ ++ - 
684 +++ +++ +++ +++ +++ +++ ++ - 
*687 +++ +++ ++ ++ ++ - ++ - 
*693 +++ +++ ++ ++ +++ + +++ - 
*718 +++ +++ +++ ++ +++ + +++    - 
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Clone # 
x pGBKT-KCNE2 
TDO 
x pGBKT7-KCNE2 
QDO 
x pGBKT7 
TDO 
x pGBKT7 
QDO 
x pGBKT-53 
TDO 
x pGBKT-53 
QDO 
x WFS1 
TDO 
x WFS1 
QDO 
774 +++ +++ ++ ++ +++ ++ +++ + 
775 ++ - +++ - +++ - ++ - 
776 ++ - ++ - ++ - ++ - 
*777 +++ +++ +++ +++ ++ ++ ++ - 
*802 +++ +++ ++ ++ +++ ++ +++ + 
817 +++ +++ +++ +++ +++ +++ ++ - 
818 +++ +++ +++ +++ +++ +++ +++ + 
870 +++ +++ +++ +++ +++ +++ +++ - 
872 +++ +++ ++ ++ +++ ++ - + 
876 +++ +++ +++ +++ +++ ++ ++ - 
887 +++ +++ +++ +++ +++ +++ ++ + 
893 +++ +++ +++ + +++ - - - 
1340 +++ - +++ - +++ - +++ - 
1482 ++ - ++ - +++ - ++ - 
1661 ++ - ++ - +++ - +++ - 
1728 ++ - ++ - ++ - ++ - 
1830 ++ - ++ - ++ - ++ - 
*2753 +++ +++ +++ +++ ++ ++ - - 
*2764 +++ +++ +++ ++ +++ - +++ - 
2792 ++ - +++ - +++ - +++ - 
*3006 +++ +++ +++ + +++ ++ - - 
3204 ++ - ++ - ++ - +++ - 
3375 ++ - ++ - ++ - ++ - 
3458 ++ - ++ - +++ - +++ - 
*3496 +++ +++ +++ +++ +++ ++ +++ + 
*3605 +++ +++ +++ +++ +++ ++ +++ - 
*3610 ++ + ++ - ++ - ++ - 
*3628 ++ ++ +++ - +++ - ++ - 
TDO = SD-Leu-Trp-His plates; QDO = SD-Leu-Trp-His-Ade plates.  Growth of colonies: +++ = very good; ++ = good; + = weak; - = no growth.  * = Clones selected for 
sequencing.  
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Table 1.3: Interaction of secondary prey clones with heterologous baits in specificity tests 
Clone # 
x pGBKT-KCNE2 
TDO 
x pGBKT7-KCNE2 
QDO 
x pGBKT7 
TDO 
x pGBKT7 
QDO 
x pGBKT-53 
TDO 
x pGBKT-53 
QDO x WFS1 TDO 
x WFS1 
QDO 
4 ++ - - - - - - - 
5 +++ +++ +++ +++ +++ +++ - +++ 
8 +++ +++ ++ + ++ ++ ++ ++ 
*15 +++ +++ +++ - ++ - - - 
17 +++ - ++ - ++ - ++ - 
*18 +++ +++ ++ - - - + - 
*22 +++ ++ ++ - ++ - +++ - 
29 +++ +++ +++ ++ +++ ++ ++ + 
*30 +++ +++ +++ + ++ - ++ - 
38 +++ +++ +++ ++ +++ +++ +++ ++ 
41 + - - - - - - - 
48 +++ +++ +++ +++ +++ +++ +++ + 
53 +++ +++ +++ +++ +++ +++ +++ +++ 
57 +++ +++ +++ ++ +++ +++ - - 
61 +++ +++ +++ +++ +++ +++ ++ - 
*64 +++ +++ +++ ++ ++ - + - 
66 +++ +++ +++ +++ +++ +++ ++ - 
67 +++ +++ +++ +++ ++ + + - 
*72 +++ +++ +++ - ++ - ++ - 
92 +++ +++ +++ +++ +++ +++ +++ ++ 
*93 +++ +++ ++ ++ +++ + ++ + 
*95 +++ +++ +++ +++ +++ - + - 
97 ++ +++ +++ - - - ++ - 
98 +++ +++ +++ +++ +++ +++ ++ - 
*101 +++ +++ +++ + - - - - 
103 ++ - - - - - - - 
105 +++ +++ +++ +++ +++ ++ ++ +++ 
111 +++ +++ +++ ++ +++ ++ - - 
118 +++ +++ +++ ++ +++ +++ +++ + 
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Clone # 
x pGBKT-KCNE2 
TDO 
x pGBKT7-KCNE2 
QDO 
x pGBKT7 
TDO 
x pGBKT7 
QDO 
x pGBKT-53 
TDO 
x pGBKT-53 
QDO x WFS1 TDO 
x WFS1 
QDO 
120 +++ +++ +++ ++ +++ ++ + ++ 
121 ++ - - - - - - - 
127 +++ +++ +++ +++ - + - - 
128 +++ +++ +++ +++ +++ ++ - - 
135 +++ +++ +++ ++ +++ ++ + - 
139 +++ +++ +++ +++ +++ +++ +++ + 
142 +++ +++ +++ ++ +++ ++ +++ + 
*144 +++ +++ +++ + ++ - - - 
145 +++ +++ +++ ++ ++ + - - 
149 +++ +++ +++ +++ +++ +++ - - 
157 +++ +++ +++ ++ +++ +++ +++ ++ 
160 ++ - - - - - - - 
*162 +++ +++ +++ - + - - - 
163 +++ +++ +++ +++ +++ + +++ +++ 
174 +++ +++ +++ ++ +++ +++ ++ - 
175 +++ +++ +++ ++ +++ +++ +++ - 
185 +++ +++ +++ - +++ +++ +++ ++ 
*192 +++ +++ +++ - +++ - ++ - 
193 +++ +++ +++ ++ +++ +++ + - 
*194 +++ +++ +++ - +++ - - - 
*197 +++ +++ +++ ++ +++ ++ - - 
202 +++ +++ +++ +++ +++ +++ +++ + 
205 +++ +++ +++ + +++ +++ +++ +++ 
216 +++ +++ +++ +++ +++ ++ + - 
222 +++ +++ +++ ++ +++ +++ +++ - 
228 +++ +++ +++ + +++ ++ +++ ++ 
229 +++ +++ +++ + +++ +++ +++ +++ 
233 +++ +++ +++ - +++ +++ - - 
*236 +++ +++ +++ + + - - - 
244 +++ +++ +++ - +++ +++ + - 
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Clone # 
x pGBKT-KCNE2 
TDO 
x pGBKT7-KCNE2 
QDO 
x pGBKT7 
TDO 
x pGBKT7 
QDO 
x pGBKT-53 
TDO 
x pGBKT-53 
QDO x WFS1 TDO 
x WFS1 
QDO 
248 +++ +++ +++ - +++ +++ +++ - 
*250 +++ +++ +++ - ++ - ++ - 
252 +++ +++ +++ + ++ + - - 
*257 +++ +++ +++ + ++ ++ - - 
*259 +++ +++ +++ - ++ + - - 
261 +++ ++ +++ - ++ - - - 
*262 +++ +++ +++ - - - + - 
265 +++ +++ +++ + +++ +++ +++ - 
*272 +++ +++ +++ ++ ++ + - - 
278 +++ +++ +++ ++ +++ +++ +++ - 
279 +++ +++ +++ ++ + - ++ + 
*285 +++ +++ ++ - ++ + - - 
*291 +++ +++ ++ ++ - - - - 
*293 +++ +++ ++ + + - + - 
295 +++ +++ +++ ++ ++ +++ ++ + 
296 +++ +++ +++ + +++ +++ +++ + 
299 +++ +++ ++ + +++ ++ +++ ++ 
*307 +++ +++ - + ++ - - - 
*321 +++ +++ +++ - ++ - ++ - 
323 +++ +++ +++ +++ +++ +++ +++ +++ 
328 + - - - - - - - 
329 +++ +++ +++ ++ +++ ++ +++ - 
330 +++ +++ ++ ++ +++ +++ ++ - 
331 +++ +++ ++ ++ +++ +++ ++ ++ 
333 ++ - - - - - - - 
336 +++ +++ +++ ++ +++ ++ - - 
358 +++ +++ +++ +++ +++ - +++ +++ 
359 +++ +++ +++ ++ +++ + +++ +++ 
375 +++ +++ +++ +++ ++ + +++ +++ 
380 +++ +++ ++ +++ +++ ++ + - 
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Clone # 
x pGBKT-KCNE2 
TDO 
x pGBKT7-KCNE2 
QDO 
x pGBKT7 
TDO 
x pGBKT7 
QDO 
x pGBKT-53 
TDO 
x pGBKT-53 
QDO x WFS1 TDO 
x WFS1 
QDO 
395 +++ +++ ++ +++ +++ +++ +++ +++ 
414 +++ +++ ++ ++ ++ - ++ ++ 
424 +++ +++ +++ ++ ++ - +++ +++ 
426 +++ +++ +++ - +++ +++ +++ - 
427 +++ +++ +++ +++ +++ +++ ++ - 
431 ++ - - - - - - - 
432 +++ +++ +++ ++ +++ +++ - - 
433 +++ +++ ++ ++ +++ ++ +++ - 
434 +++ +++ +++ +++ +++ - +++ - 
*436 +++ +++ + - ++ - +++ - 
439 - - - - - - - - 
440 - - - - - - - - 
*441 +++ +++ ++ - ++ + +++ - 
445 +++ ++ +++ - ++ - +++ - 
446 +++ +++ +++ - +++ +++ +++ - 
453 ++ - ++ - - - - - 
457 +++ +++ +++ - +++ ++ +++ ++ 
*459 +++ +++ +++ - +++ - +++ - 
461 +++ +++ +++ + +++ + +++ ++ 
470 +++ - - - - - - - 
475 +++ + +++ - +++ + + - 
480 +++ +++ +++ - +++ +++ - - 
481 +++ +++ +++ ++ +++ - +++ +++ 
*495 +++ ++ +++ - ++ - - - 
503 ++ - - - + - + - 
507 +++ +++ +++ ++ +++ +++ +++ +++ 
515 +++ +++ +++ +++ +++ ++ +++ +++ 
520 +++ +++ +++ ++ ++ +++ +++ +++ 
521 +++ +++ ++ + +++ +++ +++ +++ 
523 ++ +++ ++ + + + +++ +++ 
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Clone # 
x pGBKT-KCNE2 
TDO 
x pGBKT7-KCNE2 
QDO 
x pGBKT7 
TDO 
x pGBKT7 
QDO 
x pGBKT-53 
TDO 
x pGBKT-53 
QDO x WFS1 TDO 
x WFS1 
QDO 
525 +++ +++ +++ + ++ +++ ++ - 
*526 +++ +++ ++ + ++ + - - 
534 +++ +++ +++ ++ +++ ++ - - 
537 +++ +++ ++ +++ +++ ++ + - 
538 +++ +++ +++ +++ ++ ++ + + 
540 ++ +++ +++ +++ - - +++ +++ 
543 ++ - - - - - - - 
550 +++ +++ +++ + +++ ++ ++ - 
554 +++ +++ +++ + +++ ++ ++ - 
578 +++ +++ +++ + ++ ++ - - 
579 +++ +++ +++ ++ ++ + - - 
*590 +++ +++ +++ + ++ + - - 
594 +++ +++ +++ ++ ++ + + - 
598 +++ +++ +++ + +++ +++ - - 
*601 ++ ++ + - - - - - 
616 +++ +++ +++ ++ ++ + - - 
*623 +++ +++ +++ + - - ++ - 
630 +++ +++ +++ ++ +++ +++ +++ ++ 
645 ++ - - - - - - - 
*665 +++ +++ +++ + - + - - 
669 +++ +++ +++ ++ +++ ++ ++ - 
*686 ++ +++ ++ - ++ + - - 
691 +++ +++ +++ + +++ - - - 
695 +++ +++ +++ + +++ +++ - - 
*696 +++ +++ +++ ++ +++ - - - 
698 +++ +++ +++ - +++ +++ +++ ++ 
700 +++ +++ +++ ++ + - +++ +++ 
701 +++ ++ +++ - +++ - +++ - 
706 +++ +++ +++ +++ +++ +++ +++ + 
710 +++ +++ +++ ++ +++ +++ +++ ++ 
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Clone # 
x pGBKT-KCNE2 
TDO 
x pGBKT7-KCNE2 
QDO 
x pGBKT7 
TDO 
x pGBKT7 
QDO 
x pGBKT-53 
TDO 
x pGBKT-53 
QDO x WFS1 TDO 
x WFS1 
QDO 
711 ++ - - - - - - - 
712 +++ +++ +++ + ++ + ++ ++ 
*713 +++ +++ +++ + +++ ++ +++ - 
724 +++ +++ +++ + +++ +++ ++ - 
726 +++ +++ +++ - +++ ++ +++ + 
727 +++ +++ +++ +++ +++ +++ +++ +++ 
749 +++ +++ +++ + +++ +++ ++ - 
750 +++ +++ +++ ++ +++ - +++ +++ 
753 ++ - ++ - ++ - ++ - 
759 +++ +++ +++ + +++ +++ - - 
770 + - - - - - - - 
781 +++ +++ +++ - +++ +++ +++ - 
787 ++ - - - - - - - 
790 +++ +++ +++ - +++ +++ - - 
798 +++ +++ +++ + +++ +++ - - 
819 +++ +++ +++ + +++ +++ - - 
823 + - - - - - - - 
836 +++ +++ +++ + +++ +++ +++ +++ 
846 + - - - - - - - 
847 +++ +++ +++ ++ ++ ++ ++ - 
852 ++ - - - - - - - 
861 +++ +++ +++ - +++ +++ - - 
864 +++ +++ +++ - +++ +++ + ++ 
869 - - - - - - - - 
881 +++ +++ +++ + - - +++ +++ 
883 +++ +++ +++ ++ +++ +++ +++ - 
*1008 +++ +++ +++ + ++ ++ - - 
1363 +++ + +++ - ++ - ++ - 
1451 + - - - - - - - 
1569 ++ - - - - - - - 
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Clone # 
x pGBKT-KCNE2 
TDO 
x pGBKT7-KCNE2 
QDO 
x pGBKT7 
TDO 
x pGBKT7 
QDO 
x pGBKT-53 
TDO 
x pGBKT-53 
QDO 
x WFS1 
TDO 
x WFS1 
QDO 
1596 +++ +++ +++ + +++ +++ +++ - 
1649 +++ +++ +++ +++ +++ +++ +++ ++ 
*1808 ++ +++ - - - - - - 
*1857 +++ +++ +++ - ++ - + - 
1859 + - - - - - - - 
1860 +++ +++ +++ ++ +++ +++ ++ - 
*1880 +++ +++ +++ - ++ - - - 
1940 ++ - - - - - - - 
1962 +++ +++ +++ ++ +++ +++ +++ - 
*2011 +++ +++ +++ - +++ - +++ ++ 
2102 +++ +++ +++ - +++ +++ - - 
2138 +++ ++ +++ - ++ ++ - - 
2180 ++ - - - - - - - 
*2189 +++ +++ +++ ++ + ++ - - 
2264 +++ ++ +++ - +++ ++ - - 
2322 ++ - - - - - - - 
2391 +++ +++ +++ - ++ +++ + ++ 
2641 +++ +++ +++ +++ ++ + - - 
2736 +++ +++ +++ - +++ +++ +++ +++ 
3066 +++ +++ +++ +++ +++ - +++ +++ 
3074 +++ +++ +++ +++ +++ +++ +++ +++ 
3135 +++ - ++ - ++ - +++ - 
3167 ++ - ++ - + - +++ - 
3441 +++ +++ +++ +++ +++ +++ +++ +++ 
3481 +++ ++ ++ - ++ - ++ - 
3483 +++ - +++ - ++ - ++ - 
3507 +++ ++ +++ - ++ - +++ - 
3512 ++ - + - - - - - 
3542 +++ - +++ - ++ - +++ - 
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Clone # 
x pGBKT-KCNE2 
TDO 
x pGBKT7-KCNE2 
QDO 
x pGBKT7 
TDO 
x pGBKT7 
QDO 
x pGBKT-53 
TDO 
x pGBKT-53 
QDO 
x WFS1 
TDO 
x WFS1 
QDO 
3547 +++ +++ +++ +++ +++ +++ +++ +++ 
3570 ++ - - - - - - - 
*3640 +++ +++ +++ - + - - - 
TDO = SD-Leu-Trp-His plates; QDO = SD-Leu-Trp-His-Ade plates.  Growth of colonies: +++ = very good; ++ = good; + = weak; - = no growth.  * *Clones selected for 
sequencing. 
 
Table 1.4: Identification of primary putative KCNE2 interactor clones from the Y2H cardiac cDNA library screen 
Clone # 
Identity 
BLASTn                                                           BLASTp 
Accession # 
e-value 
Accession # 
e-value 
Cellular 
location 
11 
Homo sapiens arginine and glutamate rich 1 
(ARGLU1), mRNA 
dihydrolipoamide succinyltransferase 
[Streptomyces sviceus ATCC 29083] 
NM_018011.3 
(0.0) 
ZP_06916558.1  
(0.33) 
n/a 
16 
Homo sapiens ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta polypeptide 
(ATP5B), nuclear gene encoding 
mitochondrial protein, mRNA 
hypothetical protein Ajs_0177  
NM_001686.3 
(0.0) 
YP_984508.1 
(7.2) 
n/a 
24 
Homo sapiens interleukin 1 receptor, type I 
(IL1R1), mRNA 
RecName: Full=Probable beta-1,3-
galactosyltransferase 12 
NM_000877.2 
(0.0) 
Q66GS2.1 
 (8) 
Golgi 
apparatus 
membrane 
68 
Homo sapiens tropomyosin 1 (alpha) (TPM1), 
transcript variant 1,mRNA 
No significant similarity NM_001018005.1 
(0.0) 
n/a n/a 
79 
Homo sapiens chromosome 8 genomic contig, 
alternate assembly whole genome shotgun 
sequence 
No significant similarity 
NW_001839132.1 
(0.0) 
n/a n/a 
82 
Homo sapiens mitochondrion, complete 
genome 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NC_012920.1  
(0.0) 
ADB44568.1 
(2E-11) 
Mitochondria 
112 
Homo sapiens collagen, type I, alpha 1 
(COL1A1), mRNA 
collagen, type I, alpha 1, isoform 
CRA_a [Homo sapiens] 
NM_000088.3  
(0.0) 
EAW94630.1 
(7E-157) 
Extracellular 
matrix 
137 
Homo sapiens mitochondrion, complete 
genome 
cytochrome oxidase subunit II [Homo 
sapiens]  
NC_012920.1  
(0.0) 
ABG27224.1 
(3E-22) 
Mitochondria 
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Clone # 
Identity 
BLASTn                                                           BLASTp 
Accession # 
e-value 
Accession # 
e-value 
Cellular 
location 
 
143 
Homo sapiens mitochondrion, complete 
genome 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NC_012920.1  
(0.0) 
AAN77914.1 
(2E-15) 
Mitochondria 
218 
Homo sapiens tropomyosin 1 (alpha) (TPM1), 
transcript variant 1, mRNA 
No significant similarity NM_001018005.1 
(0.0) 
n/a n/a 
251 
Homo sapiens mitochondrion, complete 
genome 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NC_012920.1  
(0.0) 
ADB44568.1 
(2E-21) 
Mitochondria 
281 
Homo sapiens mitochondrion, complete 
genome 
hypothetical protein [Tuber 
melanosporum Mel28] 
NC_012920.1  
(0.0) 
XP_002841996.
1 (0.54) 
n/a 
303 
Homo sapiens aspartyl-tRNA synthetase 
(DARS), mRNA 
RecName: Full=Putative 
uncharacterized mitochondrial protein 
NCU16001 
NM_001349.2 
 (0.0) 
Q35137.2 (0.21) Mitochondria 
349 
Homo sapiens protein kinase, AMP-activated, 
alpha 2 catalytic subunit (PRKAA2), mRNA 
hypothetical protein 
HMPREF9473_04582 [Clostridium 
hathewayi] 
NM_006252.3  
(0.0) 
ZP_09152519.1 
(2.8) 
n/a 
355 
Homo sapiens mitochondrion, complete 
genome 
cytochrome oxidase I [Pteropus 
temminckii] 
NC_012920.1  
(0.0) 
AAA32045.2 
(5E-12) 
Mitochondria 
395 
Homo sapiens myotubularin related protein 4 
(MTMR4), mRNA 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NM_004687.4  
(0.0) 
ADB44568.1 
0.000000002 
Mitochondria 
398 
Homo sapiens mitochondrion, complete 
genome 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NC_012920.1  
(0.0) 
ADB44568.1 
6E-17 
Mitochondria 
418 
Homo sapiens mitochondrion, complete 
genome 
unnamed protein product [Bacillus 
pseudofirmus OF4] 
NC_012920.1 
(0.0) 
YP_003425713.
1 8.6 
n/a 
452 
Homo sapiens mitochondrion, complete 
genome 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NC_012920.2 
(0.0) 
AAN77914.1 
2E-15 
Mitochondria 
464 
Homo sapiens tropomyosin 1 (alpha) (TPM1), 
transcript variant 1,mRNA 
No significant similarity NM_001018005.1 
(0.0) 
n/a n/a 
484 
Homo sapiens mitochondrion, complete 
genome 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NC_012920.1 
(0.0) 
ADB44568.1 
1E-13 
Mitochondria 
*501 
Homo sapiens filamin C, gamma (FLNC), 
transcript variant 2, mRNA 
Chain A, Dimerization Of Human 
Filamin C: Crystal Structure Of the 
domain 24 
NM_001127487.1 
(0.0) 
1V05_A 2E-57 
Cytoplasm, 
Membrane, 
Sarcomere, 
Myofibril 
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Clone # 
Identity 
BLASTn                                                           BLASTp 
Accession # 
e-value 
Accession # 
e-value 
Cellular 
location 
553 
Homo sapiens mitochondrion, complete 
genome 
No significant similarity NC_012920.1 
(0.0) 
n/a n/a 
668 
Homo sapiens protein tyrosine phosphatase, 
receptor type, K (PTPRK),transcript variant 2, 
mRNA 
protein tyrosine phosphatase, receptor 
type, K, isoform CRA_e 
NM_002844.3 
(0.0) 
EAW48088.1 
1E-106 
Cell 
membrane, 
Cell junction 
687 
Homo sapiens mitochondrion, complete 
genome 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NC_012920.1 
(0.0) 
ADB44568.1 
6E-10 
Mitochondria 
693 
Homo sapiens mitochondrion, complete 
genome 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NC_012920.1 
(0.0) 
AAN77914.1 
2E-15 
Mitochondria 
718 
Homo sapiens mitochondrion, complete 
genome 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NC_012920.1 
(0.0) 
ADB44568.1 
1E-13 
Mitochondria 
777 
Homo sapiens metastasis associated lung 
adenocarcinoma transcript 
hypothetical protein, unlikely 
[Trypanosoma vivax Y486] 
NR_002819.2 
(0.0) 
CCC51287.1 1.5 n/a 
802 
Homo sapiens mitochondrion, complete 
genome 
No significant similarity NC_012920.1 
(0.0) 
n/a n/a 
872 
Homo sapiens mitochondrion, complete 
genome 
No significant similarity NC_012920.2 
(0.0) 
n/a n/a 
876 
Homo sapiens yippee-like 5 
(Drosophila)(YPEL5), transcript variant 
3,mRNA 
unnamed protein product 
[Desulfosporosinus orientis DSM 765] 
NM_001127399.1 
(0.0) 
YP_004972419.
1 (4) 
n/a 
893 
Homo sapiens chromosome 10 genomic 
contig, GRCh37.p5 Primary Assembly 
unnamed protein product [Tetraodon 
nigroviridis] 
NT_030059.13 
(0.0) 
CAF87655.1 
0.14 
n/a 
2753 
Homo sapiens MT-RNR2-like 1 
(MTRNR2L1), mRNA 
Fe(3+) ions import ATP-binding protein 
FbpC [Pseudoalteromonas] 
NM_001190452.1 
(0.0) 
ZP_09239936.1 
3.6 
Cell 
membrane 
2764 
Homo sapiens mitochondrion, complete 
genome 
2-octaprenyl-6-methoxyphenol 
hydroxylase [Collimonas fungivorans ] 
NC_012920.1 
(0.0) 
YP_004754278.
1 45 
Mitochondria 
3006 
Homo sapiens chromosome 2 genomic contig, 
GRCh37.p5 Primary Assembly 
hypothetical protein TREAZ_2861  NT_022184.15 
(0.0) 
YP_004528574.
1 22 
n/a 
3496 
Homo sapiens mitochondrion, complete 
genome 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NC_012920.1 
(0.0) 
AAN77914.12E-
15 
Mitochondria 
3605 
Homo sapiens mitochondrion, complete 
genome 
NADH dehydrogenase subunit 1 [Homo 
sapiens] 
NC_012920.2 
(0.0) 
AAN77914.12E-
15 
Mitochondria 
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Clone # 
Identity 
BLASTn                                                           BLASTp 
Accession # 
e-value 
Accession # 
e-value 
Cellular 
location 
3610 n/a n/a n/a n/a n/a 
3628 
Homo sapiens S-phase kinase-associated 
protein 1 (SKP1), transcript 
hypothetical protein 
HMPREF9074_05118 
[Capnocytophaga sp. oral ] 
NM_170679.2 
(0.0) 
ZP_08449328.1 
486 
n/a 
* = Clones selected for further investigation in the present study 
 
 
Table 1.5: Identification of primary putative KCNE2 interactor clones from the Y2H cardiac cDNA library screen 
Clone # 
Identity 
BLASTn                                     BLASTp 
Accession # 
e-value 
Accession # 
e-value 
Cellular 
location 
*15 
Homo sapiens voltage-dependent anion 
channel 1 (VDAC1),  
voltage-dependent anion-selective 
channel protein 1 
NR_036625.1 
(0) 
NP_003365.1 
(0) 
Mitochondrial 
outer 
membrane, 
Cell membrane 
18 
Homo sapiens glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
glyceraldehyde-3-phosphate 
dehydrogenase isoform 2 
NM_002046.3 
(0) 
NP_001243728.
1 
(6E-153) 
Cytoplasm, 
Nucleus 
22 
Homo sapiens titin (TTN), transcript variant 
novex-3, mRNA 
Novex-3 Titin Isoform 
NM_133379.3 
(0) 
CAD12458.1 
(2E-76) 
Cytoplasm, 
Nucleus 
30 
Homo sapiens titin (TTN), transcript variant 
N2-B, mRNA 
putative regulatory protein NosR 
NM_003319.4 
(2.00E-139) 
ZP_01737051.1 
(4.1) 
n/a 
64 
Homo sapiens stonin 1 (STON1), transcript 
variant 2, mRNA 
STON1 protein [Homo sapiens] 
NM_006873.3 
(0) 
AFE71436.1 
(1E-46) 
Cytoplasm, 
Cell membrane 
72 
Homo sapiens glucan (1,4-alpha-), branching 
enzyme 1 (GBE1),  
dsDNA-dependent ATPase (Rad54b),  
NM_000158.3 
(0) 
XP_001268743.
1 
(6.7) n/a 
93 
Homo sapiens myomesin 1, 185kDa 
(MYOM1), transcript variant 2 
myomesin-1 isoform b [Homo sapiens] 
NM_019856.1 
(0) 
NP_062830.1 
(2E-56) 
Sarcomere, M-
band 
*95 
Homo sapiens crystallin, alpha B (CRYAB), 
mRNA 
crystallin, alpha B, isoform CRA_c  
NM_001885.1 
(0) 
EAW67166.1 
(6E-55) 
Cytoplasm, 
Nucleus 
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Clone # 
Identity 
BLASTn                                     BLASTp 
Accession # 
e-value 
Accession # 
e-value 
Cellular 
location 
101 
Homo sapiens mitochondrion, complete 
genome 
cytochrome c oxidase subunit I 
[Sarcocystis neurona] 
NC_012920.1 
(0) 
AAZ39838.1 
(3E-11) 
n/a 
144 
Homo sapiens ring finger protein 145 
(RNF145), transcript variant 4 
n/a 
NM_001199382.1 
(0) 
n/a 
n/a 
162 
Homo sapiens actin, alpha 2, smooth muscle, 
aorta (ACTA2),transcript variant 1 
actin, alpha, cardiac muscle, isoform 
CRA_b 
NM_001141945.1 
(0) 
EAW92317.1 
(1E-117) 
Cytoplasm, 
Cytoskeleton 
192 
Homo sapiens family with sequence similarity 
100, member A (FAM100A) 
uncharacterized protein LOC100982856 
NM_145253.2 
(0) 
XP_003815203.
1 
(3E-75) n/a 
194 
Homo sapiens mitochondrion, complete 
genome 
PDK repeat-containing protein 
NC_012920.1 
(0) 
YP_004988500.
1 
(1.9) n/a 
197 
Homo sapiens chromosome 6 genomic contig hypothetical protein LOC100426450 
NT_007592.15 
(0) 
XP_002803747.
1 
(1.00E-07) n/a 
236 
n/a n/a n/a n/a 
n/a 
250 
Homo sapiens actin, alpha, cardiac muscle 1 
(ACTC1), mRNA 
cardiac actin ACTC1 
NM_005159.4 
(0) 
EAW92317.1 
(1E-117) 
Cytoplasm, 
Cytoskeleton 
257 
Homo sapiens chromosome 2 genomic contig n/a 
NT_005334.16 
(2E-146) 
n/a 
n/a 
259 
Homo sapiens ral guanine nucleotide 
dissociation stimulator-like  
hypothetical protein SNOG_12038  
NR_028387.1 
(5.00E-41) 
XP_001802270.
1 
(12) n/a 
262 
Homo sapiens actin, alpha, cardiac muscle 1 
(ACTC1), mRNA 
cardiac actin ACTC1 
NM_005159.4 
(0) 
EAW92317.1 
(1E-117) 
Cytoplasm, 
Cytoskeleton 
272 
Homo sapiens chromosome 14 open reading 
frame 126 (C14orf126 
unknown [Pongo pygmaeus] 
NM_080664.2 
(6E-85) 
AAY51665.1 
(8.1) 
n/a 
285 
Homo sapiens KIAA1191 (KIAA1191), 
transcript variant 3, mRNA 
PREDICTED: similar to AGAP008389-
PA [Tribolium castaneum] 
NM_001079685.1 
(0) 
XP_001815332.
1 
(1.4) n/a 
291 
Homo sapiens chromosome 1 genomic contig n/a 
NT_004487.19 
(6.00E-90) 
n/a 
n/a 
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Clone # 
Identity 
BLASTn                                     BLASTp 
Accession # 
e-value 
Accession # 
e-value 
Cellular 
location 
293 
Nitrilase family member 2 (NIT2) Nitrilase family member 2 (NIT2) 
NM_020202.4 
(0) 
BAG57372.1 
(8E-106) 
Cytoplasm 
307 
Homo sapiens inositol(myo)-1(or 4)-
monophosphatase 1 (IMPA1) 
hypothetical protein 
HMPREF1063_00697 
NM_005536.3 
(0) 
EIY30101.1 
(5) 
n/a 
321 
Homo sapiens family with sequence similarity 
46, member A (FAM46A),  
family with sequence similarity 46,  
member A 
NM_017633.2 
(8.00E-170) 
CAI23545.1 
(3E-72) 
n/a 
436 
Homo sapiens proteasome maturation protein 
(POMP), mRNA 
proteosome maturation protein 
NM_015932.5 
(0) 
NP_057016.1 
(6E-96) 
Cytoplasm, 
Nucleus, 
Microsome 
membrane 
441 
Homo sapiens lipoprotein lipase (LPL), 
mRNA 
n/a 
NM_000237.2 
(0) 
n/a 
n/a 
459 
Homo sapiens AT rich interactive domain 1B 
(SWI1-like) (ARID1B) 
novel protein ,AT rich interactive 
domain 1B (SWI1-like) 
NM_017519.2 
(0) 
CAI42305.1 
(1E-145) 
n/a 
495 
Homo sapiens chromosome 3 genomic contig, 
GRCh37.p5 
hypothetical protein DDB_G0276853 
NT_005612.16 
(0) 
XP_642945.1 
(13) 
n/a 
526 
Homo sapiens tropomyosin 1 (alpha) (TPM1) n/a 
NM_001018005.1 
(0) 
n/a 
n/a 
590 
Homo sapiens mitochondrion, complete 
genome 
site-specific recombinase 
NC_012920.1 
(0) 
YP_003425713.
1 
(9.6) n/a 
601 
Homo sapiens tropomyosin 1 (alpha) (TPM1), 
transcript variant 1, mRNA 
Retinol-binding protein 3 
NM_001018005.1 
(1.00E-98) 
P12665.1 
(92482) 
n/a 
623 
Homo sapiens adenylate kinase 4 (AK4), 
nuclear gene encoding mitochondrial protein 
n/a 
NM_013410.3 
(0) 
n/a 
n/a 
665 
Homo sapiens ATPase, Ca++ transporting, 
plasma membrane 1 (ATP2B1),  
putative Fe-S oxidoreductase [Mesotoga 
prima MesG1.Ag.4.2] 
NM_001682.2 
(0) 
YP_006345749.
1 
(4.5) n/a 
686 
n/a n/a n/a n/a 
n/a 
696 
Homo sapiens PDZ and LIM domain 5 
(PDLIM5),  
n/a 
NM_001011515.1 
(0) 
n/a 
n/a 
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Clone # 
Identity 
BLASTn                                                             BLASTp 
Accession # 
e-value 
Accession # 
e-value 
Cellular 
location 
713 
Homo sapiens CD36 molecule (CD36) 
transcript variant 3, mRNA 
IMV membrane protein [Tanapox virus] 
NM_000072.3 
(0) 
YP_001497059.
1 
(0.24) n/a 
1008 
Homo sapiens multiple coagulation factor 
deficiency 2 (MCFD2), 
hypothetical protein LOC100426989 
NM_001171509.2 
(0) 
XP_002800068.
1 
(1.00E-05) n/a 
1808 
Homo sapiens tropomyosin 1 (alpha) (TPM1) n/a 
NM_001018005.1 
(0) 
n/a 
n/a 
1857 
Homo sapiens chromosome 12 genomic 
contig 
hypothetical protein Mahau_2676  
NT_009759.16 
(0) 
YP_004464634.
1 
(3) n/a 
1880 
Branched-chain alpha-ketoacid 
dehydrogenase kinase (BCKDK) 
Branched-chain alpha-ketoacid 
dehydrogenase kinase 
NM_001122957.1 
(1.00E-104) 
AAB82714.1 
(2E-32) 
Mitochondrial 
matrix 
2011 
Homo sapiens cullin-associated and 
neddylation-dissociated 1 (CAND1) 
cullin-associated and neddylation-
dissociated 1, isoform CRA_a 
NM_018448.3 
(0) 
EAW97171.1 
(6E-75) 
Nucleus 
2189 
Homo sapiens chromosome 2 genomic contig 
hypothetical protein 
HMPREF9430_00966 
NT_022184.15 
(0) 
ZP_08028855.1 
(4.5) 
n/a 
3640 
Homo sapiens tropomyosin 1 (alpha) (TPM1), 
transcript variant 6 
n/a 
NM_001018008.1 
(7.00E-114) 
n/a 
n/a 
* = Clones selected for further investigation in the present study 
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Appendix VI 
Prokaryotic and eukaryotic phenotypes 
 
BACTERIAL STRAIN PHENOTYPE 
E.coli strain DH5α 
Φ 80d lacZΔM15 recA1, endA1, Gry A96 thi-1, hsdR17 supE44, relA1, deoR Δ (lacZYA argF) 
u169 
 
YEAST STRAIN PHNOTYPES 
Yeast strain AH109 
MATa, trp-901, leu2-3, ura3-5, his3-200, gal4Δ, gal80Δ, LYS::GAL1uas - GAL1TATA - HIS3, 
GAL2UAS - GAL2TATA - ADE2, URA::MEL1UAS - MEL1TATA - lacZ (James et al. 1999) 
 
Yeast strain Y187 
MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, gal4Δ, mef, gal80Δ, 
URA3::GAL1UAS - GAL1TATA - lacZ (Harper et al. 1993) 
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Appendix VII 
List of suppliers   
 
3-Amino-1, 2, 4-triazole     Sigma 
Agarose       Whitehead scientific 
Ampicillin        Roche 
Autoradiography film      Thermo Scientific 
β-mercapto-ethanol      Sigma 
Bacto Agar       Merck 
Bacto trypone       Fluka 
Bradford reagent      Thermo Scientific 
Bromophenol blue      Promega 
CaCl2        Merck 
Calf intestinal alkaline phosphatase    Promega 
dATP        Promega 
dCTP        Promega 
dGTP        Promega  
Dimethylformamide      Merck 
Di-Sodium tetraborate decahydrate    Merck 
DMEM       Whitehead scientific 
dTTP        Promega 
EcoRI        Promega 
EDTA        Boerhinger Mannheim 
Ethanol       Sigma 
Ethidium bromide      Roche 
Foetal bovine serum      The Scientific Group 
Glass beads       Amersham pharmacia 
Glucose       Kimix 
Glycine       Sigma 
HaeIII        Promega 
H9C2        American Type Culture Collection 
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Haemagglutinin antibody     Santa Cruz Biotechnologies 
HCl        Merck 
Herring sperm DNA      Promega 
Horse serum       Sigma 
Hybond N+ nylon membrane     BD Biosciences 
Kanamycin       Roche 
Leammli sample buffer     Bio-Rad 
LiAc        Sigma 
Matchmaker two-hybrid system 3    BD Biosciences 
MgCl2        Bioline 
Molecular size marker (100 bp)    Lasec 
NaCl        Sigma 
NdeI        Promega 
Oligonucleotide Primers Department of Molecular and Cell 
Biology, University of Cape Town 
(UCT) Cape Town, RSA 
pACT2 BD Biosciences 
PBS Sigma 
PEG4000 Merck 
Penicillin/Streptomycin The Scientific Group 
Peptone       Difco 
pGBKT7       BD Biosciences 
PIPES        Merck 
PMSF        Roche 
Protein G agarose      Whitehead scientific  
Protein ladder       Thermo Scientific 
QDO        BD Biosciences 
RsaI        Promega 
SD-Ade        BD Biosciences 
SD-Leu        BD Biosciences 
SD-Leu-Trp       BD Biosciences 
SD-Met        BD Biosciences 
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SDS        Merck 
SD-Ura        BD Biosciences 
SD-Trp         BD Biosciences 
T4 DNA Ligase      Promega 
Taq polymerase      Bioline 
TDO        BD Biosciences 
Tris        Merck 
Tris-HCl       Merck 
Triton X-100       Sigma 
Trypsin       Whitehead scientific 
Tween-20       Merck 
Wizard® SV Gel and PCR Clean-up System   Promega 
X-α-Galactosidase      Southern Cross  
Yeast extract       Difco 
Yeast nitrogem base (without amino acids)   BD Biosciences 
Zyppy™ Plasmid Miniprep Kit     Zymo Research 
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